document incorporate reference document proxy statement annual meeting iii stockholder hold april file securities exchange commission day close fiscal year cover reporttable content pag item business item risk factor cautionary factor affect future result item unresolved staff comment item property item legal proceeding item submission matter vote security holder executive officer registrant market registrant common equity relate stockholder matter issuer purchase item equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum inancial statement ote consolidated financial statement eport independent register public accounting firm upplementary data item change disagreement accountant account financial disclosure item control procedure anagement report item information iii item director executive officer corporate governance item executive compensation security ownership certain beneficial owner management relate stockholder item matter item certain relationship relate transaction director independence item principal accountant fee service item exhibit financial statement schedule signature consent independent register public accounting firm tem business merck inc merck company global researchdriven pharmaceutical company discover develop manufacture market broad range innovative product improve human animal health company operation principally manage product basis comprise reportable segment pharmaceutical segment vaccine segment pharmaceutical segment include human health pharmaceutical product market directly joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization institution vaccine segment include human health vaccine product market directly joint venture product consist preventative pediatric adolescent adult vaccine primarily administer physician office merck sell human health vaccine primarily physicians wholesaler physician distributor government entity company professional representative communicate effectiveness safety value pharmaceutical vaccine product health care professional private practice group practice manage care organization financial information information pharmaceutical segment vaccine segment item management discussion analysis financial condition result operation item financial statement supplementary datum overview merck continue execute strategy reclaim leadership position pharmaceutical industry evident successful launch novel medicine vaccine areas cancer prevention diabete advancement drug candidate phase company pipeline continue success new inline product additionally company develop new commercial model design broaden engagement customer scientific leader leverage alternative channel complement effectiveness sale force drive growth key market product receive food drug administration fda approval gardasil quadrivalent human papillomavirus type recombinant vaccine vaccine prevention cervical cancer genital wart cause certain type human papillomavirus hpv januvia sitagliptin phosphate medicine class enhance natural body system improve blood sugar control patient type diabete zostavax zoster vaccine live okamerck vaccine adult year age old reduce incidence shingle disease year afflict estimate million people united states rotateq rotavirus vaccine live oral pentavalent pediatric vaccine help prevent rotavirus gastroenteritis infant child effect life nearly child age worldwide year zolinza vorinostat novel medicine treat patient suffer advanced cutaneous tcell lymphoma ctcl addition company drug candidate currently fda review janumet previously refer mka investigational oral medicine combine sitagliptin phosphate metformin type diabete design provide additional treatment option patient need oral agent help control blood sugar emend injection intravenous therapy chemotherapyinduce nausea vomit cinv arcoxia merck selective cox inhibitor osteoarthritis additionally company anticipate file new drug application nda fda firstinclass hiv integrase inhibitor gaboxadol novel compound mercks alliance lundbeck treatment insomnia mka extendedrelease niacin combine laropiprant novel flush pathway inhibitor cholesterol management addition midyear merck expect product phase iii development additionally target acquisition year sirna therapeutics inc sirna glycofi inc glycofi abmaxis inc abmaxis alliance collaboration complement merck strong internal research capability continue help company build pipeline support longterm growth merck working deliver innovative differentiate product market fast efficiently company successfully reduce late development product cycle time anticipate reduction come year additionally merck new commercial model expect low spending primary care brand united states interim target reduction expect achieve end appropriately support product launch illustrate successful launch new product redeployment launch achieve increase sale force initial phase global restructuring program design reduce company cost structure increase efficiency enhance competitiveness underway initial step include implementation new supply strategy merck manufacturing division intend create lean costeffective customer focus manufacturing model threeyear period program merck announce plan sell close manufacture site preclinical site end manufacture site close sell cease operation preclinical site close end eliminate approximately position companywide approximately position eliminate end comprise actual headcount reduction elimination contractor vacant position company continue hire new employee company business require company sell certain facility relate asset connection restructure program pretax cost restructure program million comprise million primarily represent accelerate depreciation asset impairment cost million separation restructure relate cost expect million million end initial phase restructuring program relate manufacturing strategy expect substantially complete cumulative pretax cost program expect range billion billion merck continue expect initial phase cost reduction program yield cumulative pretax saving billion respect vioxx litigation date vioxx product liability lawsuit plaintiff claim schedule trial claim seven dismiss claim seven withdraw trial calendar plaintiff jury decide merck favor time plaintiff favor time addition recent california trial involve plaintiff jury reach verdict plaintiff mistrial declare new jersey state judge set aside merck verdict respect plaintiff verdict merck file appeal seek judicial review case federal judge overturn damage award shortly trial addition consolidated trial plaintiff currently ongoing coordinate proceed new jersey superior court judge carol higbee trial commence state court illinois company spend million aggregate include million fourth quarter vioxx legal defense cost worldwide company record charge million increase reserve solely future legal defense cost relate vioxx litigation december balance reserve million reserve base certain assumption good estimate company believe time spend vioxx litigation fully discuss item legal proceeding earning common share assume dilution include impact global restructuring program share acquire research charge relate acquisition sirna share acquire research charge relate acquisition glycofi share discuss acquisition additional reserve establish solely future legal defense cost vioxx litigation discuss item legal proceeding impact adopt new accounting standard require expense stock option discuss item management discussion analysis financial condition result operation product sale sale company product follow million singulair cozaarhyzaar fosamax zocor primaxin cosopttrusopt proscar vasotecvaseretic cancidas maxalt propecia vioxx vaccinesbiological total present net discount return amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder singulair montelukast sodium leukotriene receptor antagonist respiratory product chronic treatment asthma relief symptom allergic rhinitis cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate company significant hypertension andor heart failure product fosamax alendronate sodium fosamax plus alendronate sodiumcholecalciferol merck osteoporosis product treatment case fosamax prevention osteoporosis zocor simvastatin merck atherosclerosis product primaxin imipenem cilastatin sodium cancidas caspofungin acetate antibacterialantifungal product cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution largestselle ophthalmological product proscar finasteride urology product treatment symptomatic benign prostate enlargement maxalt rizatriptan benzoate acute migraine product propecia finasteride product treatment male pattern hair loss product include vaccinesbiological varivax varicella virus vaccine live okamerck vaccine help prevent chickenpox mmr measles mumps rubella virus vaccine live vaccine measle mump rubella proquad measle mump rubella varicella okamerck virus vaccine live pediatric combination vaccine measle mump rubella varicella gardasil vaccine prevention cervical cancer genital wart cause certain type hpv pneumovax pneumococcal vaccine polyvalent vaccine prevention pneumococcal disease rotateq vaccine help protect rotavirus gastroenteritis infant child zostavax vaccine help prevent shingles herpe zoster primarily include sale human pharmaceutical pharmaceutical animal health supply sale company joint venture revenue company relationship astrazeneca primarily relate sale nexium esomeprazole magnesium prilosec omeprazole product approval february fda approve rotateq pediatric vaccine prevent rotavirus gastroenteritis infant child rotateq oral pentavalent threedose liquid vaccine contain reassortant rotavirus merck submit application licensure rotateq country include australia canada countries asia latin america sanofi pasteur msd spmsd mercks vaccine joint venture sanofi pasteur european union rotateq receive regulatory approval mexico november fda approve zostavax prevention herpe zoster shingle individual year age old approve regulatory authority australia zostavax medical option approve prevention shingle june fda approve gardasil vaccine prevent cervical cancer vulvar vaginal precancer cause hpv type prevent lowgrade precancerous lesion genital wart cause hpv type united states estimate approximately woman diagnose cervical cancer year approximately woman die october fda approve oral zolinza treatment cutaneous manifestation patient ctcl form nonhodgkin lymphoma progressive persistent recurrent disease follow systemic therapy ctcl cancer tcell type white blood cell affect skin october fda approve januvia dipeptidyl peptidase dpp inhibitor available united states treatment type diabetes januvia approve monotherapy addon therapy type oral diabete medication metformin thiazolidinedione improve blood sugar glucose control patient type diabete diet exercise june centers disease control prevention cdc advisory committee immunization practice acip unanimously vote recommend child year age routinely receive second dose varicellacontaine vaccine help protect chickenpox committee recommend child adolescent adult receive dose varicellacontaine vaccine receive second catchup dose accomplish routine healthcare visit school collegeentry requirement merck varivax combination vaccine proquad vaccine help protect chickenpox available united states voluntary withdrawal vioxx september merck announce voluntary worldwide withdrawal vioxx arthritis acute pain medication company decision effective immediately base new threeyear datum prospective randomize placebocontrolle clinical trial approve adenomatous polyp prevention vioxx trial stop design evaluate efficacy vioxx prevent recurrence colorectal polyp patient history colorectal adenomas combination trial assess cardiovascular safety vioxx study increase relative risk confirm cardiovascular event heart attack stroke apparent beginning month treatment patient take vioxx compare take placebo approximately month approve study vioxx placebo curve appear similar respect approve result similar result placebocontrolle study describe label vioxx time withdrawal company estimate million prescription write vioxx august base estimate company estimate number patient take vioxx united states launch approximately million number patient outside united states take vioxx undetermined time october company receive letter senator charles grassley chairman senate committee finance request certain document information relate vioxx company receive request information congressional committee company cooperate inquiry continue describe reason company voluntary withdrawal vioxx answer question relate company development extensive testing medicine disclosure result study february fda hold joint meeting arthritis advisory committee drug safety risk management advisory committee committee discuss overall benefittorisk consideration include cardiovascular gastrointestinal safety concern cox selective nonsteroidal antiinflammatory drug relate agent february member committee ask vote overall risk versus benefit profile vioxx support marketing united states member committee vote support marketing vioxx united states company look forward discussion fda regulatory authority vioxx previously announce board director company appoint special committee review company action prior voluntary withdrawal vioxx act board respond shareholder litigation matter relate withdrawal vioxx advise board respect action take result review december special committee retain honorable john martin debevoise plimpton llp conduct independent investigation senior management conduct respect cardiovascular safety profile vioxx period vioxx develop market review complete quarter report include appendix public september company provide copy report appendice website wwwmerckcomnewsroomvioxxmartinreporthtml company include website address inactive textual reference intend active link website incorporate reference information contain acquisition merck acquire abmaxis privatelyheld biopharmaceutical company dedicate discovery optimization monoclonal antibody mab product human therapeutic diagnostic approximately million june merck acquire glycofi privatelyheld biotechnology company leader field yeast glycoengineere addition specific carbohydrate modification protein yeast optimization biologic drug molecule approximately million december merck acquire sirna publiclyheld biotechnology company leader develop new class medicine base rna interference rnai technology total value approximately billion acquisition sirna expect increase merck ability use rnai technology turn target gene human cell potentially render inoperative gene responsible trigger specific disease joint venture company number joint venture relate pharmaceutical vaccine segment harmaceutical company scheringplough corporation scheringplough enter agreement create separate equallyowne partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area december cholesterolmanagement partnership agreement expand include country world exclude japan october zetia ezetimibe market ezetrol outside united states new class cholesterollowere agent launch united states july vytorin market inegy outside united states combination product contain active ingredient zetia zocor approve united states company enter agreement astra astra develop market astra product united states company astra form equally own joint venture develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach line company astra restructure joint venture company acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical partnership company maintain limited partner interest partnership rename astrazeneca exclusive distributor product kbi retain right company earn certain partnership return ongoing revenue base sale current future kbi product partnership return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent company share undistribute partnership gaap earning conjunction restructure payment million astra purchase option buy company interest kbi product exclude company interest gastrointestinal medicine nexium prilosec company grant astra option share option buy company common stock interest kbi exercise price base present value estimate future net sale nexium prilosec april astra merged zeneca group plc form astrazeneca astrazeneca result merger exchange company relinquishment right future astra product exist pende patent time merger astra pay million subject trueup calculation require repayment portion merger trigger partial redemption company limited partner interest furthermore result merger astrazenecas option buy company interest kbi product exercisable company right require astrazeneca purchase interest addition share option exercisable year astra purchase company interest kbi product exercise option astra provide year combine annual sale product fall minimum provide case long merck option astrazenecas option exercise exercise price base present value estimate future net sale nexium prilosec determine time exercise company form joint venture johnson johnson develop market broad range nonprescription medicine consumer own joint venture expand europe canada significant joint venture product pepcid famotidine overthecounter form company ulcer medication pepcid famotidine pepcid complete overthecounter product combine company ulcer medication antacid calcium carbonate magnesium hydroxide march company sell johnson johnson interest european joint venture accine company connaught laboratories inc sanofi pasteur agree collaborate development marketing combination pediatric vaccine promote select vaccine united states combination vaccine development effort continue agreement vaccine currently promote company pasteur mrieux connaught sanofi pasteur form joint venture market human vaccine europe collaborate development combination vaccine distribution exist european free trade association company sanofi pasteur contribute thing european vaccine business equal share joint venture know pasteur mrieux msd snc sanofi pasteur msd snc joint venture maintain presence directly affiliate branches belgium italy germany spain france austria ireland sweden portugal netherlands switzerland united kingdom distributor rest territory ther company rhnepoulenc sanofiaventis combine respective animal health poultry genetic business form merial limited merial fully integrate animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie competition market company conduct business highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access competition involve intensive search technological innovation ability market innovation effectively longstanding emphasis research development company prepare compete search technological innovation additional resource meet competition include quality control flexibility meet customer specification efficient distribution system strong technical information service company active acquire marketing product joint venture license refine sale marketing effort address change industry condition enhance product portfolio company continue pursue external alliance earlystage latestage product opportunity include joint venture target acquisition introduction new product process competitor result price reduction product replacement product protect patent example number compound available treat disease typically increase time result slow growth sale certain company product legislation enact states united states particularly area human pharmaceutical product allow encourage instance absence specific instruction prescribe physician mandate use generic product contain active chemical innovator product brandname product governmental pressure dispense generic product significantly reduce sale certain company product long protect patent zocor lose market exclusivity company experience significant decline zocor sale distribution company sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization institution human health vaccine sell primarily physician wholesaler physician distributor government entity company professional representative communicate effectiveness safety value company pharmaceutical vaccine product health care professional private practice group practice manage care organization fourth quarter company implement new distribution program wholesaler moderate fluctuation sale cause wholesaler investment buying improve efficiency distribution company pharmaceutical product new program lower previous limit average monthly purchase company pharmaceutical product customer follow implementation program fluctuation sale cause wholesaler investment buy significantly moderate raw material raw material supply generally available multiple source purchase worldwide normally available quantity adequate meet need company pharmaceutical vaccine segment government regulation investigation pharmaceutical industry subject global regulation regional country state local agency particular importance fda united states administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states food drug administration modernization act fda modernization act pass culmination comprehensive legislative reform effort design streamline regulatory procedure fda improve regulation drug medical device food legislation principally design ensure timely availability safe effective drug biologic expedite premarket review process new product key provision legislation reauthorization prescription drug user fee act permit continue collection user fee prescription drug manufacturer augment fda resource earmark review human drug application help provide resource necessary ensure prompt approval safe effective new drug united states government expand health care access enact medicare prescription drug improvement modernization act sign law december prescription drug coverage begin january legislation support company goal improve access medicine expand insurance coverage preserve marketbase incentive pharmaceutical innovation time legislation ensure prescription drug cost control competitive pressure encourage appropriate use medicine address costcontainment pressure company continue effort demonstrate medicine help save cost overall patient health care year pharmaceutical industry federal state oversight approval process new drug drug safety advertising promotion drug purchasing reimbursement program formulary variously review company believe continue able conduct operation include introduction new drug market regulatory environment type federal initiative contain federal health care spending prospective capitate payment system implement reduce rate growth medicare reimbursement hospital system establish advance flat rate reimbursement health care patient payor fiscally responsible type payment system cost containment system widely public private payor cause hospital health maintenance organization customer company costconscious treatment decision include decision medicine available patient company continue work private federal employer slow increase health care cost company effort demonstrate medicine help save cost area encourage use company medicine helped offset effect increase cost pressure federal state government pursue method directly reduce cost drug vaccine pay example federal law require company pay specify rebate medicine reimburse medicaid provide discount outpatient medicine purchase certain public health service entity disproportionate share hospital hospital meet certain criterion provide minimum discount define nonfederal average manufacturer price purchase certain component federal government department veterans affairs department defense initiative state seek rebate minimum require medicaid legislation case patient eligible medicaid federal vaccine child entitlement program cdc fund purchase recommend pediatric vaccine public sector price immunization medicaideligible uninsured native american certain underinsured child company award cdc contract april effect march supply pediatric vaccine vaccine child program aggregate estimate value million signing january patient previously eligible medicaid medicare beneficiary year old disabled leave state administer medicaid system cover new medicare prescription drug benefit outside united states company encounter similar regulatory legislative issue country business primary thrust governmental inquiry action determine drug safety effectiveness mechanism control price reimbursement prescription drug profit prescription drug company adopt directive concern classification label advertise wholesale distribution approval marketing medicinal product human use company policy procedure consistent substance directive consequently believe material effect company business company subject jurisdiction regulatory agency subject potential administrative action action include seizure product civil criminal sanction certain circumstance company deem advisable initiate product recall company believe able compete effectively environment addition certain country recognize economic importance researchbase pharmaceutical industry value innovative medicine society work industry representative european commission proposal complete single market pharmaceutical improve competitive climate variety mean include market deregulation company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business patent trademarks license patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product pharmaceutical formulation process intermediate useful manufacture product use product protection individual product extend vary period accordance legal life patent country protection afford vary country country depend type patent scope coverage patent portfolio develop product introduce company normally provide market exclusivity basic patent effect follow major product united states cancidas comvax haemophilus conjugate hepatitis recombinant vaccine cosopt cozaar crixivan emend fosamax gardasil hyzaar invanz ertapenem sodium maxalt primaxin propecia recombivax hepatitis vaccine recombinant rotateq singulair januvia trusopt zolinza zostavax basic patent effect united states zetia vytorin develop merckscheringplough partnership basic patent effect sustivastocrin efavirenz bristolmyers squibb bms exclusive license company sell sustiva united states canada certain european country company market stocrin country world basic patent aggrastat tirofiban hydrochloride united states divest product company retain basic patent aggrastat outside united states fda modernization act include pediatric exclusivity provision provide additional month market exclusivity united states indication new currently market drug certain agree pediatric study complete applicant exclusivity provision reauthorize october good pharmaceuticals child act pass january fda grant additional month market exclusivity united states invanz august fda grant additional month market exclusivity united states trusopt october fda grant additional month market exclusivity united states cozaarhyzaar february fda grant additional month market exclusivity united states singulair august information respect company patent patent litigation expiration product patent normally result loss market exclusivity cover pharmaceutical product commercial benefit continue derive latergrante patent process intermediate relate economical method manufacture active ingredient product patent relate use product iii patent relate novel composition formulation united states market exclusivity available federal law effect product patent expiration pharmaceutical product depend factor nature market position product growth market complexity economic process manufacture active ingredient product requirement new drug provision federal food drug cosmetic act similar law regulation country addition market exclusivity seek united states country relevant law include law increase patent life benefit increase patent life partially offset general increase number incentive use generic product additionally improvement intellectual property law seek united states country reform patent relevant law implementation international treaty june zocor lose market exclusivity united states company experience significant decline zocor sale time june basic patent united states cover proscar expire result company experience significant decline proscar sale time basic patent proscar cover propecia propecia protect additional patent expire october fda grant additional month market exclusivity united states fosamax february fosamax weekly january january court appeal federal circuit washington find company patent claim onceweekly administration fosamax invalid company exhausted option appeal decision base court appeal decision fosamax lose market exclusivity united states february fosamax plus lose market exclusivity april company expect significant decline product sale product respective loss market exclusivity worldwide company important product sell trademark consider aggregate material importance trademark protection continue country long country long register registration fix term renew indefinitely royalty receive patent knowhow license right amount million company pay royalty amount million patent knowhow license hold esearch development company business characterize introduction new product new use exist product strong research development program approximately people employ company research activity expenditure company research development program billion billion billion company maintain ongoing commitment research broad range therapeutic area clinical development support new product company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development merck new research development model design increase productivity improve probability success prioritize company research development resource priority disease area alzheimer disease atherosclerosis cardiovascular disease diabete novel vaccine obesity oncology target therapy pain sleep disorder therapeutic area carefully choose base set criterion include unmet medical need scientific opportunity commercial opportunity therapeutic area merck commit resource achieve research breadth depth develop bestinclass target differentiate product value highly patient payer physician company focus investment pursue specific mechanism follow select disease area antibiotic antifungal antiviral hepatitis virus human immunodeficiency virus asthma chronic obstructive pulmonary disease neurodegeneration ophthalmology osteoporosis schizophrenia stroke addition company capitalize select opportunity outside area continue commercialize attractive clinical development candidate pipeline pursue appropriate external licensing opportunity development human health product industry practice government regulation united states foreign country provide determination effectiveness safety new chemical compound preclinical test control clinical evaluation new drug market united states record datum preclinical clinical experience include nda biologic license application fda require approval development certain product subject government regulation cover safety efficacy united states foreign country company scientist discover new compound believe promise treat medical condition company commence preclinical testing compound preclinical testing include laboratory testing animal safety study gather data chemistry pharmacology toxicology pende acceptable preclinical datum company initiate clinical testing accordance establish regulatory requirement clinical testing begin phase study design assess safety tolerability pharmacokinetic preliminary pharmacodynamic activity compound human favorable additional large phase study initiate determine efficacy compound affect population define appropriate dosing compound identify adverse effect limit compound usefulness datum phase trial satisfactory company commence largescale phase iii trial confirm compound efficacy safety completion trial satisfactory company submit regulatory filing appropriate regulatory agency world product candidate approve marketing assurance compound result particular program obtain regulatory approval necessary market united states fda approval process begin complete nda submit receive fda pursuant prescription drug user fee act fda review period target nda supplemental nda month priority review month standard review day receipt nda fda determine application sufficiently complete permit substantive review fda assess time application grant priority review standard review review timeline define fda act application timeline major amendment submit company initiative fda request pende application occur fda extend review period allow review new information day extension review period communicate company fda act application issue approval letter nonapprovable letter approvable letter base fda statistics drug development time initiation preclinical testing nda approval range year average year company drug candidate currently fda review june fda accept standard review nda intravenous prodrug emend treatment cinv company anticipate decision nda second quarter july fda accept standard review nda janumet company investigational oral medicine combine januvia metformin design provide additional treatment patient need oral agent help control blood sugar treatment type diabetes company expect fda action nda end march company move forward plan regulatory filing country outside united states arcoxia company investigational selective cox inhibitor remain standard review fda united states response fda approvable letter merck include result medal multinational etoricoxib diclofenac arthritis longterm program show rate confirm thrombotic cardiovascular event similar arcoxia diclofenac widely nonsteroidal anti inflammatory drug world company anticipate fda action april company expect fda advisory committee meeting hold prior fda action arcoxia currently available country europe latin america asiapacific region middle eastnorthern africa company anticipate file nda fda company plan file nda fda second quarter receive fast track designation indication treatmentexperience patient interim week datum doserange phase trial company investigational hiv integrase inhibitor patient advance hiv infection present annual conference retroviruse opportunistic infection february result show oral investigational medication dose study combination optimize background therapy obt great antiretroviral activity obt study result show combination obt generally tolerate patient fail antiretroviral therapy art resistant drug available class oral art limit active art option treatment american society microbiologys annual international conference antimicrobial agent chemotherapy september company present interim week datum ongoing study treatmentexperience patient demonstrate maintain viral load regression august international aids conference company present interim week datum phase doserange trial conduct treatmentnave hivinfecte patient datum show twice daily combination tenofovir lamivudine achieve comparable viral load reduction efavirenz combine agent previously untreate patient september american society microbiologys annual international conference antimicrobial agent chemotherapy company present additional interim week datum phase doseranging study treatmentnave patient demonstrate increase lipid level patient take tenofovir lamivudine company enter phase iii clinical trial mka support mkb investigational therapy lipid management mka represent novel approach lower ldlc raise hdlc lower triglyceride mkb combine mka prove benefit simvastatin potentially reduce risk coronary heart disease statin provide company plan file mka fda file mkb november company present data phase study american heart association scientific session chicago show coadministration niacin significantly reduce flush patient dyslipidemia compare patient take niacin flush characterize redness skin warm burn face neck cause dilation blood vessel near skin common niacininduce effect cause discomfort patient significant factor lead discontinuation niacin therapy october company lundbeck denmark announce submission nda gaboxadol novel investigational drug phase iii development treatment insomnia occur mid phase clinical study gaboxadol show improved sleep quality increase slowwave sleep suppress rem sleep december merck announce gaboxadol likely schedule compound midyear merck expect product phase iii development include discuss company initiate target phase iii program investigational compound treatment obesity investigational cannabinoid receptor inverse agonist result early clinical study indicate demonstrate significant weightloss efficacy versus placebo generally safe welltolerate report cannabinoid receptor inverse agonist psychiatric adverse experience observe announce december company plan start phase iii testing calcitonin gene relate peptide receptor antagonist treatment migraine headache phase iii program expect commence quarter announce december company anticipate cathepsin inhibitor treatment osteoporosis enter phase iii test mid company clinical pipeline include candidate follow area arthritis atherosclerosis cancer cardiovascular disease diabete endocrine disorder glaucoma infectious disease insomnia neurodegenerative disease obesity osteoporosis psychiatric disease pain respiratory disease urogenital disorder company supplement internal research aggressive licensing external alliance strategy focus entire spectrum collaboration early research latestage compound new technology company complete transaction include targeted acquisition research collaboration preclinical clinical compound technology transaction broad range therapeutic category march neuromed pharmaceuticals ltd neuromed merck sign research collaboration license agreement research develop commercialize novel compound treatment pain neurological disorder include neuromed lead compound nme currently phase development treatment pain march merck sign agreement nicox nicox collaborate development new antihypertensive drug nicoxs proprietary nitric oxidedonate technology september company announce expand scope exist strategic collaboration foxhollow technology inc foxhollow atherosclerotic plaque analysis addition merck acquire stake foxhollow purchase million common stock october ambrilia biopharma inc ambrilia biopharmaceutical company develop innovative therapeutic field cancer infectious disease merck announce ambrilia enter exclusive licensing agreement grant merck worldwide right ambrilias hivaid protease inhibitor program november david gladstone institutes merck announce major collaboration license agreement research development drug treat neurodegenerative disease include alzheimer disease link apoeregulated mechanism body november advinus therapeutic ltd advinus merck announce form drug discovery clinical development collaboration area metabolic disorder advinus merck work develop clinically validate drug candidate metabolic disorder merck retain right advance promise candidate latestage clinical trial december merck idera pharmaceutical idera announce form broad collaboration research develop commercialize idera tolllike receptor agonist incorporate therapeutic prophylactic vaccine develop merck oncology infectious disease alzheimer disease chart reflect company current research pipeline february candidate show phase iii include specific product candidate show phase include advanced compound specific mechanism give therapeutic area backup compound regardless phase development additional indication therapeutic area additional line extension formulation inline product show phase alzheimer disease atherosclerosis cancer cardiovascular diabete phase endocrine glaucoma infectious disease aureus flu insomnia osteoporosis parkinson disease psychiatric disease phase alzheimer disease arthritis mkatherosclerosis cancer diabete endocrine hiv hpv infectious disease pediatric migraine osteoporosis overactive bladder pain respiratory disease stroke phase iii atherosclerosis mkb mka niacin laropiprant hiv raltegravir insomnia gaboxadol obesity taranabant fda review cinv emend injection diabete janumet osteoarthritis arcoxia approval rotavirus gastroenteritis rotateq shingles zostavax cervical cancer genital wart gardasil diabete januvia cancer ctcl zolinza licensed alliance acquisition pipeline multiple license include csl ltd proofofconcept moleculeall product service mark appear type form different surround text trademark service mark own license merck subsidiary affiliate include zetia vytorin trademark own entity merckscheringplough partnership note cozaar hyzaar register trademark pont nemours company wilmington prilosec nexium trademark astrazeneca group trademark vasotec vaseretic own biovail laboratory incorporate trademark aggrastat own guilford pharmaceuticals inc mployee end company approximately employee worldwide approximately employ united state include puerto rico approximately worldwide employee company represent collective bargaining group costreduction initiative announce october complete end company eliminate position company complete similar program position eliminate december november company announce phase global restructuring program design reduce company cost structure increase efficiency enhance competitiveness initial step include implementation new supply strategy merck manufacturing division intend create lean costeffective customerfocused manufacturing model threeyear period result merck incur certain cost associate exit disposal activity global restructure program company expect eliminate approximately position manufacture division worldwide represent global work force end half position reduction expect occur united states remainder country december approximately position eliminate company inception program approximately eliminate comprise actual headcount reduction elimination contractor vacant position company continue hire new employee company business require merck intend sell close manufacture facility worldwide preclinical site reduce operation number site end manufacture facility close sell cease operation preclinical site close company sell certain facility relate asset connection restructuring program remain site identify saleclosure expect closed end subject compliance legal obligation pretax cost restructure million million expect million million end initial phase restructuring program substantially complete cumulative pretax cost restructuring activity announce november expect range billion billion approximately cumulative pretax cost non cash relate primarily accelerate depreciation facility schedule closure nvironmental matter company believe compliance material respect applicable environmental law regulation company incur capital expenditure approximately million environmental protection facility company remediate environmental contamination result past industrial activity certain site expenditure remediation environmental liability million estimate million year amount consider potential recovery insurer party company take active role identify provide cost management opinion liability environmental matter probable reasonably estimable accrue total million december possible predict certainty outcome environmental matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year eographic area information company operation outside united states conduct primarily subsidiarie sale worldwide subsidiary outside united states sale sale sale company worldwide business subject risk currency fluctuation governmental action governmental proceeding abroad company regard risk deterrent expansion operation abroad company closely review method operation adopt strategy responsive change economic political condition recent year company expand operation country locate latin america middle east africa eastern europe asia pacific change government policy economic condition make possible company earn fair return business develop area stable offer important opportunity growth time financial information geographic area company business discuss item financial statement supplementary datum vailable information company internet website address wwwmerckcom company available free charge investor information portion website annual report quarterly report form current report form amendment report file furnish pursuant section security exchange act amend soon reasonably practicable report electronically file furnish securities exchange commission sec companys corporate governance guideline charter board director seven stand committee available company website wwwmerckcomaboutcorporategovernance information available print stockholder request company tem risk factor carefully consider information set forth include follow risk factor decide invest company security risk one company face additional risk currently know company company presently deem immaterial impair business operation company business financial condition result operation prospect materially adversely affect risk contain forward look statement involve risk uncertainty company result materially differ anticipate forwardlooke statement result certain factor include risk face describe cautionary factor affect future result company face significant litigation relate vioxx september company voluntarily withdraw vioxx arthritis acute pain medication market worldwide december approximately product liability lawsuit involve approximately plaintiff group allege personal injury result use vioxx file company state federal court united states company defendant approximately purport class action relate use vioxx suit refer vioxx product liability lawsuit addition vioxx product liability lawsuit purport class action individual lawsuit bring company current officer director company allege company false misleading statement vioxx violation federal state security law suit refer vioxx security lawsuit addition putative class action bring company current employee officer director company allege violation employee retirement income security act erisa suit refer vioxx erisa lawsuit addition shareholder derivative suit previously file dismiss appeal shareholder file demand company assert claim board member company officer suit demand refer vioxx derivative lawsuit vioxx security lawsuit vioxx erisa lawsuit vioxx shareholder lawsuit company name defendant action country outside united states suit refer vioxx foreign lawsuit company sue state respect marketing vioxx company anticipate additional lawsuit relate vioxx file andor certain current officer director future sec conduct formal investigation company concern vioxx department justice issue subpoena request information relate company research marketing selling activity respect vioxx federal health care investigation criminal statute ongoe investigation certain congressional committee local authority europe group attorney general thirtyone state district columbia conduct investigation company sale marketing vioxx company cooperate authority investigation investigation refer vioxx investigation company predict outcome investigation result potential civil andor criminal liability date vioxx product liability litigation plaintiff claim schedule trial claim seven dismiss claim seven withdraw trial calendar plaintiff jury decide merck favor time plaintiff favor time addition recent california trial involve plaintiff jury reach verdict plaintiff mistrial declare new jersey state judge set aside merck verdict respect plaintiff verdict merck file appeal seek judicial review case federal judge overturn damage award shortly trial addition consolidated trial plaintiff currently ongoing coordinate proceed new jersey superior court judge higbee trial commence state court illinois vioxx product liability litigation discuss fully item legal proceeding outcome vioxx product liability trial interpret indicate trend outcome likely future vioxx trial company currently anticipate number vioxx product liability lawsuit try trial oregon security case schedule company predict trial proceed schedule timing vioxx shareholder lawsuit trial company believe meritorious defense vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit vigorously defend company insurance coverage respect vioxx lawsuit adequate cover defense cost loss company spend million include million fourth quarter aggregate legal defense cost worldwide relate vioxx product liability lawsuit vioxx shareholder lawsuit iii vioxx foreign lawsuit vioxx investigation collectively vioxx litigation quarter company record charge million fourth quarter record charge million increase reserve solely future legal defense cost relate vioxx litigation million december million december reserve base certain assumption describe legal proceeding good estimate company believe time spend company currently able estimate damage require pay connection vioxx lawsuit vioxx investigation proceeding expect continue year currently early stage company little information course proceeding view inherent difficulty predict outcome litigation particularly claimant claimant seek unspecified damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit company establish reserve potential liability relate vioxx lawsuit vioxx investigation series unfavorable outcome vioxx lawsuit vioxx investigation result payment substantial damage fine result criminal penalty material adverse effect company business cash flow result operation financial position prospect certain company major product go lose patent protection near future occur company expect significant decline sale product company depend patent provide exclusive marketing right product period time product patent company product recently expire expire united states country company face strong competition low price generic drug loss patent protection company product typically lead rapid loss sale product lower price generic version drug available case product contribute significantly company sale loss patent protection material adverse effect company result operation june zocor companys statin modifying cholesterol lose market exclusivity united states zocor lose basic patent protection market world company experience significant decline zocor sale worldwide sale zocor billion compare billion worldwide sale zocor expect billion billion september company appeal decision opposition division opposition division european patent office epo revoke company patent europe cover onceweekly administration alendronate decision uphold presently company entitle market exclusivity fosamax major european market addition merck basic patent covering use alendronate challenge european country company receive adverse decision germany holland united kingdom decision united kingdom upheld appeal company appeal decision germany holland company expect significant decline european sale fosamax loss exclusivity sale fosamax outside united states adversely affect availability generic alendronate sodium product market include united kingdom canada germany january court appeal federal circuit washington find company patent claim onceweekly administration fosamax invalid company exhausted option appeal decision base court appeal decision fosamax fosamax plus lose market exclusivity united states february april respectively company expect significant decline fosamax fosamax plus sales united states product respective loss market exclusivity company research development effort succeed develop commercially successful product company able acquire commercially successful product way consequence company able replace sale successful product lose patent protection like major pharmaceutical company order remain competitive company continue launch new product year decline sale product zocor fosamax mean company future success dependent pipeline new product include new product develop joint venture product able obtain license acquisition accomplish company commit substantial effort fund resource research development dedicate resource collaboration party support research development effort company ongoing substantial expenditure assurance effort funding result commercially successful product company commit substantial effort fund resource recruit retain high quality scientist personnel pharmaceutical research development expertise base fda statistics drug development time initiation preclinical testing nda approval range year average year description research development process research development phase test highly regulate phase substantial risk company encounter obstacle achieve goal accordingly company abandon product invest substantial amount time money risk encounter research development process include follow preclinical testing new compound yield disappointing result clinical trial new drug successful new drug effective harmful effect new drug approve fda intend use possible obtain patent new drug sale new product disappointing company state certainty product development launch able develop license acquire compound product candidate product product launch commercially successful company maintain continuous flow successful new product successful new indication brand extension exist product sufficient cover substantial research development cost replace sale lose profitable product zocor fosamax lose patent protection displace compete product therapie failure short term long term material adverse effect company business result operations cash flow financial position prospect company product include product development market company obtain maintain regulatory approval company activity include research preclinical testing clinical trial manufacturing marketing product subject extensive regulation numerous federal state local governmental authority unite states include fda foreign regulatory authority include european commission united states fda particular importance company administer requirement cover testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceutical case fda requirement increase time money necessary develop new product bring market united states regulation outside united states primarily focus drug safety effectiveness case cost reduction fda foreign regulatory authority substantial discretion require additional testing delay withhold registration marketing approval mandate product withdrawal company successful develop new product able market product obtain require regulatory approval jurisdiction propose market new product obtain company maintain approval long plan market new product jurisdiction approval require company failure obtain approval significant delay approval process failure maintain approval jurisdiction prevent sell new product jurisdiction approval obtain company able realize revenue new product jurisdiction approval company dependent patent right patent right invalidate circumvent business adversely affect patent protection consider aggregate material importance company market human health product united states major foreign market patent cover product introduce normally provide market exclusivity important successful marketing sale product company seek patent cover product market intend sell product meaningful patent protection available company succeed obtain patent cover product party government authority challenge seek invalidate circumvent patent patent application important company business defend successfully patent right provide market exclusivity product company involve patent dispute relate challenge patent infringement similar claim company company aggressively defend important patent outside united state include file claim infringement party item legal proceeding patent litigation particular manufacturer generic pharmaceutical product time time file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company company normally respond vigorously defend patent include filing lawsuit allege patent infringement patent litigation challenge company patent costly unpredictable deprive company market exclusivity patent product case party patent prevent company marketing selling product particular geographic area important product lose patent protection profitable market sale product likely decline significantly result generic version product available company result operation adversely affect lost sale company successfully launch commercially successful replacement product company face intense competition lowercost generic product general company face increase competition lowercost generic product patent right protect product vary strength duration addition country patent protection significantly weak united states united states political pressure reduce spending prescription drug lead legislation encourages use generic product company policy actively protect patent right generic challenge company product arise time able prevent emergence generic competition product loss patent protection product typically follow promptly generic substitute reduce company sale product availability generic substitute company drug adversely affect result operation cash flow addition proposal emerge time time united states country legislation encourage early rapid approval generic drug proposal enact law worsen substantial negative effect company sale potentially result operation cash flow company face intense competition new product company product face intense competition competitor product competition increase new product enter market event competitor product safer effective effectively market sell company product alternatively case generic competition equally safe effective product sell substantially low price company product result company fail maintain competitive position material adverse effect business result operation company face pricing pressure respect product company product subject increase price pressure restriction worldwide include united state include practice manage care group institutional governmental purchasers federal law regulation relate medicare medicaid include medicare prescription drug improvement modernization act act act include prescription drug benefit individual go effect january increase purchasing power entity negotiate behalf medicare beneficiary result pricing pressure company expect pricing pressure increase future change law regulation adversely affect company business aspect company business include research development manufacturing marketing pricing sale litigation intellectual property right subject extensive legislation regulation change applicable federal state law agency regulation material adverse effect company business autionary factor affect future result cautionary statement private security litigation reform act report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forward look statement guarantee actual future result vary materially company assume obligation update forwardlooke statement company caution place undue reliance forwardlooke statement possible predict identify factor include follow significant litigation relate vioxx competition generic product company product lose patent protection increase brand competition therapeutic area important company longterm business performance difficulty uncertaintie inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process latestage product candidate fail receive regulatory approval new product candidate appear promise development fail reach market efficacy safety concern inability obtain necessary regulatory approval difficulty excessive cost manufacture andor infringement patent intellectual property right furthermore sale new product prove disappointing fail reach anticipate level pricing pressure unite states abroad include rule practice manage care group judicial decision governmental law regulation relate medicare medicaid health care reform pharmaceutical reimbursement pricing general change government law regulation enforcement thereof affect company business efficacy safety concern respect market product scientifically justified lead product recall withdrawal decline sale legal factor include product liability claim antitrust litigation governmental investigation include tax dispute environmental concern patent dispute brand generic competitor preclude commercialization product negatively affect profitability exist product lose market opportunity result delay uncertaintie approval process fda foreign regulatory authority increase focus privacy issue country world include united states legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business change tax law include change relate taxation foreign earning change accounting pronouncement promulgate standardsette regulatory body include financial accounting standard board sec adverse company economic factor company control include change inflation interest rate foreign currency exchange rate list consider exhaustive statement potential risk uncertainty risk factor tem unresolved staff comment tem property companys corporate headquarters locate whitehouse station new jersey company pharmaceutical business conduct divisional headquarters locate upper gwynedd west point pennsylvania company vaccine business conduct divisional headquarters locate west point principal research facility human health product locate rahway new jersey west point company production facility human health product location united states puerto rico branch warehouse provide service country outside united states subsidiary company own interest manufacturing plant property australia canada japan singapore south africa countries western europe central south america asia capital expenditure million compare billion united states amount million million abroad expenditure amount million million company subsidiarie principal facility manufacturing plant title consider satisfactory company consider property good operating condition machinery equipment maintain plant manufacture product suitable intend purpose capacity project capacity adequate current project need exist company product capacity plant convert need modification requirement newly introduce future product tem legal proceeding company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action ioxx litigation roduct liability lawsuit previously disclose individual putative class action file company state federal court allege personal injury andor economic loss respect purchase use vioxx action file federal court coordinate multidistrict litigation district court eastern district louisiana mdl district judge eldon fallon number action file state court coordinate separate coordinate proceeding state court new jersey california texas counties philadelphia pennsylvania clark county nevada december company serve aware name defendant approximately lawsuit include approximately plaintiff group allege personal injury result use vioxx approximately putative class action allege personal injury andor economic loss action discuss paragraph collectively refer vioxx product liability lawsuit lawsuit approximately lawsuit represent approximately plaintiff group slate federal mdl approximately lawsuit represent approximately plaintiff group include coordinate proceed new jersey superior court judge carol higbee addition vioxx product liability lawsuit discuss claim plaintiff dismiss december plaintiff claim dismiss prejudice bring plaintiff court additional plaintiff claim dismiss prejudice bring mdl judge fallon july indicate schedule trial series case period november follow category heart attack short term use heart attack long term use iii stroke cardiovascular injury involve prescription write april labeling vioxx revise include result vigor trial trial begin november conclude december schedule trial mdl retrial barnett merck issue damage discuss vioxx product liability lawsuit currently schedule trial company provide list trial website wwwmerckcom periodically update appropriate company include website address inactive textual reference intend active link website incorporate reference information contain merck enter tolling agreement tolling agreement mdl plaintiff steering committee establish procedure halt run statute limitation toll certain category claim allegedly arise use vioxx nonnew jersey citizens tolling agreement apply individual file lawsuit eventually file lawsuit claimant seek toll claim allege injury result thrombotic cardiovascular event result myocardial infarction ischemic stroke tolling agreement provide counsel additional time evaluate potential claim tolling agreement require toll claim file federal court december approximately claimants enter tolling agreement merck voluntarily withdraw vioxx market september state twoyear statute limitation product liability claim require claim file year plaintiff learn learn potential cause action result view september deadline filing vioxx case important note law statute limitation complex vary state state factspecific case affect existence pende class action example state year statute limitation instance statute limitation long merck expect legal argument concern proper application statute decision judge preside individual case state federal proceeding company previously disclose outcome vioxx product liability lawsuit try prior september chart august barnett merck case judge fallon mdl jury new orleans louisiana return plaintiff verdict second federal vioxx case trial jury award million compensatory damage million punitive damage august judge fallon overturn excessive damage portion verdict order new trial damage judge fallon set retrial october issue damage merck file motion new trial issue judgment matter law currently pende court plaintiff oppose merck motion ask judge reduce award retry case jury find favor merck count fourth fifth case trial mdl jury return verdict merck mason merck november dedrick merck december november judge fallon deny motion file mdl certify nationwide class person allegedly suffer personal injury result take vioxx december jury albright merck case try state court birmingham alabama return verdict merck count company previously disclose april garza merck jury rio grande city texas return verdict favor plaintiff september texas state court grant company request investigate possible jury bias juror admit prior trial occasion borrow money plaintiff december court enter judgment plaintiff million plus interest reduce original award million texas state cap punitive damage company seek new trial appeal verdict court grant new trial october california superior court los angeles consolidated trial begin case appell merck arrigale merck january judge victoria chaney declare mistrial plaintiff jury report deadlocke october coordinate proceed new jersey superior court judge higbee dismiss claim united kingdom plaintiff plaintiff appeal case schedule trial texas coordinate proceeding rigby merck schedule begin trial november rigby case voluntarily dismiss october plaintiff file notice nonsuit court consolidated trial herman merck humeston merck begin january coordinate proceed new jersey superior court judge higbee humeston merck try judge higbee set aside november jury verdict favor merck order new trial ground newly discover evidence hermanshumeston trial separate phase general phase merck conduct plaintiffspecific phase jury question deliberation phase merck conduct jury answer question affirmative case phase phase plaintiff present specific case end phase jury deliberate answer question respect plaintiff jury answer separate verdict sheet course deliberation case move punitive phase single presentation jury deliberation plaintiff case schedule trial philadelphia coordinate proceeding mccool merck schedule begin trial february plaintiff voluntarily dismiss prejudice case january september new jersey superior court appellate division hear argument plaintiff appeal judge higbees dismissal sinclair merck case putative class action originally file december seek creation medical monitoring fund judge higbee grant company motion dismiss january appellate division reverse decision remand case judge higbee factual inquiry company petition new jersey supreme court review appellate division decision date vioxx product liability lawsuit plaintiff claim schedule trial claim seven dismiss claim seven withdraw trial calendar plaintiff jury decide merck favor time plaintiff favor time addition recent california trial involve plaintiff jury reach verdict plaintiff mistrial declare new jersey state judge set aside merck verdict respect plaintiff verdict merck file appeal seek judicial review case federal judge overturn damage award shortly trial addition consolidated trial plaintiff currently ongoing coordinate proceed new jersey superior court judge higbee trial schwaller merck commence state court madison county illinois follow chart set forth result vioxx product liability trial date state federal verdict date plaintiff court result comment aug ernst texas verdict plaintiff jury award plaintiff million court reduce approximately million plus interest judgment appeal nov humeston verdict merck judge order new trial judge overturn currently ongoing verdict feb plunkett federal mistrial jury merck prevail february retrial deadlocke trial plaintiff move new trial verdict merck retrial april mcdarby verdict plaintiff plaintiff award million damage merck motion new trial pende plaintiff motion attorney fee april cona verdict merck jury award plaintiff failure warn claim nominal sum consumer fraud act claim merck motion new trial consumer fraud act claim pende plaintiff motion attorney fee april garza texas verdict plaintiff judge reduce million jury award million plus interest merck move new trial july doherty verdict merck plaintiff move new trial aug grossberg california verdict merck plaintiff move new trial aug barnett federal verdict plaintiff plaintiff award million damage judge rule award grossly excessive schedule new trial damage october mercks motion new trial remain issue pende sept smith federal verdict merck nov mason federal verdict merck dec dedrick federal verdict merck plaintiff move new trial dec albright alabama verdict merck plaintiff move new trial jan arrigaleappell california mistrial declare jury deadlocke ther lawsuit previously disclose july new jersey state trial court certify nationwide class party payor union health insurance plan pay vioxx plan member insureds name plaintiff case seek recovery certain vioxx purchase cost plus penalty base allegation purport class member pay vioxx know product allege risk merck believe class improperly certify trial court rule procedural address merit plaintiff allegation company intend defend vigorously march new jersey superior court appellate division affirm class certification order july new jersey supreme court decide exercise discretion hear company appeal appellate division decision august appellate division order stay proceeding superior court pende rule supreme court oral argument new jersey supreme court schedule place march previously report company name defendant separate lawsuit bring attorney general alaska louisiana mississippi montana texas utah actions allege company misrepresent safety vioxx seek recovery cost vioxx purchase reimburse state agency reimbursement sum pay state agency medical service treatment person injure vioxx iii damage common law theory andor remedy state statutory theory include state consumer fraud andor fair business practice medicaid fraud statute include civil penalty hareholder lawsuit previously disclose addition vioxx product liability lawsuit company current officer director defendant putative class action individual lawsuit federal security law state security law vioxx security lawsuit vioxx security lawsuit pende federal court transfer judicial panel multidistrict litigation jpml united states district court district new jersey district judge stanley chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx security lawsuit purpose plaintiff request certification class purchaser company stock october complaint allege defendant false misleading statement vioxx violation section securities exchange act seek unspecified compensatory damage cost suit include attorney fee complaint assert claim section security exchange act certain defendant relate sale merck stock addition complaint include allegation section security act certain defendant incomplete misleading statement registration statement certain prospectus file connection merck stock investment plan dividend reinvestment plan defendant file motion dismiss complaint oral argument motion dismiss schedule place march previously disclose august complaint file oregon state court state oregon oregon state treasurer behalf oregon public employee retirement fund company certain current officer director complaint bring oregon security law allege plaintiff suffer damage connection purchase merck common stock artificially inflate price company allege violation law relate disclosure vioxx current officer director enter tolling agreement june dismiss prejudice case july court deny company motion dismiss complaint require plaintiff amend complaint plaintiff file amend complaint september merck file motion require plaintiff complaint definite certain deny court merck file answer complaint january previously disclose shareholder derivative action file federal court transfer shareholder mdl consolidated purpose judge chesler vioxx derivative lawsuit consolidate complaint arise substantially factual allegation vioxx security lawsuit vioxx derivative lawsuit purportedly bring assert right company assert claim certain member board past present certain executive officer breach fiduciary duty waste corporate asset unjust enrichment abuse control gross mismanagement judge chesler grant defendant motion dismiss deny plaintiff request leave amend complaint plaintiff appeal district court decision refuse leave amend complaint currently pende united states court appeal circuit previously disclose october individual shareholder demand board director company legal action raymond gilmartin chairman president chief executive officer individual allegedly cause damage company respect allegedly improper marketing vioxx july board receive shareholder letter demand board legal action board management merck allegedly cause damage company relate company allegedly improper marketing vioxx december demand reject board director previously announce board director appoint special committee review company action prior voluntary withdrawal vioxx act board respond shareholder litigation matter relate withdrawal vioxx advise board respect action take result review december special committee retain honorable john martin debevoise plimpton llp conduct independent investigation senior management conduct respect cardiovascular safety profile vioxx period vioxx develop market review complete quarter report include appendix public september company provide copy report appendice website wwwmerckcomnewsroomvioxxmartinreporthtml company include website address inactive textual reference intend active link website incorporate reference information contain addition previously disclose putative class action file federal court employee retirement income security act erisa company certain current officer director vioxx erisa lawsuit vioxx security lawsuit vioxx derivative lawsuit vioxx shareholder lawsuit transfer shareholder mdl consolidated purpose consolidate complaint assert claim behalf certain company current employee participant certain company retirement plan breach fiduciary duty lawsuit similar allegation allegation contain vioxx security lawsuit october defendant move dismiss erisa complaint july judge chesler grant deny defendant motion dismiss nternational lawsuit previously disclose addition lawsuit discuss company name defendant litigation relate vioxx country collectively vioxx foreign lawsuit europe canada brazil argentina australia turkey israel dditional lawsuit base medium report source company anticipate additional vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit file andor certain current officer director future nsurance previously disclose company product liability insurance claim bring vioxx product liability lawsuit state upper limit approximately million deductible coinsurance insurance provide coverage legal defense cost potential damage amount incur connection vioxx product liability lawsuit company believe insurance coverage extend additional vioxx product liability lawsuit file future company director officer insurance coverage applicable vioxx security lawsuit vioxx derivative lawsuit state upper limit approximately million company fiduciary insurance vioxx erisa lawsuit state upper limit approximately million additional insurance coverage claim available upperlevel excess policy provide coverage variety risk dispute certain insurer availability insurance coverage likely additional dispute companys insurance coverage respect vioxx lawsuit adequate cover defense cost loss previously disclose company upper level excess insurer provide excess insurance potentially applicable vioxx lawsuit commence arbitration seek thing cancel policy void obligation policy raise coverage issue respect vioxx lawsuit merck intend contest vigorously insurer claim attempt enforce right applicable insurance policy amount actually recover policy discuss section amount specify precede paragraph nvestigation previously disclose november company advise staff sec commence informal inquiry concern vioxx january company announce receive notice sec issue formal notice investigation company receive subpoenas department justice doj request information relate company research marketing selling activity respect vioxx federal health care investigation criminal statute addition previously disclose investigation conduct local authority certain city europe order determine criminal charge bring concern vioxx company cooperate governmental entity respective investigation vioxx investigation company predict outcome inquiry result potential civil andor criminal disposition previously disclose company receive number civil investigative demand cid group attorney general state district columbia investigate company violate state consumer protection law marketing vioxx company cooperate attorney general respond cid addition company receive subpoena september state california attorney general seek document information relate placement vioxx california medical formulary company cooperate attorney general respond subpoena eserves company currently anticipate number vioxx product liability lawsuit try trial oregon security case schedule company predict trial proceed schedule timing vioxx shareholder lawsuit trial company believe meritorious defense vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit company establish reserve potential liability relate vioxx lawsuit vioxx investigation include case verdict judgment enter company postverdict proceeding appeal case company believe strong point raise appeal unfavorable outcome case probable unfavorable outcome vioxx litigation define material adverse effect company financial position liquidity result operation legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december company reserve million solely future legal defense cost relate vioxx litigation company spend million aggregate include million fourth quarter legal defense cost worldwide relate vioxx product liability lawsuit vioxx shareholder lawsuit iii vioxx foreign lawsuit vioxx investigation collectively vioxx litigation quarter fourth quarter company record charge million million respectively increase reserve solely future legal defense cost relate vioxx litigation million december increase reserve company consider factor consider previously establish reserve vioxx litigation management believe well estimate company expense reasonably estimate cost significant factor consider establishment ongoing review reserve vioxx legal defense cost follow actual cost incur company development company legal defense strategy structure light scope vioxx litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial vioxx product liability lawsuit event schedule trial expect occur inherent inability predict ultimate outcome trial limit company ability reasonably estimate legal cost end company anticipate need increase reserve quarter continue monitor legal defense cost review adequacy associate reserve determine increase reserve legal defense cost time future base factor set forth believe appropriate ther product liability litigation previously disclose company defendant product liability lawsuit unite states involve fosamax fosamax litigation december case file merck federal state court include case seek class action certification damage medical monitoring action plaintiff allege thing suffer osteonecrosis jaw generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax august jpml order fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax mdl coordinated pretrial proceeding fosamax mdl transfer judge john keenan united states district court southern district new york result jpml order case judge keenan judge keenan issue case management order set forth schedule governing proceeding focus primarily resolve class action certification motion company intend defend lawsuit december company establish reserve approximately million solely future legal defense cost fosamax litigation significant factor consider establishment reserve fosamax litigation legal defense cost follow actual cost incur company far development company legal defense strategy structure light creation fosamax mdl number case bring company anticipate timing progression relate cost pretrial activity fosamax litigation company continue monitor legal defense cost review adequacy associate reserve uncertain nature litigation company unable estimate cost end unfavorable outcome fosamax litigation material adverse effect company financial position liquidity result operation ommercial litigation begin company name number antitrust suit certain certify class action institute nation retail pharmacy consumer state company settle federal class action represent single large group claim settle substantially remain case satisfactory term remain case inactive year company engage conspiracy admission wrongdoing include settlement agreement previously disclose company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level jpml order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like company defendant prior pende case court grant company motion dismiss consolidated class action dismiss company class action case subsequent company dismissal plaintiff file amend consolidated class action complaint company defendant company pharmaceutical manufacturer defendant similar complaint pende federal state court bring individually number county state new york company defendant await final rule motion dismiss suffolk county case new york county case file addition december company defendant state case bring attorney general kentucky illinois alabama wisconsin mississippi arizona hawaii alaska defend previously disclose company name defendant antitrust case federal court minnesota state court california allege unlawful conspiracy different set pharmaceutical manufacturer protect high price united states impede importation united states lowerpriced pharmaceuticals canada court dismiss federal claim minnesota case prejudice plaintiff file notice appeal federal court appeal eighth circuit affirm dismissal federal claim state claim action dismiss prejudice refiled jurisdiction california antitrust action party engage discovery defendant manufacturer file summary judgment december court grant summary judgment favor merck defendant dismiss case plaintiff file notice appeal california state appeal court previously disclose suit federal court alabama provider health service needy patient allege pharmaceutical company overcharge plaintiff class similarly situate pharmaceutical purchase plaintiff program establish section public health service act company defendant file motion dismiss complaint numerous ground recently deny court denial motion dismiss case dismiss voluntarily party previously disclose january doj notify federal court new orleans louisiana go intervene time pende federal false claim act case file seal december company court issue order unseal complaint file physician louisiana ordered complaint serve complaint allege company discount pepcid certain louisiana hospital lead increase cost medicaid dismiss amend complaint file seal case administratively closed court seal lift state louisiana file amend complaint incorporate allegation contain seal amend complaint allegation contain seal amend complaint unknown april company name qui tam lawsuit nevada false claim act suit nevada attorney general intervene allege company inappropriately offer nominal pricing marketing pricing inducement certain customer fail comply obligation medicaid good price scheme relate arrangement company motion dismiss action deny district court company defend lawsuit overnmental proceeding previously disclose company receive subpoena doj connection investigation company marketing selling activity include nominal pricing program sample company report receive cid attorney general texas company marketing selling activity relate texas previously disclose company receive cid attorney general texas ask additional information company marketing selling activity relate texas include respect certain nominal pricing program sample april company receive subpoena office inspector general district columbia connection investigation company interaction physicians district columbia maryland virginia november company receive letter request doj connection investigation company pricing pepcid september company receive subpoena illinois attorney general subpoena seek information relate repackage prescription drug activity relate merck illinois matter previously disclose company receive letter doj advise existence qui tam complaint allege company violate certain rule relate calculation good price federal pricing benchmark calculation certain affect company medicaid rebate obligation doj inform company intend intervene action close investigation lawsuit continue company cooperate investigation company predict outcome investigation possible unfavorable outcome material adverse effect company financial position liquidity result operation addition time time federal state foreign regulator authority seek information practice pharmaceutical industry company business practice inquiry investigation discuss section feasible predict outcome inquiry previously disclose february italian antitrust authority ica adopt measure commence formal investigation merck sharp dohme italia spa msd italy company article italian competition law article ascertain company msd italy commit abuse dominant position refuse grant acs dobfar spa dobfar italian company voluntary license company italian supplementary protection certificate spc pursuant domestic legislation pass permit dobfar manufacture imipenem cilastatin active ingredient tienam italy sale outside italy country patent protection expired exist hear ica hold june ica find preliminary basis company refusal grant license abuse dominant position impose interim measure require company grant license manufacture italy stockpile purpose expiration spc november italian administrative court deny company appeal ica order company spc expire january proceeding ica continue merit article investigation effort resolve matter company offer commitment ica pursuant company grant nonexclusive license italian spc finasteride respect finasteride treatment benign prostate hyperplasia deadline ica adopt final decision company commitment warrant closure case march accine litigation previously disclose company party claim bring consumer protection act united kingdom allege certain child suffer variety condition result vaccinate bivalent vaccine measle rubella andor trivalent vaccine measle mumps rubella include company mmr condition include autism inflammatory bowel disease epilepsy encephalitis encephalopathy guillainbarre syndrome transverse myelitis claimant proceed company knowledge intend proceed company company defend lawsuit previously disclose company party individual class action product liability lawsuit claim united states involve pediatric vaccine hepatitis vaccine contain thimerosal preservative vaccine merck distribute thimerosalcontaine pediatric vaccine united states fall december approximately active thimerosal relate lawsuit approximately plaintiff defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result exposure thimerosal pediatric vaccine case schedule trial dismiss state court case ohio voluntarily dismiss plaintiff second federal district court case texas court enter summary judgment favor defendant plaintiff ultimately voluntarily dismiss appeal company defend lawsuit possible unfavorable outcome material adverse effect company financial position liquidity result operation company successful case type dismiss stay ground action prohibit national childhood vaccine injury act vaccine act vaccine act prohibit person file maintain civil action state federal court seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim hereinafter vaccine court vaccine act file civil action vaccine manufacturer petitioner pursue petition conclusion vaccine court timely file election proceed civil action lieu accept vaccine court adjudication petition timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribe time period company party vaccine court proceeding petition bring united states department health human service case trial date refer precede paragraph dismiss bring plaintiff claim timely withdrawal vaccine court petition company aware approximately case pende vaccine court involve allegation thimerosalcontaine vaccine andor mmr vaccine cause autism spectrum disorder thimerosalcontaine vaccine involve vaccine court proceeding company vaccine company sole source mmr vaccine domestically june special master preside vaccine court proceeding schedule begin hear petitioner government present evidence issue vaccine cause autism spectrum disorder hearing expect number week party company participate proceeding atent litigation time time generic manufacturer pharmaceutical product file andas fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic form fosamax prilosec nexium propecia trusopt cosopt prior expiration company astrazenecas case prilosec nexium patent concern product generic company anda generally include allegation noninfringement invalidity unenforceability patent generic manufacturer receive fda approval market generic form prilosec company file patent infringement suit federal court company file andas generic alendronate fosamax finasteride propecia dorzolamide trusopt dorzolamidetimolol cosopt astrazeneca company file patent infringement suit federal court company file andas generic omeprazole prilosec esomeprazole nexium similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product february schere plough receive notice generic company indicate file anda zetia challenge patent list zetia merck schere plough market zetia joint venture consider appropriate response february company receive notice generic company indicate file anda montelukast challenge patent list singulair company consider appropriate response previously disclose january court appeal federal circuit washington find company patent claim onceweekly administration fosamax invalid company exhausted option appeal decision base court appeal decision fosamax fosamax plus lose market exclusivity united states february april respectively company expect significant decline fosamax fosamax plus sale product respective loss market exclusivity federal court canada trial division issue decision refuse bar approval generic alendronate ground mercks patent weekly alendronate likely invalid decision appeal generic alendronate launch canada june july merck sue federal court canada apotex seek damage lose sale generic weekly alendronate patent proceeding previously disclose september company appeal decision opposition division epo revoke company patent europe cover onceweekly administration alendronate march board appeal epo uphold decision opposition division presently company entitle market exclusivity fosamax major european market addition merck basic patent covering use alendronate challenge european country company receive adverse decision germany holland united kingdom decision united kingdom upheld appeal company appeal decision germany holland june company file lawsuit federal court barr laboratories inc teva pharmaceutical industries ltd teva assert respective manufacturing process make alendronate product infringe process patent company october action australia challenge validity company australian patent onceweekly administration alendronate patent find invalid decision uphold appeal addition previously disclose japan proceeding file challenge validity company japanese patent onceweekly administration alendronate january company sue hitech pharmacal inc hitech amityville new york patent infringement response hitechs application fda seek approval generic version merck ophthalmic drug trusopt cosopt treat elevated intraocular pressure people ocular hypertension glaucoma lawsuit merck sue enforce patent cover active ingredient dorzolamide present trusopt cosopt case district court enter judgment merck favor hitech appeal hearing appeal conduct december decision pende merck elect enforce patent list fda cover combination dorzolamide timolol active ingredient cosopt lawsuit automatically stay fda approval tech andas month january adverse court decision whichever occur early patent covering dorzolamide provide exclusivity trusopt cosopt october include month pediatric exclusivity time company expect sale product decline case omeprazole trial court united states render opinion october uphold validity company astrazenecas patent cover stabilize formulation omeprazole rule defendant omeprazole product infringe patent defendant product find infringe formulation patent december court appeal federal circuit affirm decision trial court respect company patent infringement claim certain generic manufacturer omeprazole product trial conclude june decision pende company astrazeneca receive notice october ranbaxy laboratory limit ranbaxy file anda esomeprazole magnesium anda contain paragraph challenge patents nexium november company astrazeneca sue ranbaxy united states district court new jersey accordingly fda approval ranbaxys anda stay month april adverse court decision whichever occur early company astrazeneca receive notice january ivax pharmaceuticals inc subsequently acquire teva file anda esomeprazole magnesium anda contain paragraph challenge patent nexium march company astrazeneca sue teva united states district court new jersey accordingly fda approval tevas anda stay month september adverse court decision whichever occur early case finasteride anda file seek approval generic version propecia allege invalidity company patent company file patent infringement lawsuit district court delaware september company reach settlement generic company reddys laboratories drl drl sell generic finasteride product begin january europe company aware company seek registration generic losartan active ingredient cozaar company patent right losartan license pont nemour company pont company pont file patent infringement proceeding company portugal spain norway ther litigation july merck serve shareholder derivative suit file new jersey superior court hunterdon county company certain current officer director lawsuit seeks recover cancel compensation award company executive officer assert claim breach fiduciary duty waste unjust enrichment july court grant defendant motion dismiss base plaintiff failure presuit demand merck board director deny plaintiff request leave amend case terminate november individual shareholder deliver letter board allege company sustain damage company adoption change control separation benefit plan cic plan november shareholder demand board legal action board current member allegedly cause damage company respect adoption cic plan response demand letter independent member board determine november board meeting board shareholder request consideration remain consideration previously disclose august united states district court district new jersey grant motion company medco health solutions inc medco health certain officer director dismiss shareholder derivative action involve claim relate company revenue recognition practice retail copayment pay individual medco health provide pharmaceutical benefit allegation complaint dismiss prejudice plaintiff appeal decision december court appeal circuit uphold district court decision dismissing suit send issue company board director properly refuse shareholder demand relate company treatment retail copayment district court reconsideration different legal standard plaintiff move remand action state court august district court grant motion february shareholder derivative suit currently pende superior court new jersey chancery division hunterdon county previously disclose prior spinoff medco health company medco health agree settle class action basis series lawsuit assert violation erisa gruer case company medco health certain plaintiff counsel file settlement agreement federal district court new york case commence number plaintiff include participant number pharmaceutical benefit plan medco health pharmacy benefit manager trustee plan consolidated medco health company agree propose settlement order avoid significant cost distraction prolong litigation propose class settlement agree plaintiff case file medco health company propose settlement company medco health agree pay total million medco health agree modify certain business practice continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december district court hold hearing hear objection fairness propose settlement approve settlement determined number class member plan properly elect participate settlement settlement final appeal resolve certain class member plan indicate participate settlement case initiate plan individual remain pende southern district new york plaintiff case assert claim base erisa federal state law similar claim assert settle class member gruer case company medco health name defendant case notice appeal file appellate court hear oral argument december appellate court issue decision vacate district court judgment remand case district court allow district court resolve certain jurisdictional issue hear hold address issue february district court issue ruling august resolve jurisdictional issue favor settle plaintiff class member party previously appeal district court judgment renew appeal renew appeal presently brief spinoff medco health medco health assume substantially liability exposure matter discuss forego paragraph case defend medco health legal proceeding principally product liability intellectual property suit involve company pende feasible predict outcome proceeding proceeding discuss item opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company proceeding separate assessment provide item nvironmental matter company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost insurer site owner operator recalcitrant potentially responsible party june potassium thiocyanate accidentally discharge company plant west point pennsylvania upper gwynedd township authoritys wastewater treatment plant wissahickon creek cause fishkill federal state agency investigate discharge company currently cooperate investigation tem submission matter vote security holder applicable executive officer registrant age february ichard clark age april chairman chief executive officer president chief executive officer president june president merck manufacturing division responsible company manufacture information service operational excellence organization worldwide january chairman president chief executive officer medco health solutions inc medco health whollyowne subsidiary company january president medco health avid anstice age september executive vice president strategy initiative responsible endtoend global support function initiative provide strategic direction key pharmaceutical emerge market china india august president human healthasia pacific responsible company prescription drug business asia pacific region japan australia new zealand company joint venture relationship scheringplough january president human health responsible company prescription drug business japan latin america canada australia new zealand company joint venture relationship scheringplough march president america human health responsible prescription drug division comprise human health company prescription drug business canada latin america company joint venture relationship schering plough ohn canan age september vice president controller responsible corporate controller group june vice president corporate audit assurance service september vice president controller asia joint ventures responsible financial operational oversight asia human health company joint venture august controller asia pacific human health elia colbert age january vice president secretary september assistant general counsel november illie deese age president merck manufacturing division responsible company global manufacturing procurement operational excellence function january senior vice president global procurement prior january deese senior vice president global procurement logistics glaxosmithkline plc enneth frazi age november executive vice president general counsel responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company december senior vice president general counsel responsible legal public affair function merck company foundation notforprofit charitable organization affiliate company irian graddickweir age september senior vice president human resource prior september graddickweir executive vice president human resource employee communication att hold senior human resource leadership position att year communication service provider teven kelmar age august vice president public affairs prior august kelmar lead global public affair communication function novartis eter kim age january president merck research laboratory mrl february executive vice president research development mrl udy lewent age august executive vice president chief financial officer responsible company strategic plan financial corporate development function internal auditing corporate licensing company joint venture relationship merck capital ventures llc subsidiary company january executive vice president chief financial officer president human health asia responsible financial corporate development function internal auditing corporate licensing company prescription drug business asia north asia south company joint venture relationship merck capital ventures llc february executive vice president chief financial officer april responsible financial corporate development function internal auditing corporate licensing company joint venture relationship merck capital ventures llc february company announce lewent intend retire july eter loescher age president global human health responsible company marketing sale division human health human health asia pacific human health intercontinental europe middle east africa canada latin america merck vaccine prior loescher serve president chief executive officer healthcare bio sciences medical diagnostic life science business acquire amersham health loescher president amersham health chief operating officer ark mcdonough age february vice president treasurer responsible company treasury function provide financial support human resource january assistant treasurer global capital market responsible managing company investment financing portfolio treasury share repurchase program september senior director human health finance responsible provide global franchisebase financial reporting analytic key customer argaret mcglynn age august president merck vaccines global responsibility vaccine business include company sanofipasteur joint venture january president human health responsible prescription drug division hospital specialty product franchise comprise human health ushh manage care group ushh august executive vice president customer marketing sale ushh tefan oschmann age september president europe middle east africa canada april senior vice president worldwide human health marketing october executive vice president worldwide marketing january manage director msd germany subsidiary company chris scalet age january senior vice president global services chief information officer cio responsible global share service human resource finance site service information service function enterprise business process redesign initiative march senior vice president information services cio responsible area information technology service include application development technical support voice datum communication computer operation worldwide prior march scalet senior vice president information technology cio international paper company global forest product paper packaging company dam schechter age july president human health commercial responsibility united states company portfolio prescription medicine october general manager human health division responsible neuropsychiatry osteoporosis migraine respiratory new product franchise february vice presidentgeneral manager merckscheringplough pharmaceutical joint venture august vice president merck human health division arthritis analgesia franchise business group endy yarno age september chief marketing officer responsible global marketing service global alliance management global pricing global human health business practice compliance franchise oncology specialty neuroscience respiratory bone arthritis analgesia infectious disease hospital product november general manager business unit human health january executive vice president worldwide human health marketing december senior vice president human resource officer list serve pleasure board director officer elect pursuant arrangement understand officer board tem market registrant common equity relate stockholder matter issuer purchase equity security principal market trading company common stock new york stock exchange nyse symbol mrk common stock market price information set forth table base historical nyse market price follow table set forth calendar period indicate dividend share information ash dividend pay common share ear ommon stock market price high low igh low january approximately stockholders record equity compensation plan information follow table summarize information option warrant right equity compensation company equity plan close business december table include information tax qualify plan merck inc employee saving security plan number security remain available number future issuance security equity issue weightedaverage compensation plan exercise exercise price exclude outstanding outstanding security option warrant option warrant reflect column plan category right right equity compensation plan approve security holder equity compensation plan approve security holder total include option purchase share company common stock right follow stockholderapprove plan incentive stock plan incentive stock plan incentive stock plan incentive stock plan nonemployee director stock option plan non employee director stock option plan nonemployee director stock option plan exclude approximately share restrict stock unit performance share unit assume maximum payout incentive stock plan exclude share phantom stock defer merck inc deferral program december additional share reserve deferral program begin january onetenth percent outstanding share merck common stock business day precede calendar year plus share authorize deferral program issue reserve future issuance december actual share issue prospectively equal participant elect defer payout company incentive program executive incentive plan phantom stock increase dividend pay equivalent number share merck common stock divide market price merck common stock table include information equity compensation plan option warrant right assume company connection merger acquisition pursuant remain outstanding option warrant right collectively assume plan include follow medco containment services inc class nonqualified stock option plan sibia neurosciences inc equity incentive plan provantage health services inc stock incentive plan rosetta inpharmatics inc employee stock plan total share merck common stock purchase assume plan weight average exercise price grant assumed plan performance graph follow graph compare cumulative total stockholder return stock price appreciation plus reinveste dividend companys common stock cumulative total return include reinveste dividend dow jones pharmaceutical index djuspr refer dow jones pharmaceutical index united states own company standard poor index index year end december amount rounded near dollar percent comparison fiveyear cumulative total return merck inc dow jones pharmaceutical index index end period value cagr merck djuspr merck djuspr assume value investment company common stock index december dividend reinveste compound annual growth rate issuer purchase equity security month period end december follow issuer purchase equity securities tota numbe millio total share purchase approx dollar value number average share share price pay publicly announce purchase period purchase share plan program plan programs october october november november december december total share repurchase plan announce july purchase billion merck share tem select financial datum follow select financial datum read conjunction item management discussion analysis financial condition result operation consolidate financial statement note thereto contain item financial statement supplementary datum report erck inc subsidiarie million share amount esult year sale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income continue operation taxis tax income income continue operation income discontinue operation net taxis net income basic earning common share continue operation discontinue operation net income earning common share assume dilution continue operation discontinue operation net income cash dividend declare cash dividend pay common share capital expenditure depreciation yearend position work capital property plant equipment net total asset longterm debt stockholder equity financial ratio income continue operation sale net income average total asset yearend statistic average common share outstanding million average common share outstanding assume dilution million number stockholder record number employee prior year amount reflect impact retrospectively adopt security exchange commission interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile note consolidated financial statement amount include impact restructuring action acquire research expense result acquisition year additional vioxx legal defense cost incremental impact expense stock option amount include impact net tax charge primarily associate american job creation act repatriation restructuring action additional vioxx legal defense cost amount include impact withdrawal vioxx vioxx legal defense cost restructuring action amount include impact implementation new distribution program wholesaler restructuring action add result round decrease primarily reflect impact spinoff medco healthi tem management discussion analysis financial condition result operation escription merck business merck global researchdriven pharmaceutical company discover develop manufacture market broad range innovative product improve human animal health company operation principally manage product basis comprise reportable segment pharmaceutical segment vaccine segment pharmaceutical segment include human health pharmaceutical product market directly joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization institution vaccine segment include human health vaccine product market directly joint venture product consist preventative pediatric adolescent adult vaccine primarily administer physician office merck sell human health vaccine primarily physicians wholesaler physician distributor government entity company professional representative communicate effectiveness safety value pharmaceutical vaccine product health care professional private practice group practice manage care organization verview merck continue execute strategy reclaim leadership position pharmaceutical industry evident successful launch novel medicine vaccine areas cancer prevention diabete advancement drug candidate phase company pipeline continue success new inline product additionally company develop new commercial model design broaden engagement customer scientific leader leverage alternative channel complement effectiveness sale force drive growth key market product receive food drug administration fda approval gardasil vaccine prevention cervical cancer genital wart cause certain type human papillomavirus hpv januvia medicine class enhance natural body system improve blood sugar control patient type diabete zostavax vaccine adult year age old reduce incidence shingle disease year afflict estimate million people united states rotateq pediatric vaccine help prevent rotavirus gastroenteritis infant child effect life nearly child age worldwide year zolinza novel medicine treat patient suffer advanced cutaneous tcell lymphoma ctcl addition company drug candidate currently fda review janumet previously refer mka investigational oral medicine combine sitagliptin phosphate metformin type diabete design provide additional treatment option patient need oral agent help control blood sugar emend injection intravenous therapy chemotherapyinduce nausea vomit cinv arcoxia merck selective cox inhibitor osteoarthritis additionally company anticipate file new drug application nda fda firstinclass hiv integrase inhibitor gaboxadol novel compound mercks alliance lundbeck treatment insomnia mka extendedrelease niacin combine laropiprant novel flush pathway inhibitor cholesterol management addition midyear merck expect product phase iii development additionally target acquisition year sirna therapeutics inc sirna glycofi inc glycofi abmaxis inc abmaxis alliance collaboration complement merck strong internal research capability continue help company build pipeline support longterm growth merck working deliver innovative differentiate product market fast efficiently company successfully reduce late development product cycle time anticipate reduction come year additionally merck new commercial model expect low spending primary care brand united states interim target reduction expect achieve end appropriately support product launch illustrate successful launch new product redeployment launch achieve increase sale force initial phase global restructuring program design reduce company cost structure increase efficiency enhance competitiveness underway initial step include implementation new supply strategy merck manufacturing division intend create lean costeffective customer focus manufacturing model threeyear period program merck announce plan sell close manufacture site preclinical site end manufacture site close sell cease operation preclinical site close end eliminate approximately position companywide approximately position eliminate end comprise actual headcount reduction elimination contractor vacant position company continue hire new employee company business require company sell certain facility relate asset connection restructure program pretax cost restructure program million comprise million primarily represent accelerate depreciation asset impairment cost million separation restructure relate cost expect million million end initial phase restructuring program relate manufacturing strategy expect substantially complete cumulative pretax cost program expect range billion billion merck continue expect initial phase cost reduction program yield cumulative pretax saving billion respect vioxx litigation date vioxx product liability lawsuit plaintiff claim schedule trial claim seven dismiss claim seven withdraw trial calendar plaintiff jury decide merck favor time plaintiff favor time addition recent california trial involve plaintiff jury reach verdict plaintiff mistrial declare new jersey state judge set aside merck verdict respect plaintiff verdict merck file appeal seek judicial review case federal judge overturn damage award shortly trial addition consolidated trial plaintiff currently ongoing coordinate proceed new jersey superior court judge carol higbee trial commence state court illinois company spend million aggregate include million fourth quarter vioxx legal defense cost worldwide company record charge million increase reserve solely future legal defense cost relate vioxx litigation december balance reserve million reserve base certain assumption good estimate company believe time spend vioxx litigation fully discuss note consolidated financial statement earning common share assume dilution include impact global restructuring program share acquire research charge relate acquisition sirna share acquire research charge relate acquisition glycofi share discuss acquisition additional reserve establish solely future legal defense cost vioxx litigation discuss impact adopt new accounting standard require expense stock option discuss sharebased compensation ompetition health care environment market company conduct business highly competitive highly regulated global effort health care cost containment continue exert pressure product pricing access united states government expand health care access enact medicare prescription drug improvement modernization act sign law december prescription drug coverage begin january legislation support company goal improve access medicine expand insurance coverage preserve marketbase incentive pharmaceutical innovation time legislation ensure prescription drug cost control competitive pressure encourage appropriate use medicine address costcontainment pressure company continue effort demonstrate medicine help save cost overall patient health care addition pricing flexibility company product portfolio encourage grow use medicine mitigate effect increase cost pressure outside united states difficult environment encumber government costcontainment action company work partnership payer allocate scarce resource optimize health care outcome limit potentially detrimental effect government policy sale growth access innovative medicine vaccine support discovery development innovative product benefit patient company work government emerge market eastern europe latin america asia encourage increase investment health improve citizen access medicine europe european institutions european commission recognize economic importance researchbase pharmaceutical industry value innovative medicine society result work industry representative complete single market pharmaceutical improve competitive climate variety mean include market deregulation order advance relate policy debate launch high level pharmaceutical forum hlpf end initiative aim improve prospect researchbase pharmaceutical industry europe health prospect patient benefit innovative therapy active dialogue stakeholder health care system payer patient initiative attempt tackle key policy issue europe promote great pricing flexibility medicine ensure health authority apply good practice evaluation relative effectiveness medicine iii improve great access information medicine patient europe company actively engage stakeholder order achieve successful outcome hlpf help european patient gain great quick access medicine company commit improve access medicine enhance quality life people world african comprehensive hivaids partnership achap botswana partnership government botswana bill melinda gates foundation merck company foundationmerck inc support botswanas response hivaids comprehensive sustainable approach hiv prevention care treatment support company initiate similar partnership people republic china focus initially sichuan province help strengthen chinas response hiv epidemic catalyze access hiv medicine develop country price reduction guideline company announce merck make profit sale current hivaids medicine world poor country hard hit pandemic offer hivaids medicine significantly reduce price mediumincome country february merck announce reduce price stocrin develop country world hard hit pandemic end patient develop country treat antiretroviral regimen contain crixivan stocrin action merck work independently partner public private sector alike focus critical barrier access medicine develop world need sustainable financing increase international assistance additional investment education training health infrastructure capacity develop country company subject number privacy datum protection law regulation globally legislative regulatory landscape privacy datum protection continue evolve increase focus privacy datum protection issue potential affect directly company business predict outcome legislative regulatory advocacy initiative company position respond evolve health care environment market force patent certain company product expire merck enter continue enter authorized generic agreement allow company benefit medicine available generic form company anticipate worldwide trend costcontainment continue result ongoing pressure health care budget company continues successfully launch new product contribute health care debate monitor reform new product policy strategy enable maintain strong position change economic environment cquisition december merck complete acquisition sirna approximately billion sirna biotechnology company leader develop new class medicine base rna interference rnai technology significantly alter treatment disease transaction account business combination excess purchase price fair value acquire net asset record goodwill million goodwill deductible tax purpose company record charge million acquire research associate sirnas compound currently development relate development treatment hepatitis hepatitis viruse preclinical development licensing agreement hold sirna charge deductible tax purpose ongoing activity respect compound development expect material company research development expense allocation purchase price result recognition intangible asset million relate defer tax liability million related sirnas develop technology acquisition sirna expect increase merck ability use rnai technology turn target gene human cell potentially render inoperative gene responsible trigger specific disease note consolidated financial statement june merck acquire glycofi privatelyheld biotechnology company leader field yeast glycoengineere addition specific carbohydrate modification protein yeast optimization biologic drug molecule million cash million purchase price net million share own net transaction cost company record million charge acquire research connection acquisition deductible tax purpose company record million intangible asset million net defer taxis relate glycofis develop technology merck acquire abmaxis privatelyheld biopharmaceutical company dedicate discovery optimization monoclonal antibody product human therapeutic diagnostic million cash substantially purchase price allocate intangible asset relate abmaxis technology platform acquisition independent scientific merit combination glycofi abmaxis platform potentially synergistic give merck ability operate entire spectrum therapeutic antibody discovery development commercialization note consolidated financial statement perate result ale worldwide sale increase total primarily drive high volume foreign exchange price change virtually impact sale growth sale performance reflect strong growth singulair onceaday oral medicine indicate chronic treatment asthma relief symptom allergic rhinitis company vaccine include gardasil help protect cervical cancer genital wart cause certain type hpv proquad combination vaccine simultaneous vaccination measle mump rubella varicella rotateq help protect rotavirus gastroenteritis infant child contribute sale growth high revenue company relationship astrazeneca azlp primarily drive nexium increase sale cozaarhyzaar high blood pressure addition sale reflect certain supply sale associate activity expect continue include company arrangement reddys laboratories drl sale generic simvastatin sale growth partially offset low sale zocor company statin modifying cholesterol proscar urology product treatment symptomatic benign prostate enlargement merck marketing exclusivity zocor expire june proscar lose marketing exclusivity june domestic sale increase foreign sale decline foreign sale represent total sale domestic sale benefit launch new vaccine foreign sale negatively affect loss marketing exclusivity continue generic erosion relate zocor fosamax product worldwide sale decrease total reflect decrease relate voluntary worldwide withdrawal vioxx offset revenue growth product growth reflect favorable effect foreign exchange favorable effect price change volume increase foreign sale represent total sale sale company product follow million singulair cozaarhyzaar fosamax zocor primaxin cosopttrusopt proscar vasotecvaseretic cancidas maxalt propecia vioxx vaccinesbiological present net discount return amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate company pharmaceutical product include therapeutic preventive agent generally sell prescription treatment human disorder singulair leukotriene receptor antagonist respiratory product chronic treatment asthma relief symptom allergic rhinitis cozaarhyzaar vasotec company significant hypertension andor heart failure product fosamax fosamax plus market fosavance european union treatment case fosamax prevention osteoporosis zocor mercks atherosclerosis product primaxin cancidas anti bacterialantifungal product cosopt trusopt largestselling ophthalmological product proscar urology product treatment symptomatic benign prostate enlargement maxalt acute migraine product propecia product treatment male pattern hair loss product include vaccinesbiological varivax vaccine help prevent chickenpox mmr vaccine measle mump rubella proquad pediatric combination vaccine measle mump rubella varicella gardasil vaccine prevention cervical cancer genital wart cause certain type hpv pneumovax vaccine prevention pneumococcal disease rotateq vaccine help protect rotavirus gastroenteritis infant child zostavax vaccine help prevent shingles herpe zoster individual year age old primarily include sale human pharmaceutical pharmaceutical animal health supply sale company joint venture revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively include certain supply sale associate activity expect continue include company arrangement drl sale generic simvastatin egment revenue million pharmaceutical segment revenue vaccine segment revenue segment revenues revenues otal revenue accordance segment reporting requirement vaccine segment revenue exclude million million million respectively vaccine sale certain nonus subsidiary manage include pharmaceutical segment include nonreportable human animal health segment revenue primarily comprise miscellaneous corporate revenue sale relate divested product business supply sale include segment result harmaceutical segment revenue sale pharmaceutical segment decrease primarily decline zocor proscar postpatent expiration partially offset increase singulair cozaarhyzaar singulair mercks onceaday oral respiratory medicine indicate treatment chronic asthma relief symptom allergic rhinitis continue strong performance reflect continued demand asthma seasonal perennial allergic rhinitis medication singulair continue number prescribe product respiratory market total sale singulair billion increase global sale cozaar companion agent hyzaar combination cozaar hydrochlorothiazide treatment hypertension billion increase cozaar hyzaar compete fastestgrowe class antihypertensive market angiotensin antagonist aiia cozaarhyzaar remain number brand aiia united states europe december company japanese subsidiary launch preminent know hyzaar worldwide market firsteverfixeddose combination japan angiotensin receptor blocker hydrochlorothiazide treatment hypertension japan second large pharmaceutical market world global sale fosamax fosamax plus treatment postmenopausal male andor glucocorticoidinduce osteoporosis billion decrease sale outside united states affect availability generic alendronate sodium product key market include united kingdom canada germany company ongoing litigation certain european country base company alendronate patent fosamax fosamax plus remain prescribed medicine worldwide treatment osteoporosis fosamax fosamax plus lose market exclusivity united states february april respectively company expect significant decline fosamax fosamax plus sale product respective loss market exclusivity august fosamax market fosamac onceweekly oral medicine osteoporosis launch japan worldwide sale zocor merck statin modify cholesterol billion decrease sale zocor negatively affected loss marketing exclusivity june global sales zocor expect billion billion february company enter agreement drl authorize sale generic simvastatin term agreement company reimburse costplus basis drl supply finish good receive share net profit record drl merck continue offer brand zocor manufacture simvastatin brand zocor vytorin company investigational compound mkb merck record million associate drl arrangement simvastatin revenue expect continue october januvia approve fda dipeptidyl peptidase dpp inhibitor available united states treatment type diabete dpp inhibitor represent new class prescription medication improve blood sugar control patient type diabete enhance natural body system call incretin system januvia approve monotherapy addon therapy oral diabetes medication metformin thiazolidinedione tzds improve blood sugar glucose control patient type diabete diet exercise january company receive positive opinion januvia committee medicinal product human use chmp european medicine agency emea europe chmp opinion recommend januvia approve treatment type diabetes follow conclusion chmp review opinion januvia transmit adopt opinion januvia prescription medication new class drug know dpp inhibitor enhance bodys ability low blood sugar glucose elevated decision applicable country member marketing authorization expect early april adoption opinion include merck anticipate approval januvia country clinical study januvia provide significant measure average blood glucose level threemonth period reduction monotherapy add commonly type diabete drug metformin tzds treatment januvia associate weight gain increase risk hypoglycemia januvia available country include united states mexico brazil regulatory filing world move forward global sale januvia million october fda approve zolinza treatment cutaneous manifestation patient ctcl progressive persistent recurrent disease follow systemic therapy approval zolinza represent anticancer treatment approve ctcl product experience growth include cosopt treat glaucoma propecia male pattern hair loss maxalt treat migraine pain arcoxia treatment arthritis pain invanz treatment select moderate severe infection adult emend prevention acute delay nausea vomiting associate moderately highly emetogenic cancer chemotherapy treatment postoperative nausea vomit contribute merck total sale revenue result company relationship azlp primarily relate sale nexium proscar merck urology product treatment symptomatic benign prostate enlargement lose marketing exclusivity united states june merck sale proscar million decrease compare company expect decline proscar sale continue basic patent proscar cover propecia propecia protect additional patent expire october accine segment revenue sale vaccine segment increase result new product launch continue success inline vaccine follow discussion vaccine include total vaccine sale vast majority include vaccine segment remainder represent certain sale vaccine nonus subsidiary manage include pharmaceutical segment amount reflect sale vaccine sell major european market sanofi pasteur msd spmsd company joint venture sanofi pasteur result reflect equity income affiliate company announce fda approval new breakthrough vaccine gardasil rotateq zostavax june fda approve gardasil vaccine available united states prevent cervical cancer vulvar vaginal precancer cause hpv type prevent lowgrade pre cancerous lesion genital wart cause hpv type gardasil approve yearold girl woman gardasil dose intra muscular vaccine give month united states estimate approximately woman diagnose cervical cancer year approximately woman die june center disease control cdc advisory committee immunization practice acip voted unanimously recommend girl woman year old vaccinated gardasil acip recommend gardasil administer yearold female female age previously vaccinate yearold female vaccinate gardasil discretion physicians november company announce cdc add gardasil cdcs vaccine children program eligible girl woman age february manage care plan represent privatelyinsure life united states currently insurance plan decide reimburse gardasil cover member benefit design insurer reimburse vaccine low price pay merck private nonhmo customer september gardasil approve vaccine use child adolescent aged year adult female aged year prevention cervical cancer high grade cervical dysplasiasprecancer cervical intraepithelial neoplasia cin highgradeprecancerous vulvar dysplastic lesion vin genital wart cause hpv type gardasil market spmsd european country include remain central eastern european country gardasil market merck sharp dohme gardasil silgard total sale gardasil record merck million gardasil approve country accelerate review regulatory application pende approximately country february company announce glaxosmithkline gsk enter cross license settlement agreement certain patent right relate hpv vaccine pursuant agreement gsk receive upfront payment receive royalty company base sale gardasil development launch agreement resolve compete intellectual property claim relate company gsk vaccine candidate addition merck enter license agreement collaboration csl limited relate technology gardasil gardasil subject thirdparty licensing agreement consequence agreement company pay royalty worldwide sale gardasil approximately aggregate clinical study evaluate efficacy gardasil female year age male year age continue country world company expect submit fda indication female year age fourth quarter indication male year age company conduct ongoing clinical study assess potential crossprotection hpv type relate hpv include hpv crossprotection prove potentially expand vaccine prevention coverage cervical cancer february fda approve rotateq company vaccine help protect rotavirus gastroenteritis infant child fda approval rotateq base datum company phase iii clinical trial nearly infant include datum rotavirus efficacy safety trial rest large prelicensure vaccine clinical trial conduct clinical trial rotateq prevent severe case rotavirus gastroenteritis prevent rotavirus gastroenteritis case severity cause serotype target vaccine compare placebo rotavirus season vaccination rotateq reduce hospitalization emergency room visit rotavirus gastroenteritis cause serotype target vaccine year dose february cdcs acip unanimously vote recommend infant start week age vaccinate rotateq rotavirus vaccine available united states acip recommend oral readyto use vaccine give current routine wellbaby visit month age april rotateq available cdc vaccine child program united states february health insurance plan represent approximately cover life eligible age group infant young child week age add rotateq formulary rotateq approve country application licensure file country nicaragua rotateq approve company provide vaccine free charge infant bear country threeyear period commence october joint demonstration project nicaraguan ministry health rotateq sale record merck million february merck update label information rotateq include postmarkete report intussusception hematochezia vaccine adverse event report system vaer national vaccine safety surveillance program february fda report licensure rotateq february january case intussusception infant receive rotateq report united states vaer number exceed number case expect base background rate rest specifically design evaluate vaccine safety respect intussusception rest increase risk intussuception rotateq compare placebo fda approve zostavax companys vaccine prevention herpe zoster shingle individual year age old approve regulatory authority australia zostavax medical option approve prevention shingle october cdc acip vote unanimously recommend adult year age old vaccinate zostavax help prevent shingle follow acip recommendation united states february manage care plan represent approximately cover life reimburse zostavax sales zostavax record merck million june acip unanimously vote recommend child year age routinely receive second dose varicella chickenpoxcontaining vaccine merck varivax combination vaccine proquad vaccine help protect chickenpox available united states acip vote recommend child adolescent adult previously receive dose varicellacontaine vaccine receive catchup second dose acip vote include second dose chickenpox vaccine vaccine children program merck recently determine bulk manufacturing process company varicella zoster virus vzvcontaine vaccine produce low amount bulk vzv intermediate expect vzv bulk question designate use fulfil future quantity vzvcontaining vaccine varivax proquad zostavax result production vzv bulk temporarily suspend company identifie cause issue situation affect quality merck vzvcontaine vaccine currently market lot vaccine inventory ready release market vaccine fill finished exist vzv bulk company work resolve issue decrease availability proquad increase availability component vaccine varivax mmr additionally company postpone introduction outside united states proquad zostavax vzv bulk issue resolve base approach view current projection company currently expect meet anticipate market demand vzvcontaine vaccine cost expense harebase compensation january company adopt financial accounting standard board fasb statement sharebase payment fas note consolidated financial statement fas require sharebase payment employee expense requisite service period base grantdate fair value award prior adopt fas company account employee stock option intrinsic value method measure sharebase compensation expense market price stock date grant exceed exercise price company elect modify prospective transition method adopt fas prior period restate method provision fas apply award grant modify january total pretax sharebase compensation expense million million million incremental pretax expense relate adoption fas million addition unrecognized expense award vest date adoption shall recognize net income period date adoption december million total pretax unrecognized compensation expense relate nonveste stock option restrict stock unit performance share unit award recognize weighted average period year segment report sharebased compensation expense record unallocated expense million change change material production marketing administrative research development restructuring cost equity income affiliate income expense net great aterial production material production cost increase compare increase sale increase primarily attributable million record related global restructure program compare million record record million represent accelerate depreciation associate plan sale closure company manufacture facility note consolidated financial statement remain million represent impairment charge associate abandonment certain fix asset long business result restructuring action material production cost include stock option expense million additionally material production cost include unfavorable impact inflation material production cost increase compare decline sale increase primarily attributable million record related global restructure program million represent impairment charge associate abandonment certain fix asset long business result restructure action remain million represents accelerate depreciation associate merck plan sell close own manufacturing facility additionally increase material production cost attributable unfavorable effect inflation variance cost relative sale decline reflect impact item note unfavorable effect sale associate voluntary worldwide withdrawal vioxx gross margin compare restructure charge note unfavorable impact percentage point percentage point addition zocor lose marketing exclusivity negatively affect gross margin impact voluntary worldwide withdrawal vioxx unfavorable effect gross margin arkete administrative marketing administrative expense increase primarily reflect million additional reserve solely legal defense cost vioxx litigation note consolidated financial statement cost associate launch new vaccine new product mainly januvia united states marketing administrative expense include million charge establish legal defense reserve fosamax litigation note consolidated financial statement stock option expense million additionally market administrative expense include unfavorable effect inflation marketing administrative expense decrease primarily cost record million voluntary worldwide withdrawal vioxx million establishment reserve solely legal defense cost vioxx litigation partially offsetting decrease additional reserve million vioxx legal defense cost record cost require prepare launch new vaccine additionally unfavorable effect inflation unfavorable effect exchange partially offset decline esearch development research development expense increase include increase million acquire research charge relate acquisition sirna million acquire research charge result glycofi acquisition addition increase reflects accelerate depreciation cost million relate closure research facility connection global restructuring program stock option expense million additionally unfavorable effect inflation contribute increase company drug candidate currently fda review june fda accept standard review nda intravenous prodrug emend treatment cinv company anticipate decision nda second quarter july fda accept standard review nda janumet company investigational oral medicine combine januvia metformin design provide additional treatment patient need oral agent help control blood sugar treatment type diabetes company expect fda action nda end march company move forward plan regulatory filing country outside united states arcoxia company investigational selective cox inhibitor remain standard review fda united states response fda approvable letter merck include result medal multinational etoricoxib diclofenac arthritis longterm program show rate confirm thrombotic cardiovascular event similar arcoxia diclofenac widely nonsteroidal anti inflammatory drug world company anticipate fda action april company expect fda advisory committee meeting hold prior fda action arcoxia currently available country europe latin america asiapacific region middle eastnorthern africa company anticipate file nda fda company plan file nda fda second quarter receive fast track designation indication treatmentexperience patient interim week datum doserange phase trial company investigational hiv integrase inhibitor patient advance hiv infection present annual conference retroviruse opportunistic infection february result show oral investigational medication dose study combination optimize background therapy obt great antiretroviral activity obt study result show combination obt generally tolerate patient fail antiretroviral therapy art resistant drug available class oral art limit active art option treatment american society microbiologys annual international conference antimicrobial agent chemotherapy september company present interim week datum ongoing study treatmentexperience patient demonstrate maintain viral load regression august international aids conference company present interim week datum phase doserange trial conduct treatmentnave hivinfecte patient datum show twice daily combination tenofovir lamivudine achieve comparable viral load reduction efavirenz combine agent previously untreate patient september american society microbiologys annual international conference antimicrobial agent chemotherapy company present additional interim week datum phase doseranging study treatmentnave patient demonstrate increase lipid level patient take tenofovir lamivudine company enter phase iii clinical trial mka support mkb investigational therapy lipid management mka represent novel approach lower ldlc raise hdlc lower triglyceride mkb combine mka prove benefit simvastatin potentially reduce risk coronary heart disease statin provide company plan file mka fda file mkb november company present data phase study american heart association scientific session chicago show coadministration niacin significantly reduce flush patient dyslipidemia compare patient take niacin flush characterize redness skin warm burn face neck cause dilation blood vessel near skin common niacininduce effect cause discomfort patient significant factor lead discontinuation niacin therapy october company lundbeck denmark announce submission nda gaboxadol novel investigational drug phase iii development treatment insomnia occur mid phase clinical study gaboxadol show improved sleep quality increase slowwave sleep suppress rem sleep december merck announce gaboxadol likely schedule compound midyear merck expect product phase iii development include mkb discuss company initiate target phase iii program investigational compound treatment obesity investigational cannabinoid receptor inverse agonist result early clinical study indicate demonstrate significant weightloss efficacy versus placebo generally safe welltolerate report cannabinoid receptor inverse agonist psychiatric adverse experience observe announce december company plan start phase iii testing calcitonin gene relate peptide receptor antagonist treatment migraine headache phase iii program expect commence quarter announce december company anticipate cathepsin inhibitor treatment osteoporosis enter phase iii test mid august merck gilead sciences inc gilead establish agreement distribution atripla oncedaily single tablet regimen treatment hiv infection adult develop country world atripla contain efavirenz nonnucleoside reverse transcriptase inhibitor emtricitabine tenofovir disoproxil fumarate nucleoside reverse transcriptase inhibitor efavirenz market merck tradename stocrin territory outside united states canada certain european country commercialize bristolmyers squibb bms tradename sustiva emtricitabine tenofovir disoproxil fumarate commercialize gilead tradename emtriva viread respectively compound commonly prescribe oncedaily fixeddose tablet market tradename truvada use combination therapy october company bms gilead announce submission marketing authorisation application maa atripla emea maa review chmp subject validation emea maa atripla file jointly company newly establish threeway collaboration base ireland review maa conduct emea centralized licensing procedure finalize provide marketing authorization member state discussion company agreement manufacture commercialization distribution atripla ongoing merck continue remain focused augment internal effort capitalize growth opportunity range target acquisition research collaboration preclinical clinical compound technology transaction drive near longterm growth company complete transaction broad range therapeutic category earlystage technology transaction merck currently evaluate opportunity actively monitor landscape range target acquisition meet company strategic criterion highlight activity year include march neuromed pharmaceuticals ltd neuromed merck sign research collaboration license agreement research develop commercialize novel compound treatment pain neurological disorder include neuromed lead compound nme currently phase development treatment pain term agreement neurome receive upfront payment million successful development launch nme initial single indication worldwide basis trigger milestone payment total million milestone increase approximately million indication nme develop approve additional compound develop approve indication neurome receive royalty worldwide sale nme additional compound develop agreement march merck nicox nicox enter new agreement collaborate development new antihypertensive drug nicoxs proprietary nitric oxidedonate technology agreement cover nitric oxidedonate derivative major class antihypertensive agent treatment high blood pressure complication hypertension cardiovascular relate disorder merck exclusive right develop commercialize antihypertensive use nicoxs nitric oxidedonate technology treatment systemic hypertension company acquire abmaxis privatelyheld biopharmaceutical company dedicate discovery optimization monoclonal antibody product human therapeutic diagnostic june company acquire glycofi privatelyheld biotechnology company leader field yeast glycoengineere optimization biologic drug molecule connection acquisition company record charge million acquire research associate glycofis technology platform research development process acquisition date technological feasibility establish alternative future use exist acquisition october merck ambrilia biopharma inc ambrilia biopharmaceutical company develop innovative therapeutic field cancer infectious disease announce enter exclusive licensing agreement grant merck worldwide right ambrilias hivaid protease inhibitor program term agreement ambrilia grant merck exclusive worldwide right lead compound ppl complete phase singledose pharmacokinetic study currently phase repeat dose pharmacokinetic study return ambrilia receive upfront licensing fee million signing eligible cash payment total million successful completion development clinical regulatory sale milestone ambrilia receive royalty future product sale november company expand scope exist strategic collaboration foxhollow technology inc foxhollow atherosclerotic plaque analysis additionally merck acquire stake foxhollow purchase million newlyissue share foxhollow common stock share represent approximately stake exist strategic collaboration enter provide foxhollow receive upfront payment opportunity additional payment collaboration continue term expand collaboration agreement merck pay million foxhollow year exchange foxhollow agreement collaborate exclusively merck specify disease area merck provide minimum million funding foxhollow year year collaboration program term research activity conduct foxhollow merck direction foxhollow receive milestone payment successful development drug product diagnostic test utilize result collaboration royalty november merck david gladstone institutes announce major collaboration license agreement research development drug treat neurodegenerative disease include alzheimer disease link apoeregulated mechanism body agreement provide merck affiliate worldwide exclusive license research develop commercialize compound direct apoeregulated pathway result collaborative research discovery field neurodegeneration gladstone institute november merck advinus therapeutic ltd advinus announce form drug discovery clinical development collaboration area metabolic disorder advinus merck work develop clinically validate drug candidate metabolic disorder merck retain right advance promise candidate latestage clinical trial advini receive upfront payment potentially receive milestone payment million target include collaboration collaboration begin target program expand include time december merck complete acquisition sirna publiclyheld biotechnology company leader develop new class medicine base rnai technology significantly alter treatment disease connection acquisition company record charge million acquire research associate sirnas compound currently development acquisition date technological feasibility establish alternative future use exist acquisition additionally december merck idera pharmaceutical idera announce form broad collaboration research develop commercialize idera tolllike receptor tlr agonist term agreement merck receive worldwide exclusive right number idera agonist compound target tlr use combination merck therapeutic prophylactic vaccine development oncology infectious disease alzheimer disease merck idera engage twoyear research development collaboration generate novel agonist target tlr tlr incorporate merck idera chemistry use license field merck pay upfront license fee million idera purchase million common stock share addition merck fund research development collaboration idera eligible receive milestone payment million vaccine successfully develop field additional milestone million payable followon indication oncology field successful development additional vaccine contain idera tlr agonist limit number vaccine merck apply idera agonist licensed field addition idera receive royalty product commercialize collaboration company maintain number longterm exploratory fundamental research program biology chemistry research program direct product development company research development program generally design focus development novel medicine address large unmet medical need merck new effort improve drug discovery involve focus priority disease area utilize new research technology build alliance external partner make targeted acquisition complement company strong internal research capability previous announce priority disease area alzheimer disease atherosclerosis cardiovascular disease diabete novel vaccine obesity oncology target therapy pain sleep disorder therapeutic area carefully choose base set criterion include unmet medical need scientific opportunity commercial opportunity chart reflect company current research pipeline february set forth item business research development expense decrease include accelerate depreciation cost million relate closure research facility addition decrease reflect impact million licensing expense initial payment certain disclose research collaboration million acquire research expense acquisition aton pharma inc partially offset decrease increase research development activity support merck pipeline unfavorable effect inflation estructure cost restructure cost million million respectively include restructuring cost separation cost associate merck plan eliminate approximately position end merck incur million million respectively separation cost associate actual headcount reduction headcount reduction probable reasonably estimate related global restructure program company eliminate position position comprise actual headcount reduction elimination contractor vacant position company record million separation cost associate restructure program restructure cost include unallocated expense segment report purpose quity income affiliate equity income affiliate reflect performance company joint venture partnership increase equity income affiliate reflect successful performance vytorin zetia merckscheringplough partnership growth attributable high partnership return azlp select joint venture affiliate information ther income expense net increase income expense net reflect increase interest income generate company investment portfolio derive high interest rate high average investment portfolio balance decrease income expense net primarily reflect million gain sale company equity stake european joint venture johnson johnson realize gain company investment portfolio record egment profit million pharmaceutical segment profit vaccine segment profit segment profit ncome income taxis segment profit comprise segment revenue certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker company allocate vast majority indirect production cost research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit exclude determination segment profit taxis pay joint venture level portion equity income additionally segment profit reflect expense corporate manufacturing cost center miscellaneous income expense unallocated item reflect table include miscellaneous corporate profit operate profit relate divested product business supply sale adjustment eliminate effect double counting certain item income expense pharmaceutical segment profit increase compare reflect high equity income primarily drive strong performance merckscheringplough partnership partially offset loss marketing exclusivity zocor proscar pharmaceutical segment profit decline primarily relate voluntary worldwide withdrawal vioxx vaccine segment profit increase driven launch new vaccine successful performance inline vaccine vaccine segment profit decline primarily reflect increase marketing administrative cost require prepare launch new vaccine vaccine segment profit reflect equity income spmsd axes income company effective income tax rate high effective tax rate reflect unfavorable impact percentage point primarily relate company decision repatriate billion foreign earning accordance american job creation act ajca effective tax rate reflect unfavorable impact percentage point relate non deductible acquire research development cost associate acquisition sirna glycofi tax rate year favorably impact restructuring charge income earning share million share amount change change net income sale average total asset earning common share assume dilution income earning common share net income decrease decline earning common share assume dilution decline compare decline decline primarily reflect impact acquire research charge high restructuring charge increase reserve legal defense cost incremental impact expense stock option increase cost partially offset growth equity income affiliate net tax charge associate repatriation foreign earning accordance ajca net income percentage sale decrease percentage sale ratio compare reflect factor discuss net income percentage average total asset elect joint venture affiliate information expand research base realize synergy combine capability opportunity asset previous year company form number joint venture note consolidated financial statement erckscheringplough partnership company scheringplough corporation scheringplough collectively partner enter agreement create separate equallyowne partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area agreement generally provide equal sharing development cost copromotion approve product company cholesterolmanagement partnership agreement expand include country world exclude japan ezetimibe new class cholesterollowere agent launch united states zetia market ezetrol outside united states july combination product contain active ingredient zetia zocor approve united states vytorin market inegy outside united states cholesterol agreement provide share operating income generate merckschere plough cholesterol partnership msp partnership base percentage vary product sale level country market partner share profit zetia vytorin sale equally exception million annual zetia sale scheringplough receive great share profit operating income include expense partner contractually agree share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service ongoing clinical research market support market research market expansion specialty sale force physician education program expense incur support msp partnership share partner market administrative expense include certain sale force cost certain manufacturing cost include equity income affiliate cost reflect overall result company certain research development expense generally share equally partner adjust earn milestone sale joint venture product follow millions zetia vytorin global sales zetia increase global sale vytorin increase vytorin single tablet cholesterol treatment provide ldl cholesterol lower dual inhibition cholesterol production absorption june msp partnership announce new datum clinical trial datum present international symposium atherosclerosis meeting show vytorin significantly effective crestor reduce ldl cholesterol study dose comparison analysis datum show average study dose vytorin bring patient high risk cardiovascular disease ldl cholesterol level mgdl compare crestor june new datum release american diabetes association ada annual scientific session show recommend usual starting dose vytorin superior lipitor lower ldl cholesterol patient type diabete high cholesterol datum publish december issue mayo clinic proceeding result company interest msp partnership record equity income affiliate merck recognize equity income million million million strazeneca company enter agreement astra astra develop market astra product united states company astra form equallyowne joint venture develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach line company astra restructure joint venture company acquire astras interest joint venture rename kbi inc kbi contribute kbis operating asset new limited partnership name astra pharmaceutical partnership company maintain limited partner interest partnership rename astrazeneca azlp exclusive distributor product kbi retain right merck earn ongoing revenue base sale current future kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning return aggregate million million million respectively erial limited merck rhnepoulenc sanofiaventis combine animal health poultry genetic business form merial limited merial fully integrate animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie sale joint venture product follow million fipronil product avermectin product biological product product broiler foreign turkey segment poultry genetic business sell domestic turkey segment divest transaction complete divestiture merial interest poultry genetic business comparative purpose amount present include revenue earn poultry genetic business anofi pasteur msd merck pasteur merieux connaught sanofi pasteur establish own joint venture market vaccine europe collaborate development combination vaccine distribution europe merck launch new vaccine approve use market spmsd certain western european country gardasil prevention cervical cancer genital wart cause certain type hpv rotateq help protect rotavirus gastroenteritis infant child zostavax help prevent shingles herpe zoster individual year age old september spmsd enter letter undertake lou emea agency concern longterm efficacy hepatitis component hexavac hepatitis component hexavac manufacture merck lou require relevant suspension hexavac license suspension hexavac distribution recall hexavac product recall hexavac number noneu country surveillance program possible future revaccination spmsd market sell hexavac notify merck reserve right seek damage merck defend indemnify hold harmless merck event party claim september emea initiate formal review longterm efficacy hepatitis vaccine hbvaxpro hepatitis component hepatitis bhib combination vaccine procomvax product market sell spmsd european territory sell different name merck extensive review emea determine vaccine continue offer effective protection hepatitis allow spmsd continue marketing product minor label change sale joint venture product follow million hepatitis vaccine viral vaccine vaccine ohnson johnsonmerck consumer pharmaceutical company merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own joint venture expand europe canada march merck sell equity stake european joint venture johnson johnson million record million gain income expense net merck continue benefit royalty certain product regain right potential future product switch prescription overthecounter status europe sale joint venture product follow million gastrointestinal product product include sale european joint venture march apital expenditure capital expenditure million billion expenditure united states million million expenditure include million production facility million research development facility million environmental project million administrative safety general site project capital expenditure estimate billion depreciation expense billion billion billion billion respectively apply location united states total depreciation expense includes accelerate depreciation million million respectively associate global restructuring plan additionally depreciation expense reflect million associate closure terling park basic research center note consolidated financial statement nalysis liquidity capital resource merck strong financial profile enable company fully fund research development focus external alliance support inline product maximize upcoming launch provide significant cash return shareholder cash provide operating activity billion continue company primary source fund finance capital expenditure treasury stock purchase dividend pay stockholder december total worldwide cash investment billion include billion cash cash equivalent shortterm investment billion longterm investment elect datum millions work capital total debt total liability equity cash provide operation total debt company begin shift mix investment shortterm longterm result reduction work capital line historical level relative level december enable execution ajca repatriation company change mix investment longterm shortterm result significant increase work capital december ajca create temporary incentive december multinational repatriate accumulate income earn outside united states december connection ajca company repatriate billion result company record income tax charge million taxis income relate repatriation million pay remainder pay quarter december approximately billion ajca repatriation invest fully collateralized overnight repurchase agreement include shortterm investment consolidate balance sheet early company begin reinveste repurchase agreement balance short longterm investment work capital level adequate meet operating requirement company ratio total debt total liability equity cash provide operation total debt reflect strength company operate cash flow ability company cover contractual obligation previously disclose internal revenue service irs examine company tax return year issue notice deficiency respect partnership transaction enter minority interest equity financing enter respectively irs recently conclude examination year issue final revenue agent report quarter february company enter closing agreement irs cover specific item include partnership transaction minority interest equity financing terms close agreement company expect payment approximately billion quarter payment offset tax refund million amount previously pay related matter million federal tax benefit relate interest include payment result net cash cost company approximately billion company previously establish reserve matters conclusion irs examination include closing agreement material effect company result operation financial position liquidity material adverse effect company cash flow quarter payment impact year subsequent partnership transaction minority interest equity financing include closing agreement year remain open respect previously disclose october company receive notice reassessment canada revenue agency cra contain adjustment relate certain intercompany pricing matter result additional taxis approximately billion dollar plus interest million dollar note consolidated financial statement company disagree position take cra believe merit company intend contest reassessment cra appeal process court necessary connection appeal process notice reassessment company require post deposit half tax interest assess january company pledge collateral consist cash cash equivalent million financial institution provide letter guarantee cra management believe resolution matter material adverse effect company financial position liquidity unfavorable resolution material adverse effect company result operation cash flow quarter adjustment record tax company contractual obligation december follow ayment period million total purchase obligation loan payable current portion longterm debt longterm debt operating lease purchase obligation consist primarily good service enforceable legally binding include obligation minimum inventory contract research development advertising research contract include milestone payment contingent future event loan payable current portion longterm debt include million note redeem company february notification remarkete agent overall rise interest rate exercise annual option remarket note loan payable current portion longterm debt reflect million longdate note subject repayment option holder annual basis require funding obligation relate company pension postretirement benefit plan expect material december company increase capacity shelf registration statement file securities exchange commission sec issue debt security additional billion february company issue billion tenyear note shelf november company issue million twentyyear note million fiveyear note shelf remain capacity company shelf registration statement approximately billion april company extend maturity date billion fiveyear revolve credit facility february april facility provide backup liquidity company commercial paper borrowing facility general corporate purpose company draw funding facility company longterm credit rating assign moodys standard poor respectively negative outlook rating continue allow access capital market flexibility obtain fund competitive term company continue maintain conservative financial profile total cash investment billion exceed sum loan payable longterm debt billion company longterm credit rating remain rate nonfinancial corporation despite strong financial profile certain contingent event realize discuss note consolidated financial statement material adverse impact company liquidity capital resource company participate offbalance sheet arrangement involve unconsolidated subsidiary provide financing potentially expose company unrecorde financial obligation july board director approve purchase time billion merck share total treasury stock purchase program billion december billion remain stock repurchase authorization approve merck board directors inancial instrument market risk disclosure oreign currency risk management dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result strengthen dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company partially hedge anticipate thirdparty sale expect occur planning cycle typically year future company layer hedge time increase portion sale hedge get close expect date transaction probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow fully offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow weak dollar result net benefit market value company hedge decline million million respectively uniform weaken dollar december market value determine foreign exchange option pricing model hold factor exchange rate constant merck principally use purchase local currency option uniform weaken dollar yield large overall potential loss market value option sensitivity measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive net asset merck routinely enter contract fully offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract limit basis deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate sensitivity analysis change value dollar foreign currency denominate derivative investment monetary asset liability indicate dollar uniformly weaken currency exposure company december income taxis decline million million respectively merck net short position relative major foreign currency consideration forward contract uniform weaken dollar yield large overall potential net loss earning exchange measurement assume change foreign currency relative dollar affect foreign currency relative dollar predictive nature company believe threshold reflect reasonably possible nearterm change merck major foreign currency exposure relative dollar cash flow contract report operating activity consolidate statement cash flow nter rate risk management addition revenue hedge balance sheet risk management program company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party seven payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fix rate note swap mature notional million swap mature notional amount million swap mature notional million swap mature notional amount million swap effectively convert fixedrate obligation float rate instrument cash flow contract report operating activity consolidate statement cash flow company investment portfolio include cash equivalent shortterm investment december include repurchase agreement market value significantly impact change interest rate market value company medium longterm fixedrate investment modestly impact change interest rate change medium longterm interest rate significant impact market value company fixedrate borrowing generally long maturity sensitivity analysis measure potential change market value company investment debt relate swap contract change interest rate indicate percentage point increase interest rate december positively impact net aggregate market value instrument million million respectively percentage point decrease december negatively impact net aggregate market value million million respectively decrease sensitivity attributable change mix investment shortterm variable rate december longterm fix rate december fair value company debt determine pricing model reflect percentage point shift appropriate yield curve fair value company investment determine combination pricing duration model ritical accounting policy matter consolidated financial statement include certain amount base management good estimate judgment estimate determine item provision sale discount return depreciable amortizable life recoverability inventory produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation assumption acquisition taxis income uncertainty inherent estimate actual result differ estimate application follow accounting policy result accounting estimate potential significant impact financial statement evenue recognition revenue sale product recognize title risk loss pass customer revenue domestic pharmaceutical sale recognize time shipment foreign subsidiary vaccine sale revenue recognize time delivery recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesale purchaser know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale provision aggregate indirect customer discount cover chargeback rebate chargeback discount occur contract customer purchase directly intermediary wholesale purchaser contract customer generally purchase product contract price plus markup wholesaler wholesaler turn charge company difference price initially pay wholesaler contract price pay wholesaler customer provision chargeback base expect sellthrough level company wholesale customer contract customer estimate wholesaler inventory level rebate amount owe base definitive contractual agreement legal requirement private sector public sector medicaid benefit provider final dispense product pharmacy benefit plan participant provision base expect payment drive patient usage contract performance benefit provider customer company assume firstin firstout movement inventory supply chain purpose estimate aggregate indirect customer discount accrual addition company use historical customer segment mix adjust know event order estimate expect provision amount accrue aggregate indirect customer discount evaluate quarterly basis comparison information provide wholesaler customer amount accrue adjustment record trend significant event indicate change estimate provision appropriate company continually monitor provision aggregate indirect customer discount material adjustment estimate associate aggregate indirect customer discount provision summarize information change aggregate indirect customer discount accrual follow millions balance january current provision adjustment prior year payment alance december accrual chargeback reflect direct reduction account receivable accrual rebate accrue expense accrue balance relative provision include account receivable accrue current liability million million respectively december million billion respectively december company maintain return policy allow customer return product specify period prior subsequent expiration date generally month month product expiration estimate provision return base historical experience actual return additionally company consider factor level inventory distribution channel product date expiration period product discontinue entrance market additional generic competition change formulary launch overthecounter product product return provision actual return net sale distribution program wholesaler company encourage wholesaler align purchase underlie demand maintain inventory specify level term program allow wholesaler earn fee provide visibility inventory level achieve certain performance parameter inventory management customer service level reduce shortage claim reduce product return information provide wholesaler distribution program include item sale trend inventory onhand onorder quantity product return wholesaler generally provide mention datum company regulatory requirement report lot level information manufacturer level information need determine remain shelf life original sale date inventory give current wholesaler inventory level generally month company believe collection order lot information wholesale customer limited use estimate sale discount return nventorie produce preparation product launch company capitalize inventory produce preparation product launch sufficient support initial market demand typically capitalization inventory begin relate product candidate phase iii clinical trial consider high probability regulatory approval company monitor status respective product regulatory approval process company generally disclose specific timing regulatory approval company aware specific risk contingency normal regulatory approval process specific issue identify research process relate safety efficacy manufacturing marketing label relate inventory generally capitalize expiry date inventory impact stage completion company manage level inventory stage optimize shelf life inventory relation anticipate market demand order avoid product expiry issue inventory capitalize anticipated future sale shelf live support realization inventory value inventory shelf life sufficient meet initial product launch requirement december inventory produce preparation product launch consist vaccine product new formulation exist vaccine product new compound type diabetes company launch accordingly significant inventory produce preparation product launch capitalize december buildup inventory produce preparation product launch material effect company liquidity ontingencie environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action note consolidated financial statement company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december company reserve million solely future legal defense cost relate vioxx lawsuit vioxx investigation company spend million aggregate include million fourth quarter legal defense cost worldwide relate vioxx product liability lawsuit vioxx shareholder lawsuit iii vioxx foreign lawsuit vioxx investigation collectively vioxx litigation fourth quarter company record charge million million respectively increase reserve solely future legal defense cost relate vioxx million december reserve base certain assumption good estimate company believe time reasonably estimate spend significant factor consider establishment ongoing review reserve vioxx legal defense cost follow actual cost incur company time development company legal defense strategy structure light scope vioxx litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial vioxx product liability lawsuit event schedule trial expect occur inherent inability predict ultimate outcome trial limit company ability reasonably estimate legal cost end company anticipate need increase reserve quarter continue monitor legal defense cost review adequacy associate reserve determine increase reserve legal defense cost time future base factor set forth believe appropriate company currently anticipate number vioxx product liability lawsuit try trial oregon security case schedule company predict trial proceed schedule timing vioxx shareholder lawsuit trial company believe meritorious defense vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit unfavorable outcome vioxx litigation material adverse effect company financial position liquidity result operation company establish reserve potential liability relate vioxx litigation december company establish reserve approximately million solely future legal defense cost fosamax litigation significant factor consider establishment reserve fosamax litigation legal defense cost follow actual cost incur company far development company legal defense strategy structure light creation fosamax multidistrict litigation number case bring company anticipate timing progression relate cost pretrial activity fosamax litigation company continue monitor legal defense cost review adequacy associate reserve uncertain nature litigation company unable estimate cost end unfavorable outcome fosamax litigation material adverse effect company financial position liquidity result operation company establish reserve potential liability relate fosamax litigation company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent legitimate claim contribution assert liability initially accrue base estimate transaction cost manage site accrual adjust feasibility study relate cost assessment remedial technique complete extent potentially responsible party prps jointly severally liable expect contribute determine company remediate environmental contamination result past industrial activity certain site take active role identify provide cost worldwide survey initially perform assess site potential contamination result past industrial activity assessment indicate physical investigation warrant investigation perform provide well evaluation need remedial action need identify remedial action initiate estimate extent contamination site initially preinvestigation stage liability potential cost remediation accrue time definitive information available course investigation andor remedial effort site estimate refined accrual adjust accordingly estimate related accrual continue refine annually company believe compliance material respect applicable environmental law regulation expenditure remediation environmental liability million estimate million year management opinion liability environmental matter probable reasonably estimable accrue total million million december december respectively liabilitie undiscounted consider potential recovery insurer party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year harebase compensation company recognize compensation cost relate sharebased payment transaction net income fairvalue measurement method accordance fas adopt january fas require sharebase payment employee include grant employee stock option recognize net income compensation expense base fair value requisite service period award company determine fair value certain sharebased award blackschole optionprice model use historical current market datum estimate fair value method incorporate assumption riskfree interest rate expect volatility expect dividend yield expect life option ension postretirement benefit plan net pension postretirement benefit cost total million million pension postretirement benefit plan information financial reporting purpose calculate actuarial assumption include discount rate plan benefit obligation expect rate return plan asset company reassesse benefit plan assumption regular basis pension postretirement benefit plan discount rate evaluate annually modify reflect prevail market rate december portfolio highquality fixedincome debt instrument provide future cash flow need pay benefit include benefit obligation come december company change discount rate pension plan postretirement benefit plan expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay develop expect rate return company consider longterm compound annualize return historical market datum actual return company plan asset apply adjustment reflect recent capital market experience reference information company develop forwardlooke return expectation asset category weight average expect longterm rate return target portfolio allocate investment category expect portfolio performance reflect contribution active management appropriate result analysis company expect rate return remain unchanged pension postretirement benefit plan target investment portfolio company pension postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio equity weighting consistent long term nature plan benefit obligation expect annual standard deviation return target portfolio approximate reflect equity allocation diversification benefit asset class portfolio invest actuarial assumption base management good estimate judgment reasonably possible change plus minus basis point discount rate assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost reasonably possible change plus minus basis point expect rate return assumption assumption hold constant estimate million favorable unfavorable impact net pension postretirement benefit cost company expect minimum pension funding requirement internal revenue code precede hypothetical change discount rate expect rate return assumption impact company funding requirement effective december company adopt fasb statement employer account define benefit pension postretirement plan amendment fasb statement fas requirement measure plan asset benefit obligation company fiscal year end balance sheet effective december connection adoption fas net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component accumulate comprehensive income expect return base calculate marketrelated value asset methodology asset gainslosse result actual return differ company expect return recognize marketrelated value asset ratably fiveyear period net loss amount accumulate comprehensive income excess certain threshold amortize net pension postretirement benefit cost average remain service life employee amortization net loss companys plan december expect increase net pension postretirement benefit cost approximately million annually cquisition company account acquire business purchase method accounting accordance fas business combination require asset acquire liability assume record date acquisition respective fair value excess purchase price estimate fair value net asset acquire record goodwill company determine acquire company development stage company commence plan principal operation acquisition account acquisition asset business combination goodwill record fair value intangible asset include acquire research base significant judgment management accordingly significant item company typically obtain assistance party valuation specialist amount allocate acquire research expense date acquisition technological feasibility establish alternative future use exist project immediately research process alternative future use company capitalize intangible asset amortize appropriate useful life valuation useful life assumption base information available near acquisition date base expectation assumption deem reasonable management judgment determine estimate fair value assign asset acquire liability assume asset live materially impact company result operation intangible asset include acquire research company typically use income approach estimate fair value base project project cash flow future cash flow predominately base net income forecast project consistent historical pricing margin expense level similar product revenue estimate base relevant market size growth factor expect industry trend individual project life cycle life research project underle patent expect revenue adjust probability technical marketing success result cash flow discount risk adjust discount rate axis income company effective tax rate base pretax income statutory tax rate tax planning opportunity available jurisdiction company operate estimate effective tax rate year apply company quarterly operating result event significant unusual time item recognize expect recognize company quarterly operating result tax attributable item separately calculate record time unusual onetime item company consider resolution prior year tax matter item significant judgment require determine company effective tax rate evaluate tax position company establish reserve despite belief tax return position fully supportable certain position likely challenge succeed note consolidated financial statement company adjust reserve light change fact circumstance close tax audit tax regulation require item include tax return different time item reflect financial statement result effective tax rate reflect financial statement different report tax return difference permanent expense deductible tax return time difference depreciation expense timing difference create defer tax asset liability defer tax asset generally represent item tax deduction credit tax return future year company record tax benefit financial statement company establish valuation allowance defer tax asset expect future taxable income likely support use deduction credit defer tax liability generally represent tax expense recognize financial statement payment defer expense company take deduction tax return recognize expense financial statement previously disclose october ajca sign law ajca create temporary incentive multinational repatriate accumulate income earn outside united states december connection ajca company repatriate billion note consolidated financial statement result repatriation company record income tax charge million taxis income relate repatriation charge partially offset million benefit associate decision implement certain tax planning strategy company change intention indefinitely reinv accumulate earning earn subsequent december december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability ecently issue accounting standard july fasb issue interpretation accounting uncertainty income taxis interpretation fasb statement fin effective january fin clarifie accounting uncertainty tax position require company recognize financial statement impact tax position position likely sustain audit base technical merit position provision fin require expand disclosure end annual period present company continue evaluate impact fin financial position result operation time effect adoption determine september fasb issue statement fair value measurement fas effective january statement clarify definition fair value establishe framework measure fair value expand disclosure fair value measurement effect adoption fas company financial position result operation expect material autionary factor affect future result report write report oral statement time time company contain socalled forwardlooke statement base management current expectation subject risk uncertainty cause result differ materially set forth statement identify forwardlooke statement use word expect plan estimate forecast project word similar meaning identify fact relate strictly historical current fact statement likely address company growth strategy financial result product development product approval product potential development program carefully consider statement understand factor cause actual result differ materially company forwardlooke statement factor include inaccurate assumption broad variety risk uncertainty include know forward look statement guarantee actual future result vary materially company assume obligation update forwardlooke statement carefully evaluate statement light factor include risk factor describe company filing securities exchange commission especially form item business annual report company discuss detail important factor cause actual result differ expect historic result company note factor investor permit private security litigation reform act understand possible predict identify factor consequently reader consider list complete statement potential risk uncertaintie tem quantitative qualitative disclosure market risk information require item incorporate reference discussion financial instrument market risk disclosure item management discussion analysis financial condition result operation tem financial statement supplementary datum financial statement consolidate balance sheet merck inc subsidiary december relate consolidated statement income retain earning comprehensive income cash flow year period end december note consolidated financial statement report date february pricewaterhousecooper llp independent register public accounting firm follow onsolidate statement income merck inc subsidiary year end december millions share amount ale ost expense material production marketing administrative research development restructuring cost equity income affiliate income expense net ncome taxis tax income income basic earning common share earning common share assume dilution onsolidate statement retain earning merck inc subsidiary year end december millions alance january income common stock dividend declare balance december onsolidate statement comprehensive income merck inc subsidiary year end december millions net income ther comprehensive income loss net unrealized loss gain derivative net tax net income realization net unrealized gain loss investment net tax net income realization minimum pension liability net tax cumulative translation adjustment relate equity investee net tax omprehensive income accompany note integral consolidated financial statement consolidate balance sheet merck inc subsidiary december million sset current asset cash cash equivalent shortterm investment account receivable inventory exclude inventory classify asset note prepay expense taxis otal current asset nvestment roperty plant equipment cost land building machinery equipment office furnishing construction progress allowance depreciation oodwill ther intangible net ther asset liabilitie stockholder equity current liability loan payable current portion longterm debt trade account payable accrue current liability income taxis payable dividend payable otal current liability ongterm debt eferre income taxis noncurrent liability inority interest tockholder equity common stock cent par value authorize share issue share paidin capital retain earning accumulate comprehensive income treasury stock cost share share otal stockholder equity accompany note integral consolidated financial statement consolidate statement cash flow merck inc subsidiary year end december million cash flow operating activity net income adjustment reconcile net income net cash provide operating activity depreciation amortization defer income taxis equity income affiliate dividend distribution equity affiliate sharebase compensation acquire research net change asset liability account receivable inventory trade account payable accrue current liability income taxis payable noncurrent liability cash provide operating activity ash flow investing activity capital expenditure purchase security subsidiary investment proceed sale security subsidiary investment cash provide investing activity ash flow financing activity net change shortterm borrowing proceed issuance debt payment debt redemption prefer unit subsidiary purchase treasury stock dividend pay stockholder proceed exercise stock option cash financing activity ffect exchange rate change cash cash equivalent decrease increase cash cash equivalent cash cash equivalent begin year ash cash equivalent end year accompany note integral consolidated financial statement ote consolidated financial statement merck inc subsidiarie million share amount nature operation merck global researchdriven pharmaceutical company discover develop manufacture market broad range innovative product improve human animal health company operation principally manage product basis comprise reportable segment pharmaceutical segment vaccine segment pharmaceutical segment include human health pharmaceutical product market directly joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization institution vaccine segment include human health vaccine product market directly joint venture product consist preventative pediatric adolescent adult vaccine primarily administer physician office merck sell human health vaccine primarily physicians wholesalers physician distributor government entity company professional representative communicate effectiveness safety value pharmaceutical vaccine product health care professional private practice group practice manage care organization summary accounting policy principle consolidation consolidated financial statement include account company subsidiary control interest maintain control interest determine majority ownership interest absence substantive thirdparty participate right case variable interest entity majority exposure expect loss residual return consolidate subsidiary merck ownership outside stockholder interest show minority interest investment affiliate company significant influence control interest interest entity own equally company party share control carry equity basis foreign currency translation dollar functional currency company foreign subsidiary cash cash equivalent cash equivalent comprise certain highly liquid investment original maturity month inventory substantially domestic inventory value low lastin firstout lifo cost market book tax purpose foreign inventory value low firstin firstout fifo cost market inventory consist currently market product certain product await regulatory approval evaluate recoverability inventory produce preparation product launch company consider probability revenue obtain future sale relate inventory status product regulatory approval process investment investment classified availableforsale report fair value unrealize gain loss extent hedge report net tax accumulate comprehensive income investment debt security classify heldtomaturity consistent management intent report cost impairment loss charge income expense net otherthantemporary decline fair value company consider available evidence evaluate potential impairment investment include duration extent fair value cost company ability intent hold investment revenue recognition revenue sale product recognize title risk loss pass customer revenue domestic pharmaceutical sale recognize time shipment foreign subsidiary vaccine sale revenue recognize time delivery recognition revenue require reasonable assurance collection sale proceed completion performance obligation domestically sale discount issue customer direct discount pointofsale indirectly intermediary wholesale purchaser know chargeback indirectly form rebate additionally sale generally limited right return certain condition revenue record net provision sale discount return establish time sale accrual chargeback reflect direct reduction account receivable accrual rebate record accrue expense accrue balance relative provision include account receivable accrue current liability million million respectively december million billion respectively december effective january company begin recognize revenue sale vaccine federal government placement stockpile relate pediatric vaccine stockpile accordance securities exchange commission sec interpretation commission guidance accounting sale vaccine bioterror countermeasure federal government placement pediatric vaccine stockpile strategic national stockpile company retrospectively apply impact adopt interpretation reduce accrue current liability million increase income taxis payable million retain earning million respectively december impact company result operation impact adoption result operation increase follow sale million material production cost million taxis income million net income million earning common share assume dilution depreciation depreciation provide estimate useful life asset principally straightline method tax purpose accelerate method estimate useful life primarily range year building year machinery equipment office furnishing acquisition company account acquire business purchase method accounting accordance financial accounting standard board fasb statement business combination require asset acquire liability assume record date acquisition respective fair value excess purchase price estimate fair value net asset acquire record goodwill company determine acquire company development stage company commence plan principal operation acquisition account acquisition asset business combination goodwill recorded accordance fasb interpretation applicability fasb statement business combination account purchase method company allocate amount acquire research expense date acquisition technological feasibility establish alternative future use exist project immediately research process alternative future use company capitalize intangible asset amortize appropriate useful life operating result acquire business reflect company consolidate financial statement result operation date acquisition goodwill intangible goodwill represent excess acquisition cost fair value net asset business purchase goodwill assign reporting unit company segment evaluate impairment annual basis fair value base test acquire intangible record cost amortize straightline basis estimate useful life range year note event circumstance warrant review company assess recoverability future operation intangible undiscounted cash flow derive low appropriate asset grouping generally subsidiary level impairment recognize operating result extent carry value exceed fair value determine base net present value estimate future cash flow research development research development expense incur upfront milestone payment party connection research development collaboration prior regulatory approval expense incur payment party subsequent regulatory approval capitalize amortize shorter remaining license product patent life sharebase compensation effective january company adopt fasb statement sharebase payment fas note fas require sharebase payment employee expense requisite service period base grantdate fair value award require unvested portion outstanding award adoption recognize fair value attribution methodology previously determine fasb statement accounting stockbase compensation company continue use blackschole valuation method apply requirement fas modify prospective method prior adoption fas employee sharebase compensation recognize intrinsic value method measure sharebase compensation expense market price stock date grant exceed exercise price accordingly compensation expense recognize company sharebase compensation plan performancebase award restrict stock unit option grant employee certain equity method investee legal defense cost legal defense cost expect incur connection loss contingency accrue probable reasonably estimable use estimate consolidated financial statement prepare conformity accounting principle generally accept united states gaap accordingly include certain amount base management good estimate judgment estimate determine item provision sale discount return depreciable amortizable life recoverability inventory produce preparation product launch amount record contingency environmental liability reserve pension postretirement benefit plan assumption sharebase compensation acquisition tax income uncertainty inherent estimate actual result differ estimate reclassification certain reclassification prior year amount conform current year presentation recently issue accounting standard fasb recently issue interpretation accounting uncertainty income taxis interpretation fasb statement fin statement fair value measurement fas fin effective january clarifie accounting uncertainty tax position require company recognize financial statement impact tax position position likely sustain audit base technical merit position provision fin require expand disclosure end annual period present company continue evaluate impact fin financial position result operation time effect adoption determine fas effective january clarifie definition fair value establishe framework measure fair value expand disclosure fair value measurement effect adoption fas company financial position result operation expect material voluntary product withdrawal september company announce voluntary worldwide withdrawal vioxx arthritis acute pain medication company decision effective immediately base new threeyear datum prospective randomize placebocontrolle clinical trial approve adenomatous polyp prevention vioxx connection withdrawal company record unfavorable adjustment net income million share adjustment pretax income million million relate estimate customer return product previously sell record reduction sale million relate writeoff inventory hold company record material production expense million relate estimate cost undertake withdrawal product record marketing administrative expense tax benefit adjustment million reflect geographical mix vioxx return cost withdrawal adjustment include charge future legal defense cost note vioxx withdrawal process complete cost associate withdrawal line original amount record company restructure lobal restructuring program november company announce initial phase global restructuring program design reduce company cost structure increase efficiency enhance competitiveness initial step include implementation new supply strategy merck manufacturing division intend create lean costeffective customerfocused manufacturing model threeyear period program merck announce plan sell close manufacture site preclinical site end eliminate approximately position companywide company sell close certain facility sell related asset connection restructure program pretax cost restructure program million million expect million million end initial phase restructuring program expect substantially complete cumulative pretax cost program expect range billion billion approximately cumulative pretax cost noncash relate primarily accelerate depreciation facility schedule closure inception global restructure program december company record total pretax accumulate cost billion eliminate approximately position comprise employee separation elimination contractor vacant position follow table summarize charge related global restructure program type cost eparation ccelerate year end december cost depreciation total material production research development restructuring cost year end december aterial production research development restructuring cost separation cost associate actual headcount reduction headcount reduction probable reasonably estimate approximately position eliminate approximately eliminate comprise actual headcount reduction elimination contractor vacant position accelerate depreciation cost primarily relate merckowned manufacturing facility ponder end united kingdom okazaki japan kirkland canada albany georgia danville pennsylvania preclinical site okazaki menuma japan sell closed end action effort reduce cost consolidate company manufacture research facility end manufacture facility close sell cease operation preclinical site close site continue operate respective closure date future cash flow sufficient recover respective book value merck require accelerate depreciation site asset write immediately site asset include manufacture research facility equipment activity include approximately million million respectively associate impairment certain fix asset long business result restructuring action write additionally activity include million million respectively relate curtailment settlement termination charge companys pension postretirement benefit plan note activity include pretax gain million result sale facility connection global restructuring program ther restructuring program costreduction initiative announce october complete end company eliminate position company complete similar program position eliminate december result restructuring action company record restructuring cost million million amount respectively million million relate employee severance benefit million million relate curtailment settlement termination charge companys pension postretirement benefit plan note million relate modification term certain employee stock option grant follow table summarize charge spend relate global restructuring program program eparation ccelerate cost depreciation total restructure reserve january expense payment receipt net noncash activity restructure reserve december expense payment receipt net noncash activity restructure reserve december include separation cost associate global restructuring program amount restructure program restructure program substantially complete end quarter include proceed sale facility connection global restructuring program company close basic research center terling park united kingdom anticipation closing company incur additional accelerate depreciation cost million record research development expense reflect table reduce asset research center net realizable value subsequent december research development perform site company record restructure activity accordance fasb statement employer account postemployment benefit amendment fasb statement fasb statement employer accounting settlement curtailment define benefit pension plan termination benefit fasb statement accounting impairment disposal longlive asset fasb statement accounting cost associate exit disposal activity segment report restructuring charge record unallocated expense research collaboration acquisition license agreement merck continue strategy establish strong external alliance complement substantial internal research capability include research collaboration acquisition license preclinical clinical compound technology transfer drive near longterm growth merck sign agreement december merck complete acquisition sirna therapeutics inc sirna share cash total value approximately billion include purchase outstanding sirna share warrant stock option aggregate purchase price billion pay january accordingly reflect liability accrue current liability company consolidate balance sheet december sirna publiclyheld biotechnology company leader develop new class medicine base rna interference rnai technology significantly alter treatment disease rnaibase therapeutic selectively catalyze destruction rna transcribed individual gene acquisition sirna expect increase merck ability use rnai technology turn target gene human cell potentially render inoperative gene responsible trigger specific disease transaction account purchase method accounting asset acquire liability assume sirna date acquisition record respective fair value acquisition date company consolidate financial statement determination fair value require management significant estimate assumption excess purchase price fair value acquire net asset record goodwill million goodwill fully allocate pharmaceutical segment deductible tax purpose company record charge million acquire research associate sirnas compound currently development acquisition date technological feasibility establish alternative future use exist acquire research charge relate development treatment hepatitis hepatitis viruse preclinical development licensing agreement hold sirna charge deductible tax purpose record research development expense determine base present value expect future cash flow new product candidate result technology adjust probability technical marketing success utilize income approach reflect appropriate riskadjuste discount rate ongoing activity respect compound development expect material company research development expense allocation purchase price result recognition intangible asset million relate defer tax liability million asset liabilitie net million intangible asset relate sirnas develop technology immediately research development process alternative future use intangible asset amortize research development expense straight line basis seven year useful life pro forma financial information require sirnas historical financial result significant compare company financial result transaction close december accordingly sirnas operating result reflect company result operation december merck idera pharmaceutical idera announce form broad collaboration research develop commercialize idera tolllike receptor tlr agonist term agreement merck receive worldwide exclusive right number idera agonist compound target tlr use combination merck therapeutic prophylactic vaccine development oncology infectious disease alzheimer disease merck idera engage twoyear research development collaboration generate novel agonist target tlr tlr incorporate merck idera chemistry use license field merck pay upfront license fee million idera record research development expense purchase million common stock share addition merck fund research development collaboration idera eligible receive milestone payment million vaccine successfully develop field additional milestone million payable followon indication oncology field successful development additional vaccine contain idera tlr agonist limit number vaccine merck apply idera agonist licensed field addition idera receive royalty product commercialize collaboration november company expand scope exist strategic collaboration foxhollow technology inc foxhollow atherosclerotic plaque analysis additionally merck acquire stake foxhollow purchase million newlyissue share foxhollow common stock share represent approximately stake share record equity method investment consolidate balance sheet december exist strategic collaboration enter provide foxhollow receive upfront payment opportunity additional payment collaboration continue term expand collaboration agreement merck pay million foxhollow year exchange foxhollow agreement collaborate exclusively merck specify disease area merck provide minimum million funding foxhollow year year collaboration program term research activity conduct foxhollow merck direction foxhollow receive milestone payment successful development drug product diagnostic test utilize result collaboration royalty october merck ambrilia biopharma inc ambrilia biopharmaceutical company develop innovative therapeutic field cancer infectious disease announce enter exclusive licensing agreement grant merck worldwide right ambrilias hivaid protease inhibitor program term agreement ambrilia grant merck exclusive worldwide right lead compound ppl complete phase singledose pharmacokinetic study currently phase repeat dose pharmacokinetic study return ambrilia receive upfront licensing fee million signing company record research development expense eligible cash payment total million successful completion development clinical regulatory sale milestone ambrilia receive royalty future product sale june company acquire outstanding equity glycofi inc glycofi approximately million cash million purchase price net million share own net transaction cost glycofi privatelyheld biotechnology company leader field yeast glycoengineere addition specific carbohydrate modification protein yeast optimization biologic drug molecule glycofis technology platform development glycoprotein optimization glycoprotein target connection acquisition company record charge million acquire research associate glycofis technology platform research development process acquisition date technological feasibility establish alternative future use exist charge deductible tax purpose company expect technology fully develop year charge record research development expense determine base present value expect future cash flow new product candidate result technology adjust probability technical marketing success utilize income approach reflect appropriate riskadjuste discount rate company record million intangible asset million net defer taxis relate glycofis develop technology immediately research development process alternative future use intangible asset amortize research development expense straightline basis year useful life remain net asset acquire transaction material glycofi development stage company commence plan principal operation transaction account acquisition asset business combination goodwill record glycofis result operation include company consolidate financial result acquisition date company acquire equity abmaxis inc abmaxis approximately million cash abmaxis privatelyheld biopharmaceutical company dedicate discovery optimization monoclonal antibody mab product human therapeutic diagnostic abmaxis develop validate breakthrough antibody engineering technology platform abmaxis insilico immunization alternative future use company significant technological engineering risk date acquisition connection acquisition company allocate substantially purchase price abmaxis technology platform record intangible asset million million net defer taxis intangible asset amortize research development expense straightline basis year useful life remain net asset acquire transaction material abmaxis development stage company commence plan principal operation transaction account acquisition asset business combination goodwill record abmaxis result operation include company consolidate financial result acquisition date march neuromed pharmaceuticals ltd neuromed merck sign research collaboration license agreement research develop commercialize novel compound treatment pain neurological disorder include neuromed lead compound nme currently phase development treatment pain term agreement neurome receive upfront payment million company record research development expense successful development launch nme initial single indication worldwide basis trigger milestone payment total million milestone increase approximately million indication nme develop approve additional compound develop approve indication neurome receive royalty worldwide sale nme additional compound develop agreement agensys inc agensys cancer biotechnology company merck announce formation global alliance jointly develop commercialize agspsca agensys fully human mab prostate stem cell antigen merck enter agreement geron corporation develop cancer vaccine telomerase enzyme active cancer cell maintain telomere length end chromosome allow cancer grow metastasize long period time company acquire aton pharma inc aton privatelyheld biotechnology company focus development novel treatment cancer disease aton clinical pipeline histone deacetylase inhibitor represent class antitumor agents potential efficacy base novel mechanism action aton lead product candidate time acquisition suberoylanilide hydroxamic acid know vorinostat treatment cutaneous tcell lymphoma approve food drug administration october market zolinza united states consideration acquisition consist upfront payment contingent payment base regulatory filing approval sale product connection transaction company record charge million include research development expense acquire research associate product development acquisition date technological feasibility establish alternative future use exist remain net asset acquire transaction material aton development stage company commence plan principal operation transaction account acquisition asset business combination goodwill record aton result operation include company acquisition date financial instrument oreign currency risk management dollar functional currency company foreign subsidiary significant portion company revenue denominate foreign currency merck rely sustain cash flow generate foreign source support longterm commitment dollarbase research development extent dollar value cash flow diminish result strengthen dollar company ability fund research dollarbase strategic initiative consistent level impair company establish revenue hedge balance sheet risk management program protect volatility future foreign currency cash flow change fair value cause volatility foreign exchange rate objective revenue hedging program reduce potential longerterm unfavorable change foreign exchange decrease dollar value future cash flow derive foreign currency denominate sale primarily euro japanese yen achieve objective company partially hedge anticipate thirdparty sale expect occur planning cycle typically year future company layer hedge time increase portion sale hedge get close expect date transaction probable hedge transaction occur portion sale hedge base assessment costbenefit profile consider natural offset exposure revenue exchange rate volatility correlation cost hedging instrument hedge anticipated sale specify component portfolio similarly denominate foreign currencybase sale transaction respond hedged risk manner merck manage anticipate transaction exposure principally purchase local currency option provide company right obligation sell foreign currency future predetermine price dollar strengthen relative currency hedge anticipate sale total change option cash flow fully offset decline expect future dollar cash flow hedge foreign currency sale conversely dollar weaken option value reduce zero company benefit increase value anticipate foreign currency cash flow designate hedge relationship base total change option cash flow accordingly entire fair value change option defer accumulate comprehensive income aoci reclassify sale hedge anticipate revenue recognize hedge relationship perfectly effective hedge ineffectiveness record fair value currency option report account receivable asset cash flow contract report operating activity consolidate statement cash flow primary objective balance sheet risk management program protect dollar value foreign currency denominate net monetary asset effect volatility foreign exchange occur prior conversion dollar merck principally utilize forward exchange contract enable company buy sell foreign currency future fix exchange rate economically offset consequence change foreign exchange dollar cash flow derive net asset merck routinely enter contract fully offset effect exchange exposure denominate developed country currency primarily euro japanese yen exposure develop country currency company enter forward contract limit basis deem economical base costbenefit analysis consider magnitude exposure volatility exchange rate cost hedge instrument company minimize effect exchange monetary asset liability manage operating activity net asset position local level foreign currency denominate monetary asset liability remeasure spot rate effect balance sheet date effect change spot rate report income expense net forward contract designate hedge mark market income expense net accordingly fair value change forward contract help mitigate change value remeasure asset liability attributable change foreign currency exchange rate extent spotforward difference difference significant shortterm nature contract typically average maturity inception year company use forward contract hedge change fair value certain foreign currency denominate availableforsale security attributable fluctuation foreign currency exchange rate change fair value hedge security fluctuation spot rate offset income expense net fair value change forward contract attributable spot rate fluctuation hedge ineffectiveness material change contract fair value spotforward difference exclude designate hedge relationship recognize income expense net amount significant year end december fair value forward exchange contract report follow balance sheet line item account receivable current portion gain position asset noncurrent portion gain position accrue current liability current portion loss position defer income taxis noncurrent liability non current portion loss position cash flow contract report operating activity consolidate statement cash flow nter rate risk management company use interest rate swap contract certain investing borrowing transaction manage net exposure interest rate change reduce overall cost borrowing company use leveraged swap general leverage investment activity principal capital risk december company party seven payfloate receivefixe interest rate swap contract designate fair value hedge fixedrate note notional amount match hedge fixedrate note swap mature notional million swap mature notional amount million swap mature notional million swap mature notional amount million swap effectively convert fixedrate obligation floatingrate instrument fair value change note fully offset interest expense fair value change swap contract fair value contract report account receivable asset accrue current liability defer income taxis noncurrent liability cash flow contract report operating activity consolidate statement cash flow air value financial instrument summarize carry value fair value companys financial instrument december fair value estimate base market price available dealer quote carry value fair value carry value fair value asset cash cash equivalent shortterm investment longterm investment purchase currency option forward exchange contract interest rate swap liabilitie loan payable current portion longterm debt longterm debt forward exchange contract connection american job creation act ajca company repatriate billion note december billion ajca repatriation invest fully collateralized overnight repurchase agreement include shortterm investment consolidate balance sheet early company reinveste repurchase agreement balance short long term investment summary december carry value fair value company investment gross unrealized gain loss companys availableforsaleinvestment record net tax aoci follow carry fair gross unrealized value value gain loss corporate note bond government agency security commercial paper municipal security mortgagedbacke security assetbacke security foreign government bond repurchase agreement debt security equity security total availableforsale substantially company unrealized loss december continuous loss position month carry fair gross unrealized value value gain loss repurchase agreement corporate note bond commercial paper municipal security government agency security debt security equity security total availableforsale availableforsale debt security mature year total billion december remain debt security billion mature year oncentration credit risk ongoing control procedure company monitor concentration credit risk associate corporate issuer security financial institution conduct business credit risk minimal credit exposure limit establish avoid concentration single issuer institution customer represent aggregate approximately onefifth company account receivable december company monitors creditworthiness customer grant credit term normal course business bad debt minimal company normally require collateral security support credit sale inventory inventory december consist finished good raw material work process supply total approximate current cost reduction lifo cost recognize inventory asset inventory value lifo method comprise approximately inventory december amount recognize asset comprise entirely raw material work process inventory include inventory product expect sell year principally vaccine december inventory produce preparation product launch intangible intangible december consist patent product right total acquire cost patent product right total accumulate amortization increase intangible primarily reflect intangible connection acquisition sirna glycofi abmaxis note aggregate amortization expense million million million estimate aggregate amortization expense year follow million million million million million joint venture equity method affiliate equity income affiliate reflect performance company joint venture equity method affiliate comprise follow ear end december merckscheringplough astrazeneca primarily reflect result merial limited joint venture sanofi pasteur johnson johnson erckscheringplough company scheringplough corporation scheringplough collectively partner enter agreement create separate equallyowne partnership develop market united states new prescription medicine cholesterolmanagement respiratory therapeutic area agreement generally provide equal sharing development cost copromotion approve product company cholesterolmanagement partnership agreement expand include country world exclude japan ezetimibe new class cholesterollowere agent launch united states zetia market ezetrol outside united states report merckscheringplough cholesterol partnership msp partnership global sale zetia total billion billion billion july combination product contain active ingredient zetia zocor approve united states vytorin market inegy outside united states global sale vytorin billion billion million cholesterol agreement provide share operating income generate msp partnership base percentage vary product sale level country market partner share profit zetia vytorin equally exception million annual zetia sale scheringplough receive great share profit operating income include expense partner contractually agree share portion manufacturing cost specifically identify promotion cost include directtoconsumer advertising direct identifiable outofpocket promotion agree cost specific service ongoing clinical research market support market research market expansion specialty sale force physician education program expense incur support msp partnership share partner market administrative expense include certain sale force cost certain manufacturing cost include equity income affiliate cost reflect overall result company certain research development expense generally share equally partner adjust earn milestone respiratory therapeutic agreement provide joint development marketing partner oncedaily fixedcombination tablet contain active ingredient montelukast sodium loratadine montelukast sodium sell merck singulair loratadine sell scheringplough claritin january respiratory partnership report result phase iii clinical trial fixedcombination tablet contain montelukast sodium loratadine phase iii study demonstrate sufficient add benefit treatment seasonal allergic rhinitis montelukast sodium loratadine combination tablet approval country phase iii clinical development ongoing strazeneca merck enter agreement astra astra develop market astra product royaltybeare license company total sale astra product reach level trigger step establishment joint venture business carry astra merck inc ami merck astra own share joint venture form develop market astra new prescription medicine united states include prilosec class medication know proton pump inhibitor slow production acid cell stomach lining merck astra complete restructure ownership operation joint venture company acquire astras interest ami rename kbi inc kbi contribute kbis operating asset new limited partnership astra pharmaceutical partnership exchange limited partner interest astra contribute net asset wholly own subsidiary astra usa inc partnership exchange general partner interest partnership rename astrazeneca azlp astras merger zeneca group plc astrazeneca merger exclusive distributor product kbi retain right maintain limited partner interest azlp merck consent protective right intend preserve business economic interest include restriction power general partner certain distribution disposition furthermore limit event default additional right grant company include power direct action remove replace partnership chief executive officer chief financial officer merck earn ongoing revenue base sale current future kbi product revenue billion billion billion respectively primarily relate sale nexium prilosec addition merck earn certain partnership return record equity income affiliate reflect table return include priority return provide partnership agreement variable return base sale certain astra usa inc product preferential return represent merck share undistribute azlp gaap earning astrazeneca merger trigger partial redemption mercks limited partnership interest redemption azlp distribute kbi base primarily multiple merck average annual variable return derive sale astra usa inc product year prior redemption limited partner share agree value conjunction restructure payment million defer astra purchase option asset option buy merck interest kbi product exclude gastrointestinal medicine nexium prilosec asset option exercisable exercise price equal net present value march project future pretax revenue receive company kbi product appraise value merck right require astra purchase interest appraise value addition company grant astra option buy merck common stock interest kbi exercisable year astra purchase merck interest kbi product exercise option astra provide year combine annual sale product fall minimum provide case long merck option astrazenecas option exercise exercise price base net present value estimate future net sale nexium prilosec determine time exercise astrazeneca merger constitute trigger event kbi restructuring agreement result merger exchange merck relinquishment right future astra product exist pende patent time merger astra pay million advance payment subject trueup calculation require repayment portion trueup directly dependent fair market value astra product right retain company accordingly recognition contingent income defer realizable determinable anticipate prior provision kbi restructuring agreement trigger event occur sum limit partner share agree value appraise value trueup guarantee minimum billion distribution limited partner share agree value payment trueup occur astrazenecas purchase mercks interest kbi product contingent exercise merck option astrazenecas option payment appraise value occur anofi pasteur msd merck pasteur mrieux connaught sanofi pasteur establish equallyowne joint venture market vaccine europe collaborate development combination vaccine distribution europe joint venture vaccine sale million million million erial limited merck rhnepoulenc sanofiaventis combine animal health poultry genetic business form merial limited merial fully integrate animal health company standalone joint venture equally own party merial provide comprehensive range pharmaceutical vaccine enhance health wellbeing performance wide range animal specie merial sale billion billion billion ohnson johnson merck consumer pharmaceutical company merck form joint venture johnson johnson develop market broad range nonprescription medicine consumer own venture expand europe canada march merck sell equity stake european joint venture johnson johnson million record million gain income expense net note merck continue benefit royalty certain product regain right potential future product switch prescription overthecounter status europe sale product market joint venture include sale european joint venture march million million million investment affiliate account equity method include joint venture total billion december billion december amount report asset summarize information affiliate follow ear end december sale material production cost expense net income taxis ecember current asset noncurrent asset current liability noncurrent liability loan payable longterm debt commitment loan payable december include million million respectively longdate note subject repayment option holder annual basis loan payable december include million note annual interest rate reset redeem company february notification remarkete agent overall rise interest rate exercise annual option remarket note loan payable december include million fixedrate note million fix rate note respectively december foreign subsidiary company enter month million line credit financial institution december borrowing line credit million include loan payable loan payable december include billion commercial paper borrowing issue foreign subsidiary billion commercial paper borrowing facility establish october provide funding portion company repatriation connection ajca note commercial paper outstanding december weight average interest rate borrowing december respectively longterm debt december consist astra note note note debenture note debenture note variablerate borrow note debenture company party interest rate swap contract effectively convert million fixedrate note floatingrate instrument note present table december consist primarily million borrowing variable rate average respectively borrowing million subject repayment option holder begin million subject repayment option holder begin year include foreign borrowing vary rate aggregate maturity longterm debt year follow million billion million million million rental expense company operating lease net sublease income million minimum aggregate rental commitment noncancellable lease follow million million million million million million company significant capital lease contingency environmental liability company involve claim legal proceeding nature consider normal business include product liability intellectual property commercial litigation additional matter antitrust action company record accrual contingency probable liability incur reasonably estimate accrual adjust periodically assessment change additional information available product liability claim portion overall accrual actuarially determine consider factor past experience number claim report estimate claim incur report individually significant contingent loss accrue probable reasonably estimable legal defense cost expect incur connection loss contingency accrue probable reasonably estimable company decision obtain insurance coverage dependent market condition include cost availability exist time decision result number factor product liability insurance available cost increase significantly company evaluate risk determine cost obtain product liability insurance outweighs likely benefit coverage available insurance certain product liability effective august include liability product sell date company continue evaluate insurance need cost availability benefit product liability insurance future ioxx litigation roduct liability lawsuit previously disclose individual putative class action file company state federal court allege personal injury andor economic loss respect purchase use vioxx action file federal court coordinate multidistrict litigation district court eastern district louisiana mdl district judge eldon fallon number action file state court coordinate separate coordinate proceeding state court new jersey california texas counties philadelphia pennsylvania clark county nevada december company serve aware name defendant approximately lawsuit include approximately plaintiff group allege personal injury result use vioxx approximately putative class action allege personal injury andor economic loss action discuss paragraph collectively refer vioxx product liability lawsuit lawsuit approximately lawsuit represent approximately plaintiff group slate federal mdl approximately lawsuit represent approximately plaintiff group include coordinate proceed new jersey superior court judge carol higbee addition vioxx product liability lawsuit discuss claim plaintiff dismiss december plaintiff claim dismiss prejudice bring plaintiff court additional plaintiff claim dismiss prejudice bring mdl judge fallon july indicate schedule trial series case period november follow category heart attack short term use heart attack long term use iii stroke cardiovascular injury involve prescription write april labeling vioxx revise include result vigor trial trial begin november conclude december schedule trial mdl retrial barnett merck issue damage discuss merck enter tolling agreement tolling agreement mdl plaintiff steering committee establish procedure halt run statute limitation toll certain category claim allegedly arise use vioxx nonnew jersey citizens tolling agreement apply individual file lawsuit eventually file lawsuit claimant seek toll claim allege injury result thrombotic cardiovascular event result myocardial infarction ischemic stroke tolling agreement provide counsel additional time evaluate potential claim tolling agreement require toll claim file federal court december approximately claimants enter tolling agreement merck voluntarily withdraw vioxx market september state twoyear statute limitation product liability claim require claim file year plaintiff learn learn potential cause action result view september deadline filing vioxx case important note law statute limitation complex vary state state factspecific case affect existence pende class action example state year statute limitation instance statute limitation long merck expect legal argument concern proper application statute decision judge preside individual case state federal proceeding company previously disclose outcome vioxx product liability lawsuit try prior september chart august barnett merck case judge fallon mdl jury new orleans louisiana return plaintiff verdict second federal vioxx case trial jury award million compensatory damage million punitive damage august judge fallon overturn excessive damage portion verdict order new trial damage judge fallon set retrial october issue damage merck file motion new trial issue judgment matter law currently pende court plaintiff oppose merck motion ask judge reduce award retry case jury find favor merck count fourth fifth case trial mdl jury return verdict merck mason merck november dedrick merck december november judge fallon deny motion file mdl certify nationwide class person allegedly suffer personal injury result take vioxx december jury albright merck case try state court birmingham alabama return verdict merck count company previously disclose april garza merck jury rio grande city texas return verdict favor plaintiff september texas state court grant company request investigate possible jury bias juror admit prior trial occasion borrow money plaintiff december court enter judgment plaintiff million plus interest reduce original award million texas state cap punitive damage company seek new trial appeal verdict court grant new trial october california superior court los angeles consolidated trial begin case appell merck arrigale merck january judge victoria chaney declare mistrial plaintiff jury report deadlocke october coordinate proceed new jersey superior court judge higbee dismiss claim united kingdom plaintiff plaintiff appeal case schedule trial texas coordinate proceeding rigby merck schedule begin trial november rigby case voluntarily dismiss october plaintiff file notice nonsuit court consolidated trial herman merck humeston merck begin january coordinate proceed new jersey superior court judge higbee humeston merck try judge higbee set aside november jury verdict favor merck order new trial ground newly discover evidence hermanshumeston trial separate phase general phase merck conduct plaintiffspecific phase jury question deliberation phase merck conduct jury answer question affirmative case phase phase plaintiff present specific case end phase jury deliberate answer question respect plaintiff jury answer separate verdict sheet course deliberation case move punitive phase single presentation jury deliberation plaintiff case schedule trial philadelphia coordinate proceeding mccool merck schedule begin trial february plaintiff voluntarily dismiss prejudice case january september new jersey superior court appellate division hear argument plaintiff appeal judge higbees dismissal sinclair merck case putative class action originally file december seek creation medical monitoring fund judge higbee grant company motion dismiss january appellate division reverse decision remand case judge higbee factual inquiry company petition new jersey supreme court review appellate division decision date vioxx product liability lawsuit plaintiff claim schedule trial claim seven dismiss claim seven withdraw trial calendar plaintiff jury decide merck favor time plaintiff favor time addition recent california trial involve plaintiff jury reach verdict plaintiff mistrial declare new jersey state judge set aside merck verdict respect plaintiff verdict merck file appeal seek judicial review case federal judge overturn damage award shortly trial addition consolidated trial plaintiff currently ongoing coordinate proceed new jersey superior court judge higbee trial schwaller merck commence state court madison county illinois follow chart set forth result vioxx product liability trial date state federal verdict date plaintiff court result comment aug ernst texas verdict plaintiff jury award plaintiff million court reduce approximately million plus interest judgment appeal nov humeston verdict merck judge order new trial currently judge overturn ongoing verdict feb plunkett federal mistrial jury merck prevail february retrial deadlocke trial plaintiff move new trial verdict merck retrial april mcdarby verdict plaintiff plaintiff award million damage merck motion new trial pende plaintiff motion attorney fee april cona verdict merck jury award plaintiff nominal sum failure warn claim consumer fraud act claim merck motion new trial consumer fraud act claim pende plaintiff motion attorney fee april garza texas verdict plaintiff judge reduce million jury award million plus interest merck move new trial july doherty verdict merck plaintiff move new trial aug grossberg california verdict merck plaintiff move new trial aug barnett federal verdict plaintiff plaintiff award million damage judge rule award grossly excessive schedule new trial damage october mercks motion new trial remain issue pende sept smith federal verdict merck nov mason federal verdict merck dec dedrick federal verdict merck plaintiff move new trial dec albright alabama verdict merck plaintiff move new trial jan arrigaleappell california mistrial declare jury deadlocke ther lawsuit previously disclose july new jersey state trial court certify nationwide class party payor union health insurance plan pay vioxx plan member insureds name plaintiff case seek recovery certain vioxx purchase cost plus penalty base allegation purport class member pay vioxx know product allege risk merck believe class improperly certify trial court rule procedural address merit plaintiff allegation company intend defend vigorously march new jersey superior court appellate division affirm class certification order july new jersey supreme court decide exercise discretion hear company appeal appellate division decision august appellate division order stay proceeding superior court pende rule supreme court oral argument new jersey supreme court schedule place march previously report company name defendant separate lawsuit bring attorney general alaska louisiana mississippi montana texas utah actions allege company misrepresent safety vioxx seek recovery cost vioxx purchase reimburse state agency reimbursement sum pay state agency medical service treatment person injure vioxx iii damage common law theory andor remedy state statutory theory include state consumer fraud andor fair business practice medicaid fraud statute include civil penalty hareholder lawsuit previously disclose addition vioxx product liability lawsuit company current officer director defendant putative class action individual lawsuit federal security law state security law vioxx security lawsuit vioxx security lawsuit pende federal court transfer judicial panel multidistrict litigation jpml united states district court district new jersey district judge stanley chesler inclusion nationwide mdl shareholder mdl judge chesler consolidated vioxx security lawsuit purpose plaintiff request certification class purchaser company stock october complaint allege defendant false misleading statement vioxx violation section securities exchange act seek unspecified compensatory damage cost suit include attorney fee complaint assert claim section security exchange act certain defendant relate sale merck stock addition complaint include allegation section security act certain defendant incomplete misleading statement registration statement certain prospectus file connection merck stock investment plan dividend reinvestment plan defendant file motion dismiss complaint oral argument motion dismiss schedule place march previously disclose august complaint file oregon state court state oregon oregon state treasurer behalf oregon public employee retirement fund company certain current officer director complaint bring oregon security law allege plaintiff suffer damage connection purchase merck common stock artificially inflate price company allege violation law relate disclosure vioxx current officer director enter tolling agreement june dismiss prejudice case july court deny company motion dismiss complaint require plaintiff amend complaint plaintiff file amend complaint september merck file motion require plaintiff complaint definite certain deny court merck file answer complaint january previously disclose shareholder derivative action file federal court transfer shareholder mdl consolidated purpose judge chesler vioxx derivative lawsuit consolidate complaint arise substantially factual allegation vioxx security lawsuit vioxx derivative lawsuit purportedly bring assert right company assert claim certain member board past present certain executive officer breach fiduciary duty waste corporate asset unjust enrichment abuse control gross mismanagement judge chesler grant defendant motion dismiss deny plaintiff request leave amend complaint plaintiff appeal district court decision refuse leave amend complaint currently pende united states court appeal circuit previously disclose october individual shareholder demand board director company legal action raymond gilmartin chairman president chief executive officer individual allegedly cause damage company respect allegedly improper marketing vioxx july board receive shareholder letter demand board legal action board management merck allegedly cause damage company relate company allegedly improper marketing vioxx december demand reject board director previously announce board director appoint special committee review company action prior voluntary withdrawal vioxx act board respond shareholder litigation matter relate withdrawal vioxx advise board respect action take result review december special committee retain honorable john martin debevoise plimpton llp conduct independent investigation senior management conduct respect cardiovascular safety profile vioxx period vioxx develop market review complete quarter report include appendix public september addition previously disclose putative class action file federal court employee retirement income security act erisa company certain current officer director vioxx erisa lawsuit vioxx security lawsuit vioxx derivative lawsuit vioxx shareholder lawsuit transfer shareholder mdl consolidated purpose consolidate complaint assert claim behalf certain company current employee participant certain company retirement plan breach fiduciary duty lawsuit similar allegation allegation contain vioxx security lawsuit october defendant move dismiss erisa complaint july judge chesler grant deny defendant motion dismiss nternational lawsuit previously disclose addition lawsuit discuss company name defendant litigation relate vioxx country collectively vioxx foreign lawsuit europe canada brazil argentina australia turkey israel dditional lawsuit base medium report source company anticipate additional vioxx product liability lawsuit vioxx shareholder lawsuit vioxx foreign lawsuit collectively vioxx lawsuit file andor certain current officer director future nsurance previously disclose company product liability insurance claim bring vioxx product liability lawsuit state upper limit approximately million deductible coinsurance insurance provide coverage legal defense cost potential damage amount incur connection vioxx product liability lawsuit company believe insurance coverage extend additional vioxx product liability lawsuit file future company director officer insurance coverage applicable vioxx security lawsuit vioxx derivative lawsuit state upper limit approximately million company fiduciary insurance vioxx erisa lawsuit state upper limit approximately million additional insurance coverage claim available upperlevel excess policy provide coverage variety risk dispute certain insurer availability insurance coverage likely additional dispute companys insurance coverage respect vioxx lawsuit adequate cover defense cost loss previously disclose company upper level excess insurer provide excess insurance potentially applicable vioxx lawsuit commence arbitration seek thing cancel policy void obligation policy raise coverage issue respect vioxx lawsuit merck intend contest vigorously insurer claim attempt enforce right applicable insurance policy amount actually recover policy discuss section amount specify precede paragraph nvestigation previously disclose november company advise staff sec commence informal inquiry concern vioxx january company announce receive notice sec issue formal notice investigation company receive subpoenas department justice doj request information relate company research marketing selling activity respect vioxx federal health care investigation criminal statute addition previously disclose investigation conduct local authority certain city europe order determine criminal charge bring concern vioxx company cooperate governmental entity respective investigation vioxx investigation company predict outcome inquiry result potential civil andor criminal disposition previously disclose company receive number civil investigative demand cid group attorney general state district columbia investigate company violate state consumer protection law marketing vioxx company cooperate attorney general respond cid addition company receive subpoena september state california attorney general seek document information relate placement vioxx california medical formulary company cooperate attorney general respond subpoena eserves company currently anticipate number vioxx product liability lawsuit try trial oregon security case schedule company predict trial proceed schedule timing vioxx shareholder lawsuit trial company believe meritorious defense vioxx lawsuit vigorously defend view inherent difficulty predict outcome litigation particularly claimant claimant seek indeterminate damage company unable predict outcome matter time reasonably estimate possible loss range loss respect vioxx lawsuit company establish reserve potential liability relate vioxx lawsuit vioxx investigation include case verdict judgment enter company postverdict proceeding appeal case company believe strong point raise appeal unfavorable outcome case probable unfavorable outcome vioxx litigation define material adverse effect company financial position liquidity result operation legal defense cost expect incur connection loss contingency accrue probable reasonably estimable december company reserve million solely future legal defense cost relate vioxx litigation company spend million aggregate include million fourth quarter legal defense cost worldwide relate vioxx product liability lawsuit vioxx shareholder lawsuit iii vioxx foreign lawsuit vioxx investigation collectively vioxx litigation quarter fourth quarter company record charge million million respectively increase reserve solely future legal defense cost relate vioxx litigation million december increase reserve company consider factor consider previously establish reserve vioxx litigation management believe well estimate company expense reasonably estimate cost significant factor consider establishment ongoing review reserve vioxx legal defense cost follow actual cost incur company development company legal defense strategy structure light scope vioxx litigation number case bring company cost outcome complete trial current information anticipated timing progression relate cost pretrial activity trial vioxx product liability lawsuit event schedule trial expect occur inherent inability predict ultimate outcome trial limit company ability reasonably estimate legal cost end company continue monitor legal defense cost review adequacy associate reserve ther product liability litigation previously disclose company defendant product liability lawsuit unite states involve fosamax fosamax litigation december case file merck federal state court include case seek class action certification damage medical monitoring action plaintiff allege thing suffer osteonecrosis jaw generally subsequent invasive dental procedure tooth extraction dental implant andor delay healing association use fosamax august jpml order fosamax product liability case pende federal court nationwide transfer consolidated multidistrict litigation fosamax mdl coordinated pretrial proceeding fosamax mdl transfer judge john keenan united states district court southern district new york result jpml order case judge keenan judge keenan issue case management order set forth schedule governing proceeding focus primarily resolve class action certification motion company intend defend lawsuit december company establish reserve approximately million solely future legal defense cost fosamax litigation significant factor consider establishment reserve fosamax litigation legal defense cost follow actual cost incur company far development company legal defense strategy structure light creation fosamax mdl number case bring company anticipate timing progression relate cost pretrial activity fosamax litigation company continue monitor legal defense cost review adequacy associate reserve uncertain nature litigation company unable estimate cost end unfavorable outcome fosamax litigation material adverse effect company financial position liquidity result operation ommercial litigation begin company name number antitrust suit certain certify class action institute nation retail pharmacy consumer state company settle federal class action represent single large group claim settle substantially remain case satisfactory term remain case inactive year company engage conspiracy admission wrongdoing include settlement agreement previously disclose company join ongoing litigation allege manipulation pharmaceutical manufacturer average wholesale price awp calculation determine public private sector reimbursement level jpml order transfer consolidation pende federal awp case federal court boston massachusetts plaintiff file consolidated class action complaint aggregate claim previously file federal district court action expand number manufacturer include like company defendant prior pende case court grant company motion dismiss consolidated class action dismiss company class action case subsequent company dismissal plaintiff file amend consolidated class action complaint company defendant company pharmaceutical manufacturer defendant similar complaint pende federal state court bring individually number county state new york company defendant await final rule motion dismiss suffolk county case new york county case file addition december company defendant state case bring attorney general kentucky illinois alabama wisconsin mississippi arizona hawaii alaska defend previously disclose company name defendant antitrust case federal court minnesota state court california allege unlawful conspiracy different set pharmaceutical manufacturer protect high price united states impede importation united states lowerpriced pharmaceuticals canada court dismiss federal claim minnesota case prejudice plaintiff file notice appeal federal court appeal eighth circuit affirm dismissal federal claim state claim action dismiss prejudice refiled jurisdiction california antitrust action party engage discovery defendant manufacturer file summary judgment december court grant summary judgment favor merck defendant dismiss case plaintiff file notice appeal california state appeal court previously disclose suit federal court alabama provider health service needy patient allege pharmaceutical company overcharge plaintiff class similarly situate pharmaceutical purchase plaintiff program establish section public health service act company defendant file motion dismiss complaint numerous ground recently deny court denial motion dismiss case dismiss voluntarily party previously disclose january doj notify federal court new orleans louisiana go intervene time pende federal false claim act case file seal december company court issue order unseal complaint file physician louisiana ordered complaint serve complaint allege company discount pepcid certain louisiana hospital lead increase cost medicaid dismiss amend complaint file seal case administratively closed court seal lift state louisiana file amend complaint incorporate allegation contain seal amend complaint allegation contain seal amend complaint unknown april company name qui tam lawsuit nevada false claim act suit nevada attorney general intervene allege company inappropriately offer nominal pricing marketing pricing inducement certain customer fail comply obligation medicaid good price scheme relate arrangement company motion dismiss action deny district court company defend lawsuit overnmental proceeding previously disclose company receive subpoena doj connection investigation company marketing selling activity include nominal pricing program sample company report receive cid attorney general texas company marketing selling activity relate texas previously disclose company receive cid attorney general texas ask additional information company marketing selling activity relate texas include respect certain nominal pricing program sample april company receive subpoena office inspector general district columbia connection investigation company interaction physicians district columbia maryland virginia november company receive letter request doj connection investigation company pricing pepcid september company receive subpoena illinois attorney general subpoena seek information relate repackage prescription drug activity relate merck illinois matter previously disclose company receive letter doj advise existence qui tam complaint allege company violate certain rule relate calculation good price federal pricing benchmark calculation certain affect company medicaid rebate obligation doj inform company intend intervene action close investigation lawsuit continue company cooperate investigation company predict outcome investigation possible unfavorable outcome material adverse effect company financial position liquidity result operation addition time time federal state foreign regulator authority seek information practice pharmaceutical industry company business practice inquiry investigation discuss section feasible predict outcome inquiry previously disclose february italian antitrust authority ica adopt measure commence formal investigation merck sharp dohme italia spa msd italy company article italian competition law article ascertain company msd italy commit abuse dominant position refuse grant acs dobfar spa dobfar italian company voluntary license company italian supplementary protection certificate spc pursuant domestic legislation pass permit dobfar manufacture imipenem cilastatin active ingredient tienam italy sale outside italy country patent protection expired exist hear ica hold june ica find preliminary basis company refusal grant license abuse dominant position impose interim measure require company grant license manufacture italy stockpile purpose expiration spc november italian administrative court deny company appeal ica order company spc expire january proceeding ica continue merit article investigation effort resolve matter company offer commitment ica pursuant company grant nonexclusive license italian spc finasteride respect finasteride treatment benign prostate hyperplasia deadline ica adopt final decision company commitment warrant closure case march accine litigation previously disclose company party claim bring consumer protection act united kingdom allege certain child suffer variety condition result vaccinate bivalent vaccine measle rubella andor trivalent vaccine measle mumps rubella include company mmr condition include autism inflammatory bowel disease epilepsy encephalitis encephalopathy guillainbarre syndrome transverse myelitis claimant proceed company knowledge intend proceed company company defend lawsuit previously disclose company party individual class action product liability lawsuit claim united states involve pediatric vaccine hepatitis vaccine contain thimerosal preservative vaccine merck distribute thimerosalcontaine pediatric vaccine united states fall december approximately active thimerosal relate lawsuit approximately plaintiff defendant include vaccine manufacturer produce pediatric vaccine contain thimerosal manufacturer thimerosal action plaintiff allege thing suffer neurological injury result exposure thimerosal pediatric vaccine case schedule trial dismiss state court case ohio voluntarily dismiss plaintiff second federal district court case texas court enter summary judgment favor defendant plaintiff ultimately voluntarily dismiss appeal company defend lawsuit possible unfavorable outcome material adverse effect company financial position liquidity result operation company successful case type dismiss stay ground action prohibit national childhood vaccine injury act vaccine act vaccine act prohibit person file maintain civil action state federal court seek damage vaccine manufacturer vaccinerelate injury petition file united states court federal claim hereinafter vaccine court vaccine act file civil action vaccine manufacturer petitioner pursue petition conclusion vaccine court timely file election proceed civil action lieu accept vaccine court adjudication petition timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribe time period company party vaccine court proceeding petition bring united states department health human service case trial date refer precede paragraph dismiss bring plaintiff claim timely withdrawal vaccine court petition company aware approximately case pende vaccine court involve allegation thimerosalcontaine vaccine andor mmr vaccine cause autism spectrum disorder thimerosalcontaine vaccine involve vaccine court proceeding company vaccine company sole source mmr vaccine domestically june special master preside vaccine court proceeding schedule begin hear petitioner government present evidence issue vaccine cause autism spectrum disorder hearing expect number week party company participate proceeding atent litigation time time generic manufacturers pharmaceutical product file abbreviate new drug application anda fda seek market generic form company product prior expiration relevant patent own company generic pharmaceutical manufacturer submit andas fda seek market united states generic form fosamax prilosec nexium propecia trusopt cosopt prior expiration company astrazenecas case prilosec nexium patent concern product generic company anda generally include allegation non infringement invalidity unenforceability patent generic manufacturer receive fda approval market generic form prilosec company file patent infringement suit federal court company file andas generic alendronate fosamax finasteride propecia dorzolamide trusopt dorzolamidetimolol cosopt astrazeneca company file patent infringement suit federal court company file andas generic omeprazole prilosec esomeprazole nexium similar patent challenge exist certain foreign jurisdiction company intends vigorously defend patent believe valid infringement generic company attempt market product prior expiration date patent litigation assurance outcome adverse result significantly shorten period exclusivity product february schere plough corporation schering plough receive notice generic company indicate file anda zetia challenge patent list zetia merck schere plough market zetia joint venture consider appropriate response february company receive notice generic company indicate file anda montelukast challenge patent list singulair company consider appropriate response previously disclose january court appeal federal circuit washington find company patent claim onceweekly administration fosamax invalid company exhausted option appeal decision base court appeal decision fosamax fosamax plus lose market exclusivity united states february april respectively company expect significant decline fosamax fosamax plus sale product respective loss market exclusivity federal court canada trial division issue decision refuse bar approval generic alendronate ground mercks patent weekly alendronate likely invalid decision appeal generic alendronate launch canada june july merck sue federal court canada apotex seek damage lose sale generic weekly alendronate patent proceeding previously disclose september company appeal decision opposition division opposition division european patent office epo revoke company patent europe cover onceweekly administration alendronate march board appeal epo uphold decision opposition division presently company entitle market exclusivity fosamax major european market addition merck basic patent covering use alendronate challenge european country company receive adverse decision germany holland united kingdom decision united kingdom upheld appeal company appeal decision germany holland june company file lawsuit federal court barr laboratories inc teva pharmaceutical industries ltd teva assert respective manufacturing process make alendronate product infringe process patent company october action australia challenge validity company australian patent onceweekly administration alendronate patent find invalid decision uphold appeal addition previously disclose japan proceeding file challenge validity company japanese patent onceweekly administration alendronate january company sue hitech pharmacal inc hitech amityville new york patent infringement response hitechs application fda seek approval generic version merck ophthalmic drug trusopt cosopt treat elevated intraocular pressure people ocular hypertension glaucoma lawsuit merck sue enforce patent cover active ingredient dorzolamide present trusopt cosopt case district court enter judgment merck favor hitech appeal hearing appeal conduct december decision pende merck elect enforce patent list fda cover combination dorzolamide timolol active ingredient cosopt lawsuit automatically stay fda approval hitech anda month january adverse court decision whichever occur early patent covering dorzolamide provide exclusivity trusopt cosopt october include month pediatric exclusivity time company expect sale product decline case omeprazole trial court united states render opinion october uphold validity company astrazenecas patent cover stabilize formulation omeprazole rule defendant omeprazole product infringe patent defendant product find infringe formulation patent december court appeal federal circuit affirm decision trial court respect company patent infringement claim certain generic manufacturer omeprazole product trial conclude june decision pende company astrazeneca receive notice october ranbaxy laboratory limit ranbaxy file anda esomeprazole magnesium anda contain paragraph challenge patents nexium november company astrazeneca sue ranbaxy united states district court new jersey accordingly fda approval ranbaxys anda stay month april adverse court decision whichever occur early company astrazeneca receive notice january ivax pharmaceuticals inc subsequently acquire teva file anda esomeprazole magnesium anda contain paragraph challenge patent nexium march company astrazeneca sue teva united states district court new jersey accordingly fda approval tevas anda stay month september adverse court decision whichever occur early case finasteride anda file seek approval generic version propecia allege invalidity company patent company file patent infringement lawsuit district court delaware september company reach settlement generic company reddys laboratories drl drl sell generic finasteride product begin january europe company aware company seek registration generic losartan active ingredient cozaar company patent right losartan license pont nemour company pont company pont file patent infringement proceeding company portugal spain norway ther litigation july merck serve shareholder derivative suit file new jersey superior court hunterdon county company certain current officer director lawsuit seeks recover cancel compensation award company executive officer assert claim breach fiduciary duty waste unjust enrichment july court grant defendant motion dismiss base plaintiff failure presuit demand merck board director deny plaintiff request leave amend case terminate november individual shareholder deliver letter board allege company sustain damage company adoption change control separation benefit plan cic plan november shareholder demand board legal action board current member allegedly cause damage company respect adoption cic plan response demand letter independent member board determine november board meeting board shareholder request consideration remain consideration previously disclose august united states district court district new jersey grant motion company medco health solutions inc medco health certain officer director dismiss shareholder derivative action involve claim relate company revenue recognition practice retail copayment pay individual medco health provide pharmaceutical benefit allegation complaint dismiss prejudice plaintiff appeal decision december court appeal circuit uphold district court decision dismissing suit send issue company board director properly refuse shareholder demand relate company treatment retail copayment district court reconsideration different legal standard plaintiff move remand action state court august district court grant motion february shareholder derivative suit currently pende superior court new jersey chancery division hunterdon county previously disclose prior spinoff medco health company medco health agree settle class action basis series lawsuit assert violation erisa gruer case company medco health certain plaintiff counsel file settlement agreement federal district court new york case commence number plaintiff include participant number pharmaceutical benefit plan medco health pharmacy benefit manager trustee plan consolidated medco health company agree propose settlement order avoid significant cost distraction prolong litigation propose class settlement agree plaintiff case file medco health company propose settlement company medco health agree pay total million medco health agree modify certain business practice continue certain specify business practice period year financial compensation intend benefit member settlement class include erisa plan medco health administer pharmacy benefit time december district court hold hearing hear objection fairness propose settlement approve settlement determined number class member plan properly elect participate settlement settlement final appeal resolve certain class member plan indicate participate settlement case initiate plan individual remain pende southern district new york plaintiff case assert claim base erisa federal state law similar claim assert settle class member gruer case company medco health name defendant case notice appeal file appellate court hear oral argument december appellate court issue decision vacate district court judgment remand case district court allow district court resolve certain jurisdictional issue hear hold address issue february district court issue ruling august resolve jurisdictional issue favor settle plaintiff class member party previously appeal district court judgment renew appeal renew appeal presently brief spinoff medco health medco health assume substantially liability exposure matter discuss forego paragraph case defend medco health legal proceeding principally product liability intellectual property suit involve company pende feasible predict outcome proceeding proceeding discuss note opinion company proceeding adequately cover insurance cover ultimately result liability material adverse effect financial position liquidity result operation company proceeding separate assessment provide note nvironmental matter company party number proceeding bring comprehensive environmental response compensation liability act commonly know superfund federal state equivalent proceeding seek require operator hazardous waste disposal facility transporter waste site generator hazardous waste dispose site clean site reimburse government cleanup cost company party proceeding allege generator waste dispose site case government allege defendant jointly severally liable cleanup cost joint liability allege proceeding frequently resolve allocation cleanup cost party nearly reflect relative contribution party site situation company potential liability vary greatly site site site potential liability minimis cost cleanup determined feasible predict outcome proceeding bring federal state agency private litigant opinion company proceeding ultimately result liability material adverse effect financial position result operation liquidity capital resource company company take active role identify provide cost amount include reduction anticipate recovery cleanup cost insurer site owner operator recalcitrant potentially responsible party june potassium thiocyanate accidentally discharge company plant west point pennsylvania upper gwynedd township authoritys wastewater treatment plant wissahickon creek cause fishkill federal state agency investigate discharge company currently cooperate investigation management opinion liability environmental matter probable reasonably estimable accrue total million million december respectively liability undiscounted consider potential recovery insurer party pay periods remediation applicable site expect occur primarily year possible predict certainty outcome matter ultimate cost remediation management believe reasonably possible expenditure incur excess liability accrue exceed million aggregate management believe expenditure result material adverse effect company financial position result operation liquidity capital resource year prefer stock subsidiary company december company redeem variablerate preferred unit subsidiary billion par value plus accrue dividend prefer security hold subsidiary level previously include minority interest consolidate financial statement connection restructure ami note company assume billion par value prefer stock obligation dividend rate annum carry kbi include minority interest small portion prefer stock carry kbi convertible kbi common share prefer security convertible company common share include common share issuable purpose compute earning common share assume dilution note stockholder equity paidin capital increase million million decrease million change primarily reflect impact share issue exercise stock option relate income tax benefit issuance restrict share addition increase reflect impact recognize sharebased compensation expense result adoption fas note summary treasury stock transaction share millions follow share cost share cost share cost alance january purchase issuance alance december issue primarily stock option plan december million share prefer stock par value authorize issue sharebased compensation plan company sharebase compensation plan employee nonemployee director employee certain company equity method investee grant option purchase share company common stock fair market value time grant addition stock option company grant performance share unit psus restrict stock unit rsus certain management level employee plan approve company shareholder december million share authorize future grant company sharebase compensation plan company settle employee sharebase compensation award primarily treasury share employee stock option grant purchase share company stock fair market value time grant award generally vest onethird year threeyear period contractual term year rsus stock award grant employee entitle holder share common stock award vest nonforfeitable dividend equivalent fair value award determine fix grant date base company stock price psus stock awards ultimate number share issue contingent company performance preset objective set objective fair value psu determined date grant base company stock price performance period number share stock expect issue adjust base probability achievement performance target final compensation expense recognize base ultimate number share issue company recognize compensation expense connection psus psu rsu payout share company stock end threeyear period subject term applicable award effective january company adopt fas employee sharebase compensation expense previously recognize intrinsic value method measure sharebase compensation expense market price stock date grant exceed exercise price fas require recognition fair value sharebase compensation net income company recognize straight line basis requisite service period additionally company elect modify prospective transition method adopt fas prior period retrospectively adjust method provision fas apply award grant modify january addition unrecognized expense award vest date adoption recognize net income relevant period date adoption effective january company adopt fasb staff position transition election relate accounting tax effect sharebase payment award provide company optional short cut method calculate historical pool windfall tax benefit adopt fas follow table provide amount sharebased compensation cost record consolidated statement income substantially amount relate rsus ear end december retax sharebase compensation expense income tax benefit otal sharebase compensation expense net tax result adoption fas effective january incremental impact company sharebase compensation expense reduce company result operation follow ear end december income taxis net income earning common share assume dilution fas require company present pro forma information period prior adoption company account employee sharebase compensation fair value method statement purpose pro forma disclosure estimate fair value award date grant include grant retirementeligible employee amortize expense requisite service period follow table illustrate effect net income earning common share company apply fair value method recognize employee sharebase compensation year end december ear end december net income report compensation expense net tax report fair value method pro forma net income earning common share basic report basic pro forma assume dilution report assume dilution pro forma pro forma amount fair value option grant estimate date grant blackschole option pricing model adoption fas compensation expense recognize immediately award grant retirementeligible employee period grant date date retirement eligibility achieve approach know nonsubstantive vest period approach company apply approach stock option grant retirementeligible employee effect pro forma earning share assume dilution year end december provide table significant pro forma compensation expense calculate blackschole model utilize assumption base historical datum expense determine separate expect term assumption vest tranche result pro forma compensation expense stock option grant january prior january calculate accelerate amortization method prescribe fasb interpretation accounting stock appreciation right variable stock option award plan adoption fas effective january company recognize compensation expense straightline method company continue use blackschole option pricing model option grant adoption fas applying model company use historical datum current market datum estimate fair value option blackschole model require assumption include expect term option riskfree rate volatility dividend yield expect term represent expect time option grant expect outstanding base historical forecast exercise behavior riskfree rate base rate grant date zerocoupon treasury notes term equal expect term option expect volatility estimate blend historical imply volatility historical component base historical monthly price change imply volatility obtain market datum company trade option weight average fair value option grant option respectively determine follow assumption ear end december expect dividend yield riskfree interest rate expect volatility expect life year summarize information relative company stock option plan option thousand follows weight weight average aggregate average remain intrinsic number exercise contractual value option price term balance december grant exercise forfeit outstanding december exercisable december additional information pertaining company stock option plan provide table ear end december total intrinsic value stock option exercise fair value stock option vest cash receive exercise stock option summary company nonveste rsus psus share thousand december follow sus sus weight weight average average number grant date number grant date share fair value share fair value nonveste december grant vest forfeit onvested december december million total pretax unrecognized compensation expense relate nonveste stock option rsu psu award recognize weight average period year segment report sharebased compensation record unallocated expense pension postretirement benefit plan company define benefit pension plan cover eligible employee united states certain international subsidiary pension benefit united states base formula consider final average pay year credit service addition company provide medical dental life insurance benefit principally eligible retiree similar benefit dependent postretirement benefit plan company use december measurement date substantially pension plan postretirement benefit plan net cost company pension postretirement benefit plan consist follow component stretir ent pension benefit benefit year end december service cost interest cost expect return plan asset net amortization termination benefit curtailment settlement pension postretirement cost net pension cost attributable plan include table million million million cost health care life insurance benefit active employee million million million connection company restructuring action note merck record termination charge pension postretirement benefit plan relate expand eligibility certain employee exit company connection restructuring activity company record curtailment loss pension postretirement benefit plan amendment change participant contribution service recognize eligibility postretirement benefit plan generate curtailment gain addition company record settlement loss settlement gain certain domestic pension plan result employee elect receive pension benefit lump sum payment effective december company adopt fasb statement employer account define benefit pension postretirement plan amendment fasb statement fas requirement measure plan asset benefit obligation company fiscal year end effective december fas require company fully recognize fund status benefit plan overfunde plan recognize asset underfunde plan recognize liability previously unrecognized net loss unrecognize plan change recognize component aoci december note effect apply fas december follow application fas application fas adjustment fas prepay expense taxis asset accrue current liability defer income taxis noncurrent liability accumulate comprehensive income loss summarize information change plan asset benefit obligation fund status amount record december follow ther treti rement pension benefit benefit fair value plan asset january actual return plan asset company contribution benefit pay plan asset air value plan asset december benefit obligation january service cost interest cost actuarial loss gain benefit pay plan amendment curtailment termination benefit enefit obligation december fund status december unrecognize net loss unrecognized plan change record recognize asset accrue current liability defer income taxis noncurrent liability accumulate comprehensive loss fair value pension plan asset include precede table billion billion pension benefit obligation plan include table billion billion weight average asset allocation investment portfolio pension postretirement benefit plan december follow ther pension postretirement benefit benefit equities international equity fixedincome investment real estate investment cash cash equivalent target investment portfolio company pension plan determine country base nature liability consider demographic composition plan participant average age year service active versus retiree status accordance local regulation weight average target allocation equities international equities fixedincome investment real estate investment cash cash equivalent investment include insurance contract certain international pension plan target investment portfolio company postretirement benefit plan allocate equity international equity fixedincome investment cash investment portfolio asset allocation consistent longterm nature plan benefit obligation diversify asset class portfolio invest contribution pension plan postretirement benefit plan expect million million respectively expect benefit payment follow pension postretirement benefit benefit expect benefit payment base assumption measure benefit obligation include estimate future employee service december accumulate benefit obligation billion billion respectively pension plan billion billion respectively pension plan company record minimum pension liability represent extent accumulate benefit obligation exceed plan asset certain company pension plan million prior adoption fas december minimum pension liability million december pension plan benefit obligation excess plan asset december fair value plan asset million million respectively benefit obligation billion billion respectively plan accumulate benefit obligation excess plan asset december fair value plan asset million million respectively accumulate benefit obligation million million respectively effective adoption fas net loss amount reflect experience differential primarily relate difference expect actual return plan asset effect change actuarial assumption record component aoci net loss amount excess certain threshold amortize net pension postretirement benefit cost average remain service life employee estimate net loss prior service cost credit amount amortize aoci net pension postretirement benefit cost million million respectively pension plan million million respectively postretirement benefit plan company reassesse benefit plan assumption regular basis weight average assumption determine pension plan pension postretirement benefit plan information follow sion postretirement pension plan benefit plan december net cost iscount rate expect rate return plan asset salary growth rate enefit obligation iscount rate salary growth rate postretirement benefit plan expect rate return pension postretirement benefit plan represent average rate return earn plan asset period benefit include benefit obligation pay determined country basis develop expect rate return country longterm historical return datum consider actual return plan asset capital market experience reference information longterm return expectation asset category weight average expect return countrys target portfolio develop accord allocation investment category expect portfolio performance reflect contribution active management appropriate company expect rate return remain unchanged pension postretirement benefit plan health care cost trend rate assumption postretirement benefit plan follow ecember health care cost trend rate assume year rate cost trend rate assume decline year trend rate reach ultimate trend rate percentage point change health care cost trend rate follow effect rcen tage point increase decrease effect total service interest cost component effect benefit obligation income expense net ear end december interest income interest expense exchange gain minority interest net increase interest income reflect interest income generate company investment portfolio derive high interest rate high average investment portfolio balance interest pay million million million reduce minority interest attributable redemption subsidiary variablerate preferred unit note net primarily reflect million gain sale company equity stake european joint venture johnson johnson realize gain company investment portfolio taxis income reconciliation company effective tax rate statutory rate follow rat statutory rate apply income taxis differential arise foreign earning tax exemption puerto rico operation acquire research state taxis ajca include tax effect minority interest contingency reserve research credit export incentive miscellaneous item domestic company contribute approximately consolidated income taxis tax income consist ear end december current provision federal foreign state eferre provision federal foreign state defer income taxis december consist asset liability asset liability intangible inventory relate accelerated depreciation advance payment equity investment pension opeb compensation relate vioxx legal defense cost reserve net operating loss subtotal valuation allowance otal defer taxis deferred income taxis recognize prepay expense taxis asset income taxis payable deferred income taxis noncurrent liability company net operating loss nol carryforward number jurisdiction significant united kingdom nol carryforward million expiration date valuation allowance year primarily relate certain canadian nol carryforward result legal entity reorganization income taxis pay billion billion billion respectively stock option exercise significant impact taxis pay stock option exercise reduce income taxis pay million previously disclose internal revenue service irs examine company tax return year issue notice deficiency respect partnership transaction enter minority interest equity financing enter respectively irs recently conclude examination year issue final revenue agent report quarter february company enter closing agreement irs cover specific item include partnership transaction minority interest equity financing terms close agreement company expect payment approximately billion quarter payment offset tax refund million amount previously pay related matter million federal tax benefit relate interest include payment result net cash cost company approximately billion company previously establish reserve matters conclusion irs examination include closing agreement material effect company result operation financial position liquidity material adverse effect company cash flow quarter payment impact year subsequent partnership transaction minority interest equity financing include closing agreement year remain open respect previously disclose merck canadian tax return year examine canada revenue agency cra october cra issue company notice reassessment contain adjustment relate certain intercompany pricing matter result additional tax approximately billion dollar plus interest million dollar company disagree position take cra believe merit company intend contest assessment cra appeal process court necessary connection appeal process notice reassessment company require post deposit half tax interest assess january company pledge collateral consist cash cash equivalent million financial institution provide letter guarantee cra management believe resolution matter material adverse effect company financial position liquidity unfavorable resolution material adverse effect company result operation cash flow quarter adjustment record tax previously disclose october ajca sign law ajca create temporary incentive multinational repatriate accumulate income earn outside united states december accordance ajca company repatriate billion company record income tax charge million taxis income relate repatriation million pay remainder pay quarter charge partially offset million benefit associate decision implement certain tax planning strategy company change intention indefinitely reinv accumulate earning earn subsequent december december foreign earning billion retain indefinitely subsidiary company reinvestment provision income taxis payable distribution earning practicable determine relate unrecognized deferred income tax liability addition company subsidiary operate puerto rico singapore tax incentive grant expire respectively earning share weight average common share computation basic earning common share earning common share assume dilution share million follow ear end december average common share outstanding common share issuable verage common share outstanding assume dilution issuable primarily sharebased compensation plan million million million common share issuable company sharebase compensation plan exclude computation earning common share assume dilution effect antidilutive comprehensive income component comprehensive income loss follow etax tax fter tax year end december unrealize loss derivative net loss realization erivative unrealized gain investment net loss realization nvestment inimum pension liability umulative translation adjustment relate equity investee year end december unrealized gain derivative net loss realization erivative unrealized loss investment net loss realization nvestment inimum pension liability umulative translation adjustment relate equity investee etax tax fter tax year end december unrealize loss derivative net loss realization erivative unrealized loss investment net income realization nvestment inimum pension liability umulative translation adjustment relate equity investee net applicable minority interest component accumulate comprehensive income loss follow ecember net unrealized loss gain derivative net unrealized gain investment minimum pension liability pension plan net loss postretirement benefit plan net loss pension plan change postretirement benefit plan change cumulative translation adjustment relate equity investee december million net unrealized loss derivative associate option mature month hedge anticipate foreign currency denominate sale period segment reporting company operation principally manage product basis comprise reportable segment pharmaceutical segment vaccine segment fourth quarter vaccine segment previously include meet reportable segment criterion pursuant fasb statement disclosure segment enterprise relate information prior period recast reflect vaccine reportable segment pharmaceutical segment include human health pharmaceutical product market directly joint venture product consist therapeutic preventive agent sell prescription treatment human disorder merck sell human health pharmaceutical product primarily drug wholesaler retailer hospital government agency manage health care provider health maintenance organization institution vaccine segment include human health vaccine product market directly joint venture product consist preventative pediatric adolescent adult vaccine primarily administer physician office merck sell human health vaccine primarily physicians wholesaler physician distributor government entity vaccine segment include vast majority company vaccine sale exclude certain sale vaccine nonus subsidiary manage include pharmaceutical segment large component pediatric adolescent vaccine fund government center disease control prevention vaccine child program include nonreportable human animal health segment accounting policy segment describe describe note revenue profit segment follow harmaceutical accine total year end december egment revenue segment profit include segment profit equity income affiliate depreciation amortization ear end december egment revenue segment profit include segment profit equity income affiliate depreciation amortization ear end december egment revenue segment profit include segment profit equity income affiliate depreciation amortization accordance segment reporting requirement vaccine segment revenue exclude million million million respectively vaccine sale certain nonus subsidiary manage include pharmaceutical segment segment profit comprise segment revenue certain element material production cost operating expense include component equity income loss affiliate depreciation amortization expense internal management reporting present chief operating decision maker company allocate vast majority indirect production cost research development expense general administrative expense cost financing activity separate division maintain responsibility monitor managing cost include depreciation relate fix asset utilize division include segment profit reconciliation total segment revenue consolidate sale follow ear end december segment revenue revenue revenue primarily comprise miscellaneous corporate revenue sale relate divested product business supply sale include segment result sale company product follow ear end december singulair cozaarhyzaar fosamax zocor primaxin cosopttrusopt proscar vasotecvaseretic cancidas maxalt propecia vioxx vaccinesbiological present net discount return amount reflect sale vaccine sell major european market company joint venture sanofi pasteur msd result reflect equity income affiliate primarily include sale human pharmaceutical pharmaceutical animal health supply sale company joint venture revenue company relationship azlp primarily relate sale nexium prilosec revenue azlp billion billion billion respectively consolidate revenue geographic area derive follow ear end december united states europe middle east africa japan reconciliation total segment profit consolidate income taxis follow ear end december segment profit profit adjustment unallocate interest income interest expense equity income affiliate depreciation amortization research development expense net profit primarily comprise miscellaneous corporate profit operating profit relate divested product business supply sale adjustment represent elimination effect double count certain item income expense equity income affiliate include taxis pay joint venture level portion equity income report segment profit expense net include expense corporate manufacturing cost center miscellaneous income expense net longlived assets geographic area locate follow ear end december united states europe middle east africa japan longlive asset comprise property plant equipment net goodwill intangible asset net company disaggregate asset product service basis internal management report information present eport independent register public accounting firm stockholder board directors merck inc complete integrate audits merck inc consolidated financial statement internal control financial reporting december accordance standard public company accounting oversight board united states opinion base audit present onsolidate financial statement opinion accompany consolidated balance sheet relate consolidated statement income retain earning comprehensive income cash flow present fairly material respect financial position merck inc subsidiaries december december result operation cash flow year period end december conformity accounting principle generally accept united states america financial statement responsibility company management responsibility express opinion financial statement base audit conduct audits statement accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit financial statement include examine test basis evidence support amount disclosure financial statement assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion discuss note consolidated financial statement company change manner account sharebase compensation discuss note consolidated financial statement company change manner account define benefit pension postretirement plan effective december nternal control financial reporting lso opinion management assessment include accompany management report internal control financial reporting company maintain effective internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso fairly state material respect base criterion furthermore opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting responsibility express opinion management assessment effectiveness company internal control financial reporting base audit conduct audit internal control financial reporting accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit internal control financial reporting include obtain understand internal control financial reporting evaluate management assessment testing evaluate design operating effectiveness internal control perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition assets company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company iii provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement ecause inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate ricewaterhousecooper llp florham park new jersey february supplementary datum select quarterly financial datum contain condense interim financial datum table ondense interim financial datum unaudite million share amount ale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income taxis net income basic earning common share earning common share assume dilution ale material production cost market administrative expense research development expense restructure cost equity income affiliate income expense net income taxis net income basic earning common share earning common share assume dilution amount include acquire research expense associate acquisition amount fourth quarter fourth quarter include impact additional vioxx legal defense reserve note amount fourth quarter include impact fosamax legal defense reserve note amount include impact net tax charge primarily associate ajca repatriation note amount include impact restructuring action note amount reflect incremental impact expense stock option tem change disagreement accountant account financial disclosure applicable tem control procedure management company participation chief executive officer chief financial officer evaluate effectiveness company disclosure control procedure base evaluation end period cover company chief executive officer chief financial officer conclude company disclosure control procedure define rule securities exchange act amend act effective management responsible establish maintain adequate internal control financial reporting term define rule act management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission coso base evaluation management conclude internal control financial reporting effective december base criteria internal control integrate framework issue coso management assessment effectiveness internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm pricewaterhousecooper llp issue report management assessment effectiveness company internal control financial reporting change internal control financial reporting period cover report materially affect reasonably likely materially affect company internal control financial reporting anagement report anagement responsibility financial statement responsibility integrity objectivity company financial statement rest management financial statement report management stewardship company asset statement prepare conformity generally accept accounting principle accordingly include amount base management good estimate judgment nonfinancial information include annual report prepare management consistent financial statement assure financial information reliable asset safeguard management maintain effective system internal control procedure important element include careful selection training development operate financial manager organization provide appropriate division responsibility communication aim assure company policy procedure understand organization staff internal auditor regularly monitor adequacy application internal control worldwide basis ensure personnel continue understand system internal control procedure policy concern good prudent business practice company periodically conduct management stewardship program key management financial personnel program reinforce importance understand internal control review key corporate policy procedure system addition company compliance program include ethical business practice program reinforce company longstanding commitment high ethical standard conduct business financial statement financial information include annual report fairly present material respect companys financial condition result operation cash flow formal certification security exchange commission include filing addition company submit new york stock exchange nyse certificate ceo certify aware violation company nyse corporate governance list standard anagement report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define exchange act rule management conduct evaluation effectiveness internal control financial reporting base framework internal control integrate framework issue committee sponsor organization treadway commission coso base evaluation management conclude internal control financial reporting effective december base criteria internal control integrate framework issue coso management assessment effectiveness internal control financial reporting december audit pricewaterhousecooper llp independent register public accounting firm pricewaterhousecooper llp issue report management assessment effectiveness company internal control financial reporting include richard clark judy lewent chief executive officer executive vice president president chief financial officer tem information iii tem director executive officer corporate governance require information director nominee incorporate reference discussion item election director company proxy statement annual meeting stockholder hold april information executive officer set forth document page require information compliance section security exchange act incorporate reference discussion head section beneficial ownership report compliance company proxy statement annual meeting stockholder hold april company adopt code conduct value standard applicable employee include principal executive officer principal financial officer principal accounting officer code conduct available company website wwwmerckcomaboutcorporategovernance company intend post website amendment waivers code conduct print copy send charge stockholder request write chief ethic officer merck inc merck drive whitehouse station require information identification audit committee audit committee financial expert incorporate reference discussion head board committee companys proxy statement annual meeting stockholder hold april tem executive compensation information require executive compensation incorporate reference discussion heading compensation discussion analysis summary compensation table compensation table grant planbase award table outstanding equity awards fiscal year end table option exercise stock vest table retirement plan benefit relate pension benefit table nonqualifie defer compensation relate table potential payment termination change control include discussion subheading separation separation plan payment benefit estimate table individual agreement change control change control payment benefit estimate table footnote information table company proxy statement annual meeting stockholder hold april require information director compensation incorporate reference discussion head director compensation relate director compensation table schedule director fee table company proxy statement annual meeting stockholder hold april require information heading compensation committee interlock insider participation compensation committee report incorporate reference company proxy statement annual meeting stockholder hold april tem security ownership certain beneficial owner management relate stockholder matter information respect security authorize issuance equity compensation plan incorporate reference discussion head equity compensation plan information company proxy statement annual meeting stockholder hold april information respect security ownership certain beneficial owner management incorporate reference discussion head security ownership certain beneficial owner management company proxy statement annual meeting stockholder hold april tem certain relationship relate transaction director independence require information transaction relate person incorporate reference discussion head relationship outside firm discussion respect loan kim subheade perquisitie compensation discussion analysis company proxy statement annual meeting stockholder hold april require information director independence incorporate reference discussion head independence director company proxy statement annual meeting stockholder hold april tem principal accountant fee service information require item incorporate reference discussion audit committee beginning caption preapproval policy service independent register public accounting firm fee companys proxy statement annual meeting stockholder hold april tem exhibit financial statement schedule follow document file financial statement consolidate statement income year end december consolidated statement retain earning year end december consolidate statement comprehensive income year end december consolidated balance sheet december consolidate statement cash flow year end december note consolidated financial statement report pricewaterhousecooper llp independent register public accounting firm financial statement schedule schedule omit require applicable financial statement affiliate carry equity basis omit consider individually aggregate affiliate constitute significant subsidiary exhibit hib number description master restructuring agreement date june astra merck inc astra merck inc astra usa inc usa astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical portion exhibit subject request confidential treatment file commission incorporate reference form quarterly report period end june agreement plan merger merck inc spinnaker acquisition corp wholly own subsidiary merck inc sirna therapeutics inc date october incorporate reference current report form date october restate certificate incorporation merck inc october incorporate reference form quarterly report period end september bylaw merck inc amend effective incorporate reference current report form date indenture date april merck inc morgan guaranty trust company new york trustee incorporate reference exhibit registration statement form supplemental indenture merck inc trust new york national association trustee incorporate reference exhibit registration statement form executive incentive plan amend effective february incorporate reference annual report fiscal year end december base salary deferral plan adopt october effective january incorporate reference annual report fiscal year end december merck inc deferral program amend restate september incorporate reference current report form date september incentive stock plan amend restate december incentive stock plan amend restate december incentive stock plan amend restate december incentive stock plan amend effective december merck inc change control separation benefit plan incorporate reference current report form date november merck inc separation benefit plan nonunion employee amend restate effective july incorporate reference current report form date july nonemployee directors stock option plan amend restate february incorporate reference annual report fiscal year end december nonemployee director stock option plan amend april incorporate reference form quarterly report period end june nonemployee directors stock option plan amend april incorporate reference form quarterly report period end june hib number description nonemployee directors stock option plan effective april amend restate february supplemental retirement plan amend effective january incorporate reference annual report fiscal year end december retirement plan director merck inc amend restate june incorporate reference form quarterly report period end june plan defer payment director compensation amend restate october incorporate reference current report form date september offer letter merck inc peter kim date december incorporate reference annual report fiscal year end december offer letter merck inc peter loescher date march incorporate reference form quarterly report period end march letter agreement merck inc woldolsen date july incorporate reference current report form date july letter agreement merck inc bradley sheare date august letter agreement merck inc david anstice date december amend restate license option agreement date july astra astra merck inc incorporate reference form quarterly report period end june kbi share option agreement date july astra merck inc merck holdings inc incorporate reference form quarterly report period end june kbie asset option agreement date july astra merck inc astra merck inc astra merck enterprises inc incorporate reference form quarterly report period end june kbi supply agreement date july astra merck inc astra pharmaceutical portion exhibit subject request confidential treatment file commission incorporate reference form quarterly report period end june second amend restate manufacturing agreement date july merck inc astra astra merck inc astra usa inc incorporate reference quarterly report period end june limited partnership agreement date july usa kbi sub inc incorporate reference form quarterly report period end june distribution agreement date july astra merck enterprises inc astra pharmaceutical incorporate reference form quarterly report period end june agreement incorporate define term date june astra merck inc astra merck inc astra usa inc usa astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical incorporate reference form quarterly report period end june form voting agreement enter october merck inc sirna therapeutics inc incorporate reference current report form date october computation ratio earning fix charge subsidiary merck inc hib number description consent independent register public accounting firm contain report power attorney certify resolution board director rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer management contract compensatory plan arrangement copy exhibit obtain stockholder write request direct stockholder service department merck inc box whitehouse station new jersey signatures pursuant requirement section securities exchange act registrant duly cause report sign behalf undersigned thereunto duly authorize ate february merck inc richard clark chief executive officer president celia colbert celia colbert attorneyinfact pursuant requirement securities exchange act report sign follow person behalf registrant capacity date indicate signature title date richard clark chief executive officer president february principal executive officer director judy lewent executive vice president chief february financial officer principal financial officer john canan vice president controller principal february accounting officer lawrence bossidy director february william bowen director february johnnetta cole director february william harrison director february william kelley director february rochelle lazarus director february thomas shenk director february anne tatlock director february samuel thier director february wendell weeks director february peter wendell director february celia colbert signing hereto sign document pursuant power attorney duly execute person name file security exchange commission exhibit document behalf person capacity date state person include majority director company celia colbert celia colbert attorneyinfact exhibit consent independent register public accounting firm consent incorporation reference registration statement form nos form nos merck inc report date february relate consolidated financial statement management assessment effectiveness internal control financial reporting effectiveness internal control financial reporting incorporate reference annual report ricewaterhousecoopers llp lorham park new jersey february exhibit index hib number description master restructuring agreement date june astra merck inc astra merck inc astra usa inc usa astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical portion exhibit subject request confidential treatment file commission incorporate reference form quarterly report period end june agreement plan merger merck inc spinnaker acquisition corp wholly own subsidiary merck inc sirna therapeutics inc date october incorporate reference current report form date october restate certificate incorporation merck inc october incorporate reference form quarterly report period end september bylaw merck inc amend effective incorporate reference current report form date indenture date april merck inc morgan guaranty trust company new york trustee incorporate reference exhibit registration statement form supplemental indenture merck inc trust new york national association trustee incorporate reference exhibit registration statement form executive incentive plan amend effective february incorporate reference annual report fiscal year end december base salary deferral plan adopt october effective january incorporate reference annual report fiscal year end december merck inc deferral program amend restate september incorporate reference current report form date september incentive stock plan amend restate december incentive stock plan amend restate december incentive stock plan amend restate december incentive stock plan amend effective december merck inc change control separation benefit plan incorporate reference current report form date november merck inc separation benefit plan nonunion employee amend restate effective july incorporate reference current report form date july nonemployee directors stock option plan amend restate february incorporate reference annual report fiscal year end december nonemployee director stock option plan amend april incorporate reference form quarterly report period end june nonemployee directors stock option plan amend april incorporate reference form quarterly report period end june nonemployee directors stock option plan effective april amend restate february supplemental retirement plan amend effective january incorporate reference annual report fiscal year end december retirement plan director merck inc amend restate june incorporate reference form quarterly report period end june plan defer payment director compensation amend restate october incorporate reference current report form date september hib number description offer letter merck inc peter kim date december incorporate reference annual report fiscal year end december offer letter merck inc peter loescher date march incorporate reference form quarterly report period end march letter agreement merck inc woldolsen date july incorporate reference current report form date july letter agreement merck inc bradley sheare date august letter agreement merck inc david anstice date december amend restate license option agreement date july astra astra merck inc incorporate reference form quarterly report period end june kbi share option agreement date july astra merck inc merck holdings inc incorporate reference form quarterly report period end june kbie asset option agreement date july astra merck inc astra merck inc astra merck enterprises inc incorporate reference form quarterly report period end june kbi supply agreement date july astra merck inc astra pharmaceutical portion exhibit subject request confidential treatment file commission incorporate reference form quarterly report period end june second amend restate manufacturing agreement date july merck inc astra astra merck inc astra usa inc incorporate reference quarterly report period end june limited partnership agreement date july usa kbi sub inc incorporate reference form quarterly report period end june distribution agreement date july astra merck enterprises inc astra pharmaceutical incorporate reference form quarterly report period end june agreement incorporate define term date june astra merck inc astra merck inc astra usa inc usa astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceutical incorporate reference form quarterly report period end june form voting agreement enter october merck inc sirna therapeutics inc incorporate reference current report form date october computation ratio earning fix charge subsidiary merck inc consent independent register public accounting firm contain report power attorney certify resolution board director rule aada certification chief executive officer rule aada certification chief financial officer section certification chief executive officer section certification chief financial officer management contract compensatory plan arrangement exhibit merck inc incentive stock plan amend restate december incentive stock plan incentive stock plan isp effective january establish encourage employee merck inc company subsidiary affiliate joint ventures merck institute therapeutic research acquire common stock company believe isp stimulate employee effort company behalf tend maintain strengthen desire remain company interest company stockholder encourage employee great personal financial investment company ownership common stock administration isp shall administered compensation benefit committee board director company committee committee authorize subject provision isp establish rule regulation deem necessary proper administration isp determination action connection therewith relation isp deem necessary advisable consistent isp committee delegate power authority hereunder chief executive officer senior member management committee deem appropriate provide committee delegate authority regard matter action affect officer subject section security exchange act purpose section subsequent section isp shall deem include plan comparable subplans establish subsidiary aggregate shall constitute plan govern term set forth eligibility regular fulltime parttime employee company subsidiary affiliate joint ventures merck institute therapeutic research include officer director company employee joint venture partner affiliate company provide service joint venture partner affiliate director officer company purpose section securities exchange act shall eligible participate isp eligible employee designate committee delegate director regular employee eligible incentive incentive isp grant combination incentive stock option statutory stock option nonqualified stock option stock appreciation right restrict stock grant performance share incentive incentive shall subject term condition set forth term condition establish committee determination committee isp include limitation determination eligible employee form timing incentive term provision incentive agreement evidence incentive need uniform selectively eligible employee receive eligible receive incentive hereunder eligible employee similarly situate share available incentive share subject issuance transfer subject adjustment provide section hereof reserve issuance isp million share companys common stock common stock share available grant award shall increase number share option benefit grant plan lapse expire terminate cancel addition share reserve issuance company incentive stock plan incentive stock plan prior plan excess number share option benefit award thereunder plus share option benefit grant prior plan lapse expire terminate cancel shall reserve available issuance reissuance isp share plan deliver company authorize unissued share common stock common stock hold treasury limit individual incentive give year eligible employee receive incentive cover million share companys common stock number share adjust accordance section adjustment share event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination share merger consolidation right offer spin split split similar change capital structure company committee shall equitable adjustment number kind share authorize issuance isp number kind share subject outstanding incentive iii option price stock option grant value stock appreciation right determination shall final bind conclusive party stock option committee grant option qualify incentive stock option internal revenue code amend successor code thereto code statutory option code nonqualified option collectively stock option stock option shall subject follow term condition term condition committee prescribe option price option price share respect stock option shall determine committee shall fair market value common stock date stock option grant determined committee period option period stock option shall fix committee shall exceed year payment option price shall payable cash time stock option exercise share shall issue payment grantee stock option shall right stockholder share issue exercise option share cover stock option purchase installment exercise date committee delegate determine share purchase applicable exercise date purchase time prior final expiration stock option event include specify paragraph section shall stock option exercisable specify expiration period termination employment termination stock option grantee employment reason retirement death termination deliberate willful gross misconduct stock option privilege shall limit share immediately exercisable date termination committee discretion provide stock option outstanding exercisable termination stock option grantee employment exercisable accordance schedule determine committee stock option privilege shall expire exercise surrender stock appreciation right period time date termination employment establish committee event later expiration date stock option stock option grantee employment terminate deliberate willful gross misconduct determine company right stock option shall expire receipt notice termination retirement retirement stock option grantee stock option privilege shall apply share immediately exercisable date retirement committee discretion provide stock option outstanding exercisable retirement stock option grantee exercisable accordance schedule determine committee stock option privilege shall expire exercise period time establish committee event later expiration date stock option death death stock option grantee stock option privilege shall apply share immediately exercisable time death committee discretion provide stock option outstanding exercisable death stock option grantee exercisable accordance schedule determine committee privilege shall expire exercised legal representative period time determine committee event later expiration date stock option limit incentive stock option permit code committee shall grant eligible employee incentive stock option aggregate exercisable calendar year extent aggregate fair market value common stock time incentive stock option grant exceed stock appreciation right committee discretion grant right receive appreciation fair market value share common stock stock appreciation right singly combination underlie stock option grant hereunder prior plan stock appreciation right shall subject follow term condition term condition committee prescribe time period grant stock appreciation right grant respect underlie stock option grant time stock option grant time prior expiration stock option grant stock appreciation right grant respect underlie stock option time stock appreciation right grant committee limit exercise period stock appreciation right period stock appreciation right shall attach underlie stock option event shall exercise period stock appreciation right grant respect underlie stock option exceed exercise period stock option stock appreciation right grant underlie stock option period exercise stock appreciation right shall set committee value stock appreciation right stock appreciation right grant respect underlie stock option grantee entitle surrender stock option exercisable receive exchange equal excess fair market value common stock date election surrender receive company stock option price multiply number share cover stock option surrender stock appreciation right grant underlie stock option grantee receive exercise stock appreciation right equal excess fair market value common stock date election surrender stock appreciation right receive company fair market value common stock date grant multiply number share cover grant stock appreciation right payment stock appreciation right payment stock appreciation right shall form share common stock cash combination share cash form payment exercise right shall determine committee time grant stock appreciation right time exercise stock appreciation right performance share awards committee grant award payment share common stock cash combination share cash performance company subsidiary division affiliate company select committee award period meet certain goal establish committee performance share award performance share award shall subject follow term condition term condition committee prescribe award period performance goal committee shall determine include performance share award grant period time performance share award award period committee shall establish performance objective performance goal meet company subsidiary division award period condition payment performance share award performance goal include earning share return stockholder equity return asset net income financial measurement establish committee performance goal include minimum optimum objective single set objective payment performance share awards committee shall establish method calculate payment performance share award performance goal meet include fix maximum payment performance share award shall express term share common stock refer performance share completion award period performance company subsidiary division shall measure performance goal committee shall determine portion performance share award shall pay committee discretion elect payment share common stock cash combination share cash cash payment shall base fair market value performance share soon practicable prior date payment revision performance goal time prior end award period committee revise performance goal computation payment unforeseen event occur substantial effect performance company subsidiary division judgment committee application performance goal unfair revision requirement employment grantee performance share award remain employ company completion award period order entitle payment performance share award provide committee sole discretion provide partial payment exception deem equitable dividend committee discretion time grant performance share award provide dividend declare common stock award period pay respect performance share own grantee pay grantee accumulate benefit grantee increase number performance share grantee limit performance share award incentive grant performance share award section restrict stock grant section shall exceed aggregate million share common stock number share adjust accordance section restrict stock grant committee award share common stock grantee share shall subject follow term condition term condition committee prescribe restrict stock grant requirement employment grantee restrict stock grant remain employment company period designate committee restriction period order retain share restrict stock grant grantee leave employment company prior end restriction period restrict stock grant shall terminate share common stock shall return immediately company provide committee time grant provide employment restriction lapse respect portion portion restrict stock grant different time restriction period committee discretion provide complete partial exception employment restriction deem equitable restriction transfer legend stock certificate restriction period grantee sell assign transfer pledge dispose share common stock successor section hereof certificate share common stock issue hereunder shall contain legend give appropriate notice restriction grant escrow agreement committee require grantee enter escrow agreement provide certificate represent restricted stock grant remain physical custody escrow holder restriction remove expire lapse restriction restriction impose restricted stock grant shall lapse expiration restriction period condition employment set forth meet grantee shall entitle legend remove certificate dividend committee shall discretion time restrict stock grant provide dividend declare common stock restriction period shall pay grantee accumulate benefit grantee pay grantee expiration restriction period limit restrict stock grant incentive grant restrict stock grant section performance share award section shall exceed aggregate million share common stock number share adjust accordance section discontinuance amendment plan board director discontinue isp time time time amend revise term isp permit applicable statute revoke alter manner unfavorable grantee incentive hereunder incentive outstanding board amend isp stockholder approval absence approval cause plan fail comply rule securities exchange act requirement applicable law regulation incentive shall grant isp december incentive grant theretofore extend date nontransferability incentive stock option grant isp shall transferable law descent distribution incentive grant isp transferable subject term condition establish committee accordance regulation promulgate securities exchange act applicable law regulation right employment isp incentive grant hereunder shall confer eligible employee right continue employment company subsidiary affiliate joint ventures merck institute therapeutic research affect way right entity terminate employment eligible employee time reason taxis company shall entitle withhold tax attributable option grant payable share deliverable isp give person entitle receive share notice far advance practicable merck change control option vest option key option occurrence change control stock option outstanding immediately prior change control key option shall immediately fully vest exercisable vest key option subject aii schedule occurrence change control key option shall continue subject performancebase vest schedule applicable thereto immediately prior change control notwithstanding schedule stock option continue outstanding follow change control exchange converted option purchase security successor entity successor option occurrence change control portion key option shall immediately vest exercisable follow percentage key option milestone reach date change control thenunveste portion key option shall vest exercisable remainder shall forfeit key option milestone reach date change control thenunveste portion key option shall vest exercisable remainder shall forfeit key option second milestone reach date change control thenunveste portion key option shall vest exercisable posttermination exercise period stock option continue outstanding follow change control exchange converted successor option portion stock option successor option applicable vested exercisable immediately follow termination employment holder thereof change control shall remain exercisable follow termination year date termination remainder term thereof provide termination reason gross misconduct death retirement term apply award grant plan provision plan applicable termination reason gross misconduct death retirement shall apply termination effect vest pursuant section cause stock option successor stock option terminate early accelerate vest occur term stock option shall expire early accelerate vest occur cashout stock option stock option continue outstanding follow change control exchange converted successor option holder vest exercisable option shall entitle receive soon practicable follow change control share common stock subject vest exercisable option cash determine committee prior change control event excess change control price exercise price thereof subject exist deferral election effect consideration pay change control entirely share common stock acquire result corporation committee prior change control provide cancellation outstanding stock option time change control cash pursuant provision provide exchange conversion outstanding stock option time change control connection provision shall obligate permit holder stock option election relate thereto determine appropriate incentive stock option amend section apply incentive stock option mean section internal revenue code restrict stock unit performance share unit vest restrict stock unit occurrence change control unvested restrict stock unit award outstanding immediately prior change control plan shall immediately fully vested vest performance share unit occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately vested equal psu pro rata settlement restrict stock unit performance share unit common stock continue widely hold freely tradable follow change control exchange converted security successor entity widely hold freely tradable restricted stock unit vest performance share unit shall pay share common stock security soon practicable date change control subject exist deferral election effect common stock continue widely hold freely tradable follow change control exchange converted security successor entity widely hold freely tradable restricted stock unit vest performance share unit shall pay cash soon practicable date change control subject exist deferral election effect provision extent require applicable law entirety protection period material term plan shall modify manner materially adverse qualifying participant understand section schedule shall require specific type level equity award grant qualifying participant follow change control protection period plan amend modify reduce eliminate protection set forth section schedule terminate company shall pay legal fee relate expense include cost expert evidence counsel reasonably good faith incur qualifying participant qualifying participant prevail claim relief action qualifying participant claim provision section schedule violate avoidance doubt exclude claim plan benefit ordinary course applicable company qualifying participant employer enforce post termination covenant qualify participant section apply incentive stock option mean section internal revenue code plan amend schedule notwithstanding company reserve right change require extent require avoid adverse consequence american job creation act amend definition purpose schedule follow term shall follow meaning change control shall mean set forth company change control separation benefit plan provide award plan consist defer compensation subject section code definition change control shall deem modify extent necessary comply section code change control price shall mean respect share common stock higher highest report sale price regular way share transaction report new york stock exchange composite tape national exchange share list nasdaq national market day period prior include date change control change control result tender exchange offer merger similar corporate transaction high price share pay tender exchange offer merger similar corporate transaction provide extent consideration pay transaction consist security noncash consideration value security noncash consideration shall determine committee key option shall mean performancebase option grant employee key research development program describe applicable schedule rule regulation plan protection period shall mean period begin date change control end second anniversary date change control psu pro rata shall mean performance share unit award determine multiplying number target share subject performance share unit award times assume performance percentage fraction numerator number partial calendar month elapse applicable performance period count partial month month purpose denominator total number month applicable performance period assume performance percentage shall determine average rank award period follows complete performance year change control actual rank few day elapse completion performance year target rank shall performance year incomplete begin change control target rank round average rank calculate pursuant forego clause near number ordinary numerical round final award percentage associate number determine forego clause target rank rank associate chart final award percentage qualify participant shall mean individual participate plan current employee immediately prior change control application schedule shall apply stock option restrict stock unit award performance share unit award plan grant prior november exhibit merck inc incentive stock plan amend restate december incentive stock plan incentive stock plan isp effective january establish encourage employee merck inc company subsidiary affiliate joint venture acquire common stock company common stock believe isp stimulate employee effort company behalf tend maintain strengthen desire remain company interest company stockholder encourage employee great personal financial investment company ownership common stock incentive incentive isp grant combination incentive stock option statutory stock options nonqualified stock option stock appreciation right restrict stock grant performance share collectively incentive incentive shall subject term condition set forth term condition establish compensation benefit committee board director committee eligibility regular fulltime parttime employee company subsidiary affiliate joint venture include officer director company employee joint venture partner affiliate company provide service joint venture partner affiliate shall eligible participate isp eligible employee designate committee director company regular employee eligible participate isp administration isp shall administer committee committee shall responsible administration isp include limitation determine eligible employee receive incentive kind incentive isp number share term condition incentive determination committee isp include limitation determination eligible employee form timing incentive term provision incentive agreement evidence incentive need uniform selectively eligible employee receive eligible receive incentive hereunder eligible employee similarly situate committee shall responsibility construe interpret isp establish amending rule regulation deem necessary desirable proper administration isp decision action take take committee arise connection construction administration interpretation effect isp rule regulation shall maximum extent permit applicable law absolute discretion specifically provide shall conclusive bind company eligible employee person claim eligible employee committee delegate power authority hereunder chief executive officer senior member management committee deem appropriate provide committee delegate authority regard matter action affect officer subject section security exchange act purpose section subsequent section isp shall deem include plan comparable subplans establish subsidiary aggregate shall constitute plan govern term set forth share available incentive share subject issuance transfer subject adjustment provide section hereof reserve issuance isp million share common stock share available grant award shall increase number share option benefit grant isp lapse expire terminate cancel addition share reserve issuance company incentive stock plan incentive stock plan prior plan excess number share option benefit award thereunder plus share option benefit grant prior plan lapse expire terminate cancel shall reserve available issuance reissuance isp share isp deliver company authorize unissued share common stock common stock hold treasury limit individual incentive give year eligible employee receive incentive cover million share companys common stock number share shall adjust accordance section adjustment share event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination share merger consolidation right offer spin split split similar change capital structure company committee shall equitable adjustment number kind share authorize issuance isp number kind share subject outstanding incentive iii option price stock option grant value stock appreciation right determination shall final bind conclusive party stock option committee grant option qualify incentive stock option internal revenue code amend successor code thereto code statutory option code nonqualified option collectively stock option stock option shall subject follow term condition term condition committee prescribe option price option price share respect stock option shall determine committee shall fair market value common stock date stock option grant determined committee period option period stock option shall fix committee shall exceed year payment share shall issue payment option price option price pay cash committee determine share common stock combination cash share committee approve use share common stock payment method committee shall establish condition deem appropriate use common stock exercise stock option stock option award isp shall exercise company brokerassiste stock option exercise program provide program available time option exercise mean committee determine time time committee establish rule procedure permit optionhold defer recognition gain exercise stock option exercise option committee shall determine share cover stock option purchase committee establish waiting period date option exercisable vested exercise period provide event include specify paragraph section shall stock option exercisable specify expiration period termination employment termination stock option grantee employment reason retirement death termination deliberate willful gross misconduct stock option privilege shall limit share immediately exercisable date termination committee discretion provide stock option outstanding exercisable termination stock option grantee employment exercisable accordance schedule determine committee stock option privilege shall expire exercise surrender stock appreciation right period time date termination employment establish committee event later expiration date stock option retirement retirement stock option grantee stock option privilege shall apply share immediately exercisable date retirement committee discretion provide stock option outstanding exercisable retirement stock option grantee exercisable accordance schedule determine committee stock option privilege shall expire exercise period time establish committee event later expiration date stock option death death stock option grantee stock option privilege shall apply share immediately exercisable time death committee discretion provide stock option outstanding exercisable death stock option grantee exercisable accordance schedule determine committee privilege shall expire exercised legal representative period time determine committee event later expiration date stock option termination misconduct stock option grantee employment terminate deliberate willful gross misconduct determine company right stock option shall expire receipt notice termination limit incentive stock option permit code committee shall grant eligible employee incentive stock option aggregate exercisable calendar year extent aggregate fair market value common stock time incentive stock option grant exceed internal revenue service decide time time stock appreciation right committee discretion grant right receive appreciation fair market value share common stock stock appreciation right singly combination underlie stock option grant hereunder prior plan stock appreciation right shall subject follow term condition term condition committee prescribe time period grant stock appreciation right grant respect underlie stock option grant time stock option grant time prior expiration stock option grant stock appreciation right grant respect underlie stock option time stock appreciation right grant committee limit exercise period stock appreciation right period stock appreciation right shall attach underlie stock option event shall exercise period stock appreciation right grant respect underlie stock option exceed exercise period stock option stock appreciation right grant underlie stock option period exercise stock appreciation right shall set committee value stock appreciation right stock appreciation right grant respect underlie stock option grantee entitle surrender stock option exercisable receive exchange therefor equal excess fair market value common stock date election surrender receive company stock option price multiply number share cover stock option surrender stock appreciation right grant underlie stock option grantee receive exercise stock appreciation right equal excess fair market value common stock date election surrender stock appreciation right receive company fair market value common stock date grant multiply number share cover grant stock appreciation right payment stock appreciation right payment stock appreciation right shall form share common stock cash combination share cash form payment exercise right shall determine committee time grant stock appreciation right time exercise stock appreciation right performance share awards committee grant award payment share common stock cash combination share cash performance company subsidiary division affiliate joint venture company select committee award period meet certain goal establish committee performance share award performance share award shall subject follow term condition term condition committee prescribe award period performance goal committee shall determine include performance share award grant period time performance share award award period committee shall establish performance objective performance goal meet company subsidiary division joint venture award period condition payment performance share award performance goal include earning share return stockholder equity return asset net income financial measurement establish committee performance goal include minimum optimum objective single set objective payment performance share awards committee shall establish method calculate payment performance share award performance goal meet include fix maximum payment performance share award shall express term share common stock refer performance share completion award period performance company subsidiary division joint venture shall measure performance goal committee shall determine portion performance share award shall pay committee discretion elect payment share common stock cash combination share cash cash payment shall base fair market value performance share soon practicable prior date payment revision performance goal time prior end award period committee revise performance goal computation payment unforeseen event occur substantial effect performance company subsidiary division joint venture judgment committee application performance goal unfair revision requirement employment grantee performance share award remain employ company completion award period order entitle payment performance share award provide committee discretion provide partial payment exception deem equitable dividend committee discretion time grant performance share award provide dividend declare common stock award period pay respect performance share own grantee pay grantee accumulate benefit grantee increase number performance share grantee limit performance share award incentive grant performance share award section restrict stock grant section shall exceed aggregate million share common stock number share shall adjust accordance section restrict stock grant committee award share common stock grantee share shall subject follow term condition term condition committee prescribe restrict stock grant requirement employment grantee restrict stock grant remain employment company period designate committee restriction period order retain share restrict stock grant grantee leave employment company prior end restriction period restrict stock grant shall terminate share common stock shall return immediately company provide committee time grant provide employment restriction lapse respect portion portion restrict stock grant different time restriction period committee discretion provide complete partial exception employment restriction deem equitable restriction transfer legend stock certificate restriction period grantee sell assign transfer pledge dispose share common stock certificate share common stock issue hereunder shall contain legend give appropriate notice restriction grant escrow agreement committee require grantee enter escrow agreement provide certificate represent restricted stock grant remain physical custody escrow holder restriction remove expire lapse restriction restriction impose restricted stock grant shall lapse expiration restriction period condition employment set forth meet grantee shall entitle legend remove certificate dividend committee shall discretion time restrict stock grant provide dividend declare common stock restriction period shall pay grantee accumulate benefit grantee pay grantee expiration restriction period limit restrict stock grant incentive grant restrict stock grant section performance share award section shall exceed aggregate million share common stock number share shall adjust accordance section transferability incentive stock option grant isp shall transferable law descent distribution incentive grant isp transferable assignable recipient subject execution attachment similar procedure law descent distribution determine committee accordance regulation promulgate securities exchange act applicable law regulation discontinuance amendment plan board director discontinue isp time time time amend revise term isp permit applicable statute revoke alter manner unfavorable grantee incentive hereunder incentive outstanding board amend isp stockholder approval absence approval cause plan fail comply rule securities exchange act requirement applicable law regulation approve company stockholder adjustment reduction exercise price outstanding incentive shall cancellation outstanding incentive subsequent regranting incentive low price individual incentive shall grant isp december incentive grant theretofore extend date right employment participation isp incentive grant hereunder shall confer eligible employee right continue employment company subsidiary affiliate joint venture affect way right entity terminate employment eligible employee time reason individual shall right grant incentive grant incentive receive future incentive limitation compensation isp shall construe limit right company establish plan pay compensation employee cash property manner expressly authorize isp impact benefit specifically state employee benefit plan policy program payable respect incentive shall treat compensation purpose calculate employee right plan policy program constraint corporate action isp shall construe limit impair affect company right power adjustment reclassification reorganization change capital business structure merge consolidate dissolve liquidate sell transfer business asset provide section limit right power company subsidiary action entity deem necessary appropriate withholding taxis company shall entitle deduct payment isp regardless form payment applicable income employment taxis require law withhold respect payment require eligible employee pay tax prior condition make payment accordance applicable administrative guideline establishe committee allow eligible employee pay taxis require law withhold incentive withholding payment common stock result incentive permit eligible employee deliver company share common stock fair market value determine committee equal require withholding taxis govern law isp agreement hereunder shall construe accordance govern law state new jersey merck change control option vest option key option occurrence change control stock option outstanding immediately prior change control key option shall immediately fully vest exercisable vest key option subject aii schedule occurrence change control key option shall continue subject performancebase vest schedule applicable thereto immediately prior change control notwithstanding schedule stock option continue outstanding follow change control exchange converted option purchase security successor entity successor option occurrence change control portion key option shall immediately vest exercisable follow percentage key option milestone reach date change control unvested portion key option shall vest exercisable remainder shall forfeit key option milestone reach date change control thenunveste portion key option shall vest exercisable remainder shall forfeit key option second milestone reach date change control thenunveste portion key option shall vest exercisable posttermination exercise period stock option continue outstanding follow change control exchange converted successor option portion stock option successor option applicable vested exercisable immediately follow termination employment holder thereof change control shall remain exercisable follow termination year date termination remainder term thereof provide termination reason gross misconduct death retirement term apply award grant plan provision plan applicable termination reason gross misconduct death retirement shall apply termination effect vest pursuant section cause stock option successor stock option terminate early accelerate vest occur term stock option shall expire early accelerate vest occur cashout stock option stock option continue outstanding follow change control exchange converted successor option holder vest exercisable option shall entitle receive soon practicable follow change control share common stock subject vest exercisable option cash determine committee prior change control event excess change control price exercise price thereof subject exist deferral election effect consideration pay change control entirely share common stock acquire result corporation committee prior change control provide cancellation outstanding stock option time change control cash pursuant provision provide exchange conversion outstanding stock option time change control connection provision shall obligate permit holder stock option election relate thereto determine appropriate incentive stock option amend section apply incentive stock option mean section internal revenue code restrict stock unit performance share unit vest restrict stock unit occurrence change control unvested restrict stock unit award outstanding immediately prior change control plan shall immediately fully vested vest performance share unit occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately vested equal psu pro rata settlement restrict stock unit performance share unit common stock continue widely hold freely tradable follow change control exchange converted security successor entity widely hold freely tradable restricted stock unit vest performance share unit shall pay share common stock security soon practicable date change control subject exist deferral election effect common stock continue widely hold freely tradable follow change control exchange converted security successor entity widely hold freely tradable restricted stock unit vest performance share unit shall pay cash soon practicable date change control subject exist deferral election effect provision extent require applicable law entirety protection period material term plan shall modify manner materially adverse qualifying participant understand section schedule shall require specific type level equity award grant qualifying participant follow change control protection period plan amend modify reduce eliminate protection set forth section schedule terminate company shall pay legal fee relate expense include cost expert evidence counsel reasonably good faith incur qualifying participant qualifying participant prevail claim relief action qualifying participant claim provision section schedule violate avoidance doubt exclude claim plan benefit ordinary course applicable company qualify participant employer enforce posttermination covenant qualify participant section apply incentive stock option mean section internal revenue code plan amend schedule notwithstanding company reserve right change require extent require avoid adverse consequence american job creation act amend definition purpose schedule follow term shall follow meaning change control shall mean set forth company change control separation benefit plan provide award plan consist defer compensation subject section code definition change control shall deem modify extent necessary comply section code change control price shall mean respect share common stock higher highest report sale price regular way share transaction report new york stock exchange composite tape national exchange share list nasdaq national market day period prior include date change control change control result tender exchange offer merger similar corporate transaction high price share pay tender exchange offer merger similar corporate transaction provide extent consideration pay transaction consist security noncash consideration value security non cash consideration shall determine committee key option shall mean performancebase option grant employee key research development program describe applicable schedule rule regulation plan protection period shall mean period begin date change control end second anniversary date change control psu pro rata shall mean performance share unit award determine multiplying number target share subject performance share unit award times assume performance percentage fraction numerator number partial calendar month elapse applicable performance period count partial month month purpose denominator total number month applicable performance period assume performance percentage shall determine average rank award period follows complete performance year change control actual rank few day elapse completion performance year target rank shall performance year incomplete begin change control target rank round average rank calculate pursuant forego clause near number ordinary numerical round final award percentage associate number determine forego clause target rank rank associate chart final award percentage qualify participant shall mean individual participate plan current employee immediately prior change control application schedule shall apply stock option restrict stock unit award performance share unit award plan grant prior november exhibit merck inc incentive stock plan amend restate december merck inc incentive stock plan amend december purpose incentive stock plan plan effective establish encourage employee merck inc company subsidiary affiliate joint venture acquire common stock company common stock believe plan serve interest company stockholder allow employee great personal financial interest company ownership right acquire common stock turn stimulate employee effort company behalf maintain strengthen desire remain company believe plan assist recruitment employee administration plan shall administer compensation benefit committee board director company committee director company serve committee nonemployee director purpose rule securities exchange act amended exchange act satisfie requirement outside director purpose section internal revenue code code committee shall responsible administration plan include limitation determine eligible employee receive incentive type incentive receive plan number share cover incentive grant plan term condition incentive determination committee plan include limitation determination eligible employee form timing incentive term provision incentive writing evidence incentive need uniform selectively eligible employee receive eligible receive incentive hereunder eligible employee similarly situate committee shall responsibility construe interpreting plan include right construe dispute doubtful plan provision establish amend construing rule regulation deem necessary desirable proper administration plan decision action take take committee arise connection construction administration interpretation effect plan rule regulation shall maximum extent permit applicable law absolute discretion specifically provide shall final bind conclusive company eligible employee person claim eligible employee committee permit applicable state law delegate power authority hereunder chief executive officer senior member management committee deem appropriate provide committee delegate authority regard matter action affect officer subject section exchange act delegation shall case incentive intend qualified section code purpose section subsequent section plan shall deem include plan comparable subplans establish subsidiary aggregate shall constitute plan govern term set forth eligibility employee regular fulltime parttime employee employ company parent subsidiary affiliate joint venture include officer director company employee joint venture partner affiliate company provide service joint venture partner affiliate person employee shall eligible participate plan designate committee eligible employee nonemployee term employee shall include follow collectively exclude person director employee officer person independent contractor agree agree heshe independent contractor person agreement understand company affiliate joint venture partner heshe employee eligible employee heshe previously employee eligible employee person employ temporary employment agency regardless control supervision training provide company affiliate lease employee define section code exclude person eligible employee receive incentive court agency authority rule heshe commonlaw employee company affiliate right continue employment plan shall interfere limit way right company parent subsidiary affiliate joint venture terminate employment participant time confer participant right continue employ company parent subsidiary affiliate joint venture eligible employee shall right receive incentive benefit plan grant incentive benefit receive additional incentive benefit award incentive benefit arise incentive shall constitute employment contract company parent subsidiary affiliate joint venture accordingly plan benefit hereunder terminate time sole exclusive discretion company give rise liability company parent subsidiary affiliate joint venture severance specifically state employee benefit plan policy program incentive plan realize incentive shall treat compensation purpose calculate employee benefit plan policy program term plan plan shall effective subject approval plan affirmative vote stockholder company entitle vote thereon time approval incentive shall grant plan april term exercise incentive grant theretofore extend date incentive incentive plan grant combination incentive stock option nonqualified stock option stock appreciation right restrict stock grant performance share share awards phantom stock award collectively incentive incentive shall subject term condition set forth term condition establish committee share available incentive share available subject provision section maximum number share common stock company issue plan million share plan predecessor incentive stock plan purchase award incentive lapsed expired terminate cancel grant incentive plan incentive similar award issue entity merge company acquire company involve similar corporate transaction company consider issue plan share plan deliver company authorize unissued share common stock issue reacquire common stock hold treasury stock event shall fractional share common stock issue plan limit individual incentive calendar year eligible employee receive incentive cover million share companys common stock number share shall adjust accordance section incentive person own percent stock company mean section code iii incentive stock option define section code result person receive grant incentive stock option stock aggregate fair market value excess determine time incentive stock option grant exercisable time person calendar year adjustment share event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination share merger consolidation right offer spin split split similar change capital structure company committee shall equitable adjustment number kind share authorize issuance plan number kind share subject outstanding incentive iii option price stock option grant value stock appreciation right determination shall final bind conclusive party stock option committee grant option qualify incentive stock option define section code option incentive stock option nonqualifie option collectively stock option stock option shall subject follow term condition term condition committee prescribe stock option price option price share respect stock option shall determine committee shall percent fair market value common stock date stock option grant determined committee period stock option period stock option shall fix committee provide period stock option shall exceed year grant provide event death optionee prior expiration nonqualified option nonqualified option committee determine exercisable year date grant committee subsequent grant stock option extend term thereof event shall extend term exceed year original grant date exercise stock option payment share shall issue payment option price option price pay cash committee determine share common stock combination cash share common stock committee approve use share common stock payment method committee shall establish condition deem appropriate use common stock exercise stock option stock option award plan shall exercise procedure program committee establish define time time include designate broker exercise stock option committee establish rule procedure permit optionhold defer recognition gain exercise stock option exercisable date committee shall determine share cover stock option purchase committee establish waiting period date stock option exercisable vested subject paragraph section exercise period committee accelerate exercisability stock option portion thereof termination employment determine committee termination stock option grantee employment reason gross misconduct stock option privilege shall limit share immediately exercisable date termination committee discretion provide stock option outstanding exercisable termination stock option grantee employment exercisable accordance schedule determine committee stock option privilege shall expire exercise period time date termination employment establish committee event later expiration date stock option termination misconduct stock option grantee employment terminate gross misconduct determine company right stock option shall expire date termination limit incentive stock option permit code eligible employee receive grant incentive stock option stock aggregate fair market value excess internal revenue service decide time time determine time incentive stock option grant exercisable time person calendar year stock appreciation right committee discretion grant right receive appreciation fair market value share common stock stock appreciation right singly combination underlie stock option grant hereunder stock appreciation right shall subject follow term condition term condition committee prescribe time period grant stock appreciation right grant respect underlie stock option grant time stock option grant time prior expiration stock option grant stock appreciation right grant respect underlie stock option time stock appreciation right grant committee limit exercise period stock appreciation right period stock appreciation right shall attach underlie stock option event shall exercise period stock appreciation right grant respect underlie stock option exceed exercise period stock option stock appreciation right grant underlie stock option period exercise stock appreciation right shall set committee value stock appreciation right stock appreciation right grant respect underlie stock option grantee entitle surrender stock option exercisable receive exchange therefor equal excess fair market value common stock date election surrender receive company accordance exercise procedure establish company stock option price spread multiply number share cover stock option surrender stock appreciation right grant underlie stock option grantee receive exercise stock appreciation right equal excess fair market value common stock date election surrender stock appreciation right receive company accordance exercise procedure establish company fair market value common stock date grant multiply number share cover grant stock appreciation right notwithstanding forego sole discretion committee time grant stock appreciation right provide spread cover stock appreciation right exceed specify payment stock appreciation right payment stock appreciation right shall form share common stock cash combination share cash form payment exercise right shall determine committee time grant stock appreciation right time exercise stock appreciation right performance share awards committee grant award payment share common stock cash combination share cash performance company parent subsidiary division affiliate joint venture company select committee award period meet certain goal establish committee performance share award performance share award shall subject follow term condition term condition committee prescribe award period performance goal committee shall determine include performance share award grant period time performance share award award period committee shall establish performance objective performance goal meet company parent subsidiary division affiliate joint venture company award period condition payment performance share award performance goal include share price pretax profit earning share return stockholder equity return asset sale net income combination forego solely award intend constitute performancebase compensation section code financial measurement establish committee performance goal include minimum optimum objective single set objective payment performance share awards committee shall establish method calculate payment performance share award performance goal meet include fix maximum payment performance share award shall express term share common stock refer performance share completion award period performance company parent subsidiary division affiliate joint venture company shall measure performance goal committee shall determine accordance term performance share award portion performance share award shall pay committee discretion elect payment share common stock cash combination share cash cash payment shall base fair market value performance share soon practicable prior date payment committee establish rule procedure permit grantee defer recognition income attainment performance share award revision performance goal award intend constitute performancebase compensation section code time prior end award period committee revise performance goal computation payment unforeseen event occur substantial effect performance company parent subsidiary division affiliate joint venture company judgment committee application performance goal unfair revision requirement employment grantee performance share award remain employ company parent subsidiary affiliate joint venture completion award period order entitle payment performance share award provide committee discretion provide partial payment exception deem equitable dividend committee discretion time grant performance share award provide dividend declare common stock award period pay respect performance share own grantee pay grantee accumulate benefit grantee increase number performance share grantee limit performance share award incentive grant performance share award section restrict stock grant section share base award section shall exceed aggregate million share common stock number share shall adjust accordance section restrict stock grant committee award share common stock eligible employee share shall subject follow term condition term condition committee prescribe restrict stock grant requirement employment grantee restrict stock grant remain employment company period designate committee restriction period order retain share restrict stock grant grantee leave employment company prior end restriction period restrict stock grant shall terminate share common stock shall return immediately company provide committee time grant provide employment restriction lapse respect portion portion restrict stock grant different time restriction period committee discretion provide complete partial exception employment restriction deem equitable restriction transfer legend stock certificate restriction period grantee sell assign transfer pledge dispose share common stock certificate share common stock issue hereunder shall contain legend give appropriate notice restriction grant escrow agreement committee require grantee enter escrow agreement provide certificate represent restricted stock grant remain physical custody escrow holder restriction remove expire lapse restriction restriction impose restricted stock grant shall lapse expiration restriction period condition employment set forth meet grantee shall entitle legend remove certificate committee establish rule procedure permit grantee defer recognition income expiration restriction period dividend committee shall discretion time restrict stock grant provide dividend declare common stock restriction period shall pay grantee accumulate benefit grantee pay grantee expiration restriction period performance goal committee designate restrict stock grant intend performancebase compensation term section code restrict stock grant designate performancebase compensation shall condition achievement performance goal define section extent require section limit restrict stock grant incentive grant restrict stock grant section performance share award section share base award section shall exceed aggregate million share common stock number share shall adjust accordance section sharebased awards committee grant award share common stock share award eligible employee term condition committee determine sole discretion share award additional compensation service render eligible employee lieu cash compensation eligible employee entitle company incentive grant share base award section performance share award section restrict stock grant section shall exceed aggregate million share common stock number share shall adjust accordance section transferability incentive stock option grant plan shall transferable law descent distribution incentive grant plan transferable assignable recipient subject execution attachment similar procedure law descent distribution determine committee accordance regulation promulgate securities exchange act applicable law regulation notwithstanding forego committee discretion adopt rule permit transfer solely gift grantee lifetime stock option incentive stock option member grantee immediate family trust family partnership similar entity benefit immediate family member purpose immediate family member mean grantee spouse parent child stepchild grandchild spouse family member term stock option shall final bind conclusive beneficiary executor administrator heir successor grantee discontinuance amendment plan board director discontinue plan time time time amend revise term plan permit applicable statute consent grantee affect revoke alter manner unfavorable grantee incentive hereunder incentive outstanding board amend plan stockholder approval absence approval cause plan fail comply rule exchange act requirement applicable law regulation approve company stockholder specifically provide plan adjustment reduction exercise price outstanding incentive shall event decline stock price reduce exercise price outstanding incentive cancellation outstanding incentive connection regrante incentive low price individual limitation compensation plan shall construe limit right company establish plan pay compensation employee cash property manner expressly authorize plan constraint corporate action plan shall construe limit impair affect company right power adjustment reclassification reorganization change capital business structure merge consolidate dissolve liquidate sell transfer business asset provide section limit right power company parent subsidiary affiliate joint venture action entity deem necessary appropriate withholding taxis company shall entitle deduct payment plan regardless form payment applicable income employment taxis require law withhold respect payment require eligible employee pay tax prior condition make payment accordance applicable administrative guideline establishe committee allow eligible employee pay taxis require law withhold incentive withholding payment common stock result incentive permit eligible employee deliver company share common stock fair market value determine committee equal require withholding taxis compliance section respect eligible employee subject section exchange act section officer transaction plan intend comply applicable condition rule successor exchange act extent compliance plan provision applicable solely section officer require order bring transaction section officer compliance rule shall deem null void transaction extent permit law deem advisable committee delegee extent provision plan action plan administrator involve section officer deem comply applicable condition rule shall deem null void section officer extent permit law deem advisable plan administrator use proceed proceed receive company sale stock plan shall add general fund company shall corporate purpose board director shall direct govern law plan agreement hereunder shall construe accordance govern law state new jersey give effect principle conflict law offset suspension exercise contrary plan notwithstanding plan administrator offset incentive amount reasonably believe owe company grantee disallow incentive exercise payable time company investigate reasonably reliable allegation gross misconduct grantee effect change control option vest option key option occurrence change control stock option outstanding immediately prior change control key option shall immediately fully vest exercisable vest key option subject section aii occurrence change control key option shall continue subject performancebase vest schedule applicable thereto immediately prior change control notwithstanding section stock option continue outstanding follow change control exchange converted option purchase security successor entity successor option occurrence change control portion key option shall immediately vest exercisable follow percentage key option milestone reach date change control thenunveste portion keyrd option shall vest exercisable remainder shall forfeit key option milestone reach date change control thenunveste portion key option shall vest exercisable remainder shall forfeit key option second milestone reach date change control thenunveste portion key option shall vest exercisable posttermination exercise period stock option continue outstanding follow change control exchange converted successor option portion stock option successor option applicable vested exercisable immediately follow termination employment holder thereof change control shall remain exercisable follow termination year date termination remainder term thereof provide termination reason gross misconduct death retirement term apply award grant plan provision plan applicable termination reason gross misconduct death retirement shall apply termination cashout stock option stock option continue outstanding follow change control exchange converted successor option holder vest exercisable option shall entitle receive soon practicable follow change control share common stock subject vest exercisable option cash determine committee prior change control event excess change control price exercise price thereof subject exist deferral election effect consideration pay change control entirely share common stock acquire result corporation committee prior change control provide cancellation outstanding stock option time change control cash pursuant section provide exchange conversion outstanding stock option time change control connection provision shall obligate permit holder stock option election relate thereto determine appropriate restricted stock unit performance share unit vest restrict stock unit occurrence change control unvested restrict stock unit award outstanding immediately prior change control plan shall immediately fully vested vest performance share unit occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately vested equal psu pro rata settlement restrict stock unit performance share unit common stock continue widely hold freely tradable follow change control exchange converted security successor entity widely hold freely tradable restricted stock unit vest performance share unit shall pay share common stock security soon practicable date change control subject exist deferral election effect common stock continue widely hold freely tradable follow change control exchange converted security successor entity widely hold freely tradable restricted stock unit vest performance share unit shall pay cash soon practicable date change control subject exist deferral election effect provision extent require applicable law entirety protection period material term plan shall modify manner materially adverse qualifying participant understand section shall require specific type level equity award grant qualifying participant follow change control protection period plan amend modify reduce eliminate protection set forth section terminate company shall pay legal fee relate expense include cost expert evidence counsel reasonably good faith incur qualifying participant qualifying participant prevail claim relief action qualifying participant claim provision section plan violate avoidance doubt exclude claim plan benefit ordinary course applicable company qualify participant employer enforce posttermination covenant qualify participant definition purpose section follow term shall follow meaning change control shall mean set forth company change control separation benefit plan provide award plan consist defer compensation subject section code definition change control shall deem modify extent necessary comply section code change control price shall mean respect share common stock higher highest report sale price regular way share transaction report new york stock exchange composite tape national exchange share list nasdaq national market tenday period prior include date change control change control result tender exchange offer merger similar corporate transaction high price share pay tender exchange offer merger similar corporate transaction provide extent consideration pay transaction consist security noncash consideration value security noncash consideration shall determine committee key option shall mean performancebase option grant employee key research development program describe applicable schedule rule regulation plan protection period shall mean period begin date change control end second anniversary date change control psu pro rata shall mean performance share unit award determine multiplying number target share subject performance share unit award times assume performance percentage fraction numerator number partial calendar month elapse applicable performance period count partial month month purpose denominator total number month applicable performance period assume performance percentage shall determine average rank award period follows complete performance year change control actual rank few day elapse completion performance year target rank shall performance year incomplete begin change control target rank round average rank calculate pursuant forego clause near number ordinary numerical round final award percentage associate number determine forego clause target rank rank associate chart final award percentage qualify participant shall mean individual participate plan current employee immediately prior change control application section shall apply stock option restrict stock unit award performance share unit award grant november note incentive grant november merck change control schedule merck change control option vest option key option occurrence change control stock option outstanding immediately prior change control key option shall immediately fully vest exercisable vest key option subject aii schedule occurrence change control key option shall continue subject performancebase vest schedule applicable thereto immediately prior change control notwithstanding schedule stock option continue outstanding follow change control exchange converted option purchase security successor entity successor option occurrence change control portion key option shall immediately vest exercisable follow percentage key option milestone reach date change control thenunveste portion key option shall vest exercisable remainder shall forfeit key option milestone reach date change control thenunveste portion key option shall vest exercisable remainder shall forfeit key option second milestone reach date change control unvested portion key option shall vest exercisable posttermination exercise period stock option continue outstanding follow change control exchange converted successor option portion stock option successor option applicable vested exercisable immediately follow termination employment holder thereof change control shall remain exercisable follow termination year date termination remainder term thereof provide termination reason gross misconduct death retirement term apply award grant plan provision plan applicable termination reason gross misconduct death retirement shall apply termination effect vest pursuant section cause stock option successor stock option terminate early accelerate vest occur term stock option shall expire early accelerate vest occur cashout stock option stock option continue outstanding follow change control exchange converted successor option holder vest exercisable option shall entitle receive soon practicable follow change control share common stock subject vest exercisable option cash determine committee prior change control event excess change control price exercise price thereof subject exist deferral election effect consideration pay change control entirely share common stock acquire result corporation committee prior change control provide cancellation outstanding stock option time change control cash pursuant provision provide exchange conversion outstanding stock option time change control connection provision shall obligate permit holder stock option election relate thereto determine appropriate incentive stock option amend section apply incentive stock option mean section internal revenue code restrict stock unit performance share unit vest restrict stock unit occurrence change control unvested restrict stock unit award outstanding immediately prior change control plan shall immediately fully vested vest performance share unit occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately vested equal psu pro rata settlement restrict stock unit performance share unit common stock continue widely hold freely tradable follow change control exchange converted security successor entity widely hold freely tradable restricted stock unit vest performance share unit shall pay share common stock security soon practicable date change control subject exist deferral election effect common stock continue widely hold freely tradable follow change control exchange converted security successor entity widely hold freely tradable restricted stock unit vest performance share unit shall pay cash soon practicable date change control subject exist deferral election effect provision extent require applicable law entirety protection period material term plan shall modify manner materially adverse qualifying participant understand section schedule shall require specific type level equity award grant qualifying participant follow change control protection period plan amend modify reduce eliminate protection set forth section schedule terminate company shall pay legal fee relate expense include cost expert evidence counsel reasonably good faith incur qualifying participant qualifying participant prevail claim relief action qualifying participant claim provision section schedule violate avoidance doubt exclude claim plan benefit ordinary course applicable company qualify participant employer enforce posttermination covenant qualify participant section apply incentive stock option mean section internal revenue code plan amend schedule notwithstanding company reserve right change require extent require avoid adverse consequence american job creation act amend definition purpose schedule follow term shall follow meaning change control shall mean set forth company change control separation benefit plan provide award plan consist defer compensation subject section code definition change control shall deem modify extent necessary comply section code change control price shall mean respect share common stock higher highest report sale price regular way share transaction report new york stock exchange composite tape national exchange share list nasdaq national market day period prior include date change control change control result tender exchange offer merger similar corporate transaction high price share pay tender exchange offer merger similar corporate transaction provide extent consideration pay transaction consist security noncash consideration value security non cash consideration shall determine committee key option shall mean performancebase option grant employee key research development program describe applicable schedule rule regulation plan protection period shall mean period begin date change control end second anniversary date change control psu pro rata shall mean performance share unit award determine multiplying number target share subject performance share unit award times assume performance percentage fraction numerator number partial calendar month elapse applicable performance period count partial month month purpose denominator total number month applicable performance period assume performance percentage shall determine average rank award period follows complete performance year change control actual rank few day elapse completion performance year target rank shall performance year incomplete begin change control target rank round average rank calculate pursuant forego clause near number ordinary numerical round final award percentage associate number determine forego clause target rank rank associate chart final award percentage qualify participant shall mean individual participate plan current employee immediately prior change control application schedule shall apply stock option restrict stock unit award performance share unit award plan grant prior november exhibit merck inc incentive stock plan amend effective december merck inc incentive stock plan effective december purpose incentive stock plan plan effective establish encourage employee merck inc company subsidiary affiliate joint venture acquire common stock company common stock believe plan serve interest company stockholder allow employee great personal financial interest company ownership right acquire common stock turn stimulate employee effort company behalf maintain strengthen desire remain company believe plan assist recruitment employee administration plan shall administer compensation benefit committee board director company committee director company serve committee nonemployee director purpose rule securities exchange act amended exchange act satisfie requirement outside director purpose section internal revenue code code committee shall responsible administration plan include limitation determine eligible employee receive incentive type incentive receive plan number share cover incentive grant plan term condition incentive determination committee plan include limitation determination eligible employee form timing incentive term provision incentive writing evidence incentive need uniform selectively eligible employee receive eligible receive incentive hereunder eligible employee similarly situate committee shall responsibility construe interpreting plan include right construe dispute doubtful plan provision establish amend construing rule regulation deem necessary desirable proper administration plan decision action take take committee arise connection construction administration interpretation effect plan rule regulation shall maximum extent permit applicable law absolute discretion specifically provide shall final bind conclusive company eligible employee person claim eligible employee committee permit applicable state law delegate power authority hereunder chief executive officer senior member management committee deem appropriate provide committee delegate authority regard matter action affect officer term define rule exchange act section officer delegation shall case incentive intend qualified section code purpose section subsequent section plan shall deemed include plan comparable subplans establish subsidiary aggregate shall constitute plan govern term set forth eligibility employee regular fulltime parttime employee employ company parent subsidiary affiliate joint venture include officer director company employee joint venture partner affiliate company provide service joint venture partner affiliate person employee shall eligible participate plan designate committee eligible employee nonemployee term employee shall include follow collectively exclude person director employee officer person independent contractor agree agree heshe independent contractor person agreement understand company affiliate joint venture partner heshe employee eligible employee heshe previously employee eligible employee person employ temporary employment agency regardless control supervision training provide company affiliate lease employee define section code exclude person eligible employee receive incentive court agency authority rule heshe commonlaw employee company affiliate right continue employment plan shall interfere limit way right company parent subsidiary affiliate joint venture terminate employment participant time confer participant right continue employ company parent subsidiary affiliate joint venture eligible employee shall right receive incentive benefit plan grant incentive benefit receive additional incentive benefit award incentive benefit arise incentive shall constitute employment contract company parent subsidiary affiliate joint venture accordingly plan benefit hereunder terminate time sole exclusive discretion company give rise liability company parent subsidiary affiliate joint venture severance specifically state employee benefit plan policy program incentive plan realize incentive shall treat compensation purpose calculate employee benefit plan policy program term plan plan shall effective subject approval plan majority vote cast annual meeting stockholder company april incentive shall grant plan april early date plan terminate board term exercise incentive grant theretofore extend date incentive incentive plan grant combination incentive stock option isos nonqualified option isos stock option stock appreciation right restrict stock grant performance awards share awards phantom stock award collectively incentive incentive shall subject term condition set forth term condition establish committee general incentive vest stock option stock appreciation right exercisable early year grant date case intervene event example change control company grantee death retirement termination employment cause company event establish committee require applicable law share available incentive share available subject provision section maximum number share common stock company issue plan million stock option stock appreciation right shall count share purpose limit set forth section time grant combination tandem sar stock option exercise tandem sar stock option result cancellation shall count share purpose limit set forth section time grant restrict stock grant performance share share award phantom stock award shall count share purpose limit set forth section time grant iii share plan incentive stock plan purchase award incentive incentive lapsed expired terminate cancel grant incentive plan notwithstanding contrary share tender payment exercise price stock option shall add maximum share limitation describe share withhold company satisfy tax withholding obligation shall add maximum share limitation describe share cover stock appreciation right extent exercise share common stock actually exercise right shall considered issue transfer pursuant plan incentive similar award issue entity merge company acquire company involve similar corporate transaction company consider issue plan share plan deliver company authorize unissued share common stock issue reacquire common stock hold treasury stock event shall fractional share common stock issue plan limit individual incentive calendar year eligible employee receive respect incentive denominate respect share common stock incentive cover million share companys common stock number share shall count provide section shall adjust accordance section respect incentive denominate cash incentive fair market value exceed million share common stock determine date incentive grant adjustment share event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination share merger consolidation right offer spin split split similar change capital structure company committee shall equitable adjustment number kind share authorize issuance plan number kind share subject outstanding incentive iii option price stock option grant value stock appreciation right determination shall final bind conclusive party stock option committee grant option qualify isos define section code option isos nonqualified option stock option shall subject follow term condition term condition committee prescribe stock option price option price share respect stock option shall determine committee shall percent fair market value common stock date stock option grant determined committee period stock option period stock option shall fix committee provide period stock option shall exceed year grant provide event death optionee prior expiration nonqualified option nonqualified option committee determine exercisable year date grant committee subsequent grant stock option extend term thereof event shall extend term exceed year original grant date exercise stock option payment share shall issue payment option price option price pay cash committee determine share common stock combination cash share common stock cashless exercise procedure allow grantee sell immediately share underlie exercise portion option order generate sufficient cash pay option price committee approves use share common stock payment method committee shall establish condition deem appropriate use common stock exercise stock option stock option award plan shall exercise procedure program committee establish define time time include designate broker exercise stock option committee establish rule procedure permit option holder defer recognition gain exercise stock option exercisable date committee shall determine share cover stock option purchase committee establish waiting period date stock option exercisable vested subject paragraph section exercise period committee accelerate exercisability stock option portion thereof termination employment determine committee termination stock option grantee employment reason gross misconduct stock option privilege shall limit share immediately exercisable date termination committee discretion provide stock option outstanding exercisable termination stock option grantee employment exercisable accordance schedule determine committee stock option privilege shall expire exercise period time date termination employment establish committee event later expiration date stock option termination misconduct stock option grantee employment terminate gross misconduct determine company right stock option shall expire date termination limit isos permit code eligible employee receive grant isos stock aggregate fair market value excess internal revenue service decide time time determine time iso grant exercisable time person calendar year grant excess limit provide code grant shall automatically nonqualified option dividend equivalent plan contrary notwithstanding dividend dividend equivalent pay stock option stock appreciation right committee discretion grant right receive appreciation fair market value share common stock stock appreciation right singly combination underlie stock option grant hereunder stock appreciation right shall subject follow term condition term condition committee prescribe time period grant stock appreciation right grant respect underlie stock option tandem sar grant time stock option grant time prior expiration stock option grant time tandem sar grant committee limit exercise period stock appreciation right period stock appreciation right shall attach underlie stock option event shall exercise period tandem sar exceed exercise period stock option stock appreciation right grant underlie stock option stand sar period exercise stock appreciation right shall set committee value stock appreciation right grantee tandem sar entitle surrender stock option exercisable receive exchange equal excess fair market value common stock date election surrender receive company accordance exercise procedure establish company stock option price spread multiply number share cover stock option surrender grantee stand sar receive exercise stock appreciation right equal excess fair market value common stock date election surrender stand sar receive company accordance exercise procedure establish company fair market value common stock date grant multiply number share cover grant stand sar notwithstanding forego sole discretion committee time grant stock appreciation right provide spread cover stock appreciation right exceed specify payment stock appreciation right payment stock appreciation right shall form share common stock cash combination share cash form payment exercise right shall determine committee time grant stock appreciation right time exercise stock appreciation right dividend equivalent plan contrary notwithstanding dividend dividend equivalent pay stock appreciation right performance awards committee grant award denominate share common stock performance share denominate dollarsperformance unit performance company parent subsidiary division affiliate joint venture company select committee award period meet certain goal establish committee performance award performance award shall subject follow term condition term condition committee prescribe award period performance goal committee shall determine include performance share award grant period time performance share award award period committee shall establish performance objective performance goal meet company parent subsidiary division affiliate joint venture company award period condition payment performance award performance goal include share price pretax profit earning share return stockholder equity return asset sale net income total shareholder return combination forego solely award intend constitute performancebase compensation section code financial measurement establish committee performance goal include minimum optimum objective single set objective payment performance awards committee shall establish method calculate payment performance award performance goal meet include fix maximum payment completion award period performance company parent subsidiary division affiliate joint venture company shall measure performance goal committee shall determine accordance term performance award portion performance award shall pay committee discretion elect payment share common stock cash combination share cash cash payment shall base fair market value share common stock soon practicable prior date payment committee establish rule procedure permit grantee defer recognition income attainment performance award revision performance goal award intend constitute performancebase compensation section code time prior end award period committee revise performance goal computation payment unforeseen event occur substantial effect performance company parent subsidiary division affiliate joint venture company judgment committee application performance goal unfair revision requirement employment grantee performance award remain employ company parent subsidiary affiliate joint venture completion award period order entitle payment performance award provide committee discretion provide partial payment exception deem equitable dividend committee discretion time grant performance award provide dividend declare common stock award period pay respect performance share own grantee pay grantee accumulate benefit grantee increase number performance share grantee iii pay accumulate restrict stock grant committee award actual share common stock restrict stock phantom share common stock restrict stock unit eligible employee share shall subject follow term condition term condition committee prescribe restrict stock grant requirement employment grantee restrict stock grant remain employment company period designate committee restrict period order receive share cash combination thereof restrict stock grant grantee leave employment company prior end restrict period restrict stock grant shall terminate share common stock shall return immediately company provide committee time grant provide employment restriction lapse respect portion portion restrict stock grant different time restrict period committee discretion provide complete partial exception employment restriction deem equitable restriction transfer legend stock certificate restrict period grantee sell assign transfer pledge dispose restricted stock grant include limited share common stock certificate share common stock issue hereunder shall contain legend give appropriate notice restriction grant escrow agreement committee require grantee enter escrow agreement provide certificate represent restricted stock grant remain physical custody escrow holder restriction remove expire lapse restriction restriction impose restricted stock grant shall lapse expiration restrict period condition employment set forth meet grantee shall entitle legend remove certificate restrict stock restrict stock unit pay form share common stock cash combination share cash determined committee committee establish rule procedure permit grantee defer recognition income expiration restrict period dividend committee discretion time restrict stock grant provide dividend declare common stock restrict period dividend equivalent pay grantee accumulate benefit grantee pay grantee expiration restrict period iii pay accumulate performance goal committee designate restrict stock grant intend performancebase compensation term section code restrict stock grant designate performancebase compensation shall condition achievement performance goal define section extent require section sharebase awards committee grant award actual share common stock share award phantom share common stock phantom stock award eligible employee term condition committee determine sole discretion share award additional compensation service render eligible employee lieu cash compensation eligible employee entitle company transferability iso grant plan shall transferable law descent distribution incentive grant plan transferable assignable recipient subject execution attachment similar procedure law descent distribution determine committee accordance exchange act applicable law regulation notwithstanding forego committee discretion adopt rule permit transfer solely gift grantee lifetime stock option isos member grantee immediate family trust family partnership similar entity benefit immediate family member purpose immediate family member mean grantee spouse parent child stepchild grandchild spouse family member term stock option shall final bind conclusive beneficiary executor administrator heir successor grantee discontinuance amendment plan board director discontinue plan time time time amend revise term plan permit applicable statute consent grantee affect revoke alter manner unfavorable grantee incentive hereunder incentive outstanding board amend plan stockholder approval absence approval cause plan fail comply rule exchange act requirement applicable law regulation notwithstanding forego consent affect grantee incentive amend revise revoke necessary avoid penalty section internal revenue code amend approve company stockholder specifically provide plan adjustment reduction exercise price outstanding incentive shall event decline stock price reduce exercise price outstanding incentive cancellation outstanding incentive connection regrante incentive low price individual limitation compensation plan shall construe limit right company establish plan pay compensation employee cash property manner expressly authorize plan constraint corporate action plan shall construe limit impair affect company right power adjustment reclassification reorganization change capital business structure merge consolidate dissolve liquidate sell transfer business asset provide section limit right power company parent subsidiary affiliate joint venture action entity deem necessary appropriate withholding taxis company shall entitle deduct payment plan regardless form payment applicable income employment taxis require law withhold respect payment require eligible employee pay tax prior condition make payment accordance applicable administrative guideline establishe committee allow eligible employee pay taxis require law withhold incentive withholding payment common stock result incentive permit eligible employee deliver company share common stock fair market value determine committee equal require withholding taxis compliance section respect eligible employee section officer transaction plan intend comply applicable condition rule successor exchange act extent compliance plan provision applicable solely section officer require order bring transaction section officer compliance rule shall deem null void transaction extent permit law deem advisable committee delegee extent provision plan action plan administrator involve section officer deem comply applicable condition rule shall deem null void section officer extent permit law deem advisable plan administrator use proceed proceed receive company plan shall add general fund company shall corporate purpose board director shall direct govern law plan agreement hereunder shall construe accordance govern law state new jersey give effect principle conflict law offset suspension exercise contrary plan notwithstanding plan administrator offset incentive amount reasonably believe owe company grantee disallow incentive exercise payable time company investigate reasonably reliable allegation gross misconduct grantee effect change control option vest option key option occurrence change control stock option outstanding immediately prior change control key option shall immediately fully vest exercisable vest key option subject section aii occurrence change control key option shall continue subject performancebase vest schedule applicable thereto immediately prior change control notwithstanding section stock option continue outstanding follow change control exchange converted option purchase security successor entity successor option occurrence change control portion key option shall immediately vest exercisable follow percentage key option milestone reach date change control thenunveste portion key option shall vest exercisable remainder shall forfeit key option milestone reach date change control thenunveste portion key option shall vest exercisable remainder shall forfeit key option second milestone reach date change control thenunveste portion key option shall vest exercisable posttermination exercise period stock option continue outstanding follow change control exchange converted successor option portion stock option successor option applicable vested exercisable immediately follow termination employment holder thereof change control shall remain exercisable follow termination year date termination remainder term thereof provide termination reason gross misconduct death retirement term apply award grant plan provision plan applicable termination reason gross misconduct death retirement shall apply termination cashout stock option stock option continue outstanding follow change control exchange converted successor option holder vest exercisable option shall entitle receive soon practicable follow change control share common stock subject vest exercisable option cash determine committee prior change control event excess change control price exercise price thereof subject exist deferral election effect consideration pay change control entirely share common stock acquire result corporation committee prior change control provide cancellation outstanding stock option time change control cash pursuant section provide exchange conversion outstanding stock option time change control connection provision shall obligate permit holder stock option election relate thereto determine appropriate restrict stock grant performance share award vest restrict stock grant occurrence change control unvested restricted stock grant outstanding immediately prior change control plan shall immediately fully vested vest performance award occurrence change control unvested performance award outstanding immediately prior change control plan shall immediately vested equal psu pro rata settlement restrict stock grant performance award common stock continue widely hold freely tradeable follow change control exchange converted security successor entity widely hold freely tradeable vested incentive shall pay share common stock security soon practicable date change control form cash respect performance unit subject exist deferral election effect common stock continue widely hold freely tradeable follow change control exchange converted security successor entity widely hold freely tradeable vested incentive shall pay cash soon practicable date change control subject exist deferral election effect provision extent require applicable law entirety protection period material term plan shall modify manner materially adverse qualifying participant understand section shall require specific type level equity award grant qualifying participant follow change control protection period plan amend modify reduce eliminate protection set forth section terminate company shall pay legal fee relate expense include cost expert evidence counsel reasonably good faith incur qualifying participant qualifying participant prevail claim relief action qualifying participant claim provision section plan violate avoidance doubt exclude claim plan benefit ordinary course applicable company qualify participant employer enforce posttermination covenant qualify participant definition purpose section follow term shall follow meaning change control shall mean set forth company change control separation benefit plan provide award plan consist defer compensation subject section code definition change control shall deem modify extent necessary comply section code change control price shall mean respect share common stock higher highest report sale price regular way share transaction report new york stock exchange composite tape national exchange share list nasdaq national market tenday period prior include date change control change control result tender exchange offer merger similar corporate transaction high price share pay tender exchange offer merger similar corporate transaction provide extent consideration pay transaction consist security noncash consideration value security noncash consideration shall determine committee key option shall mean performancebase option grant employee key research development program describe applicable schedule rule regulation plan protection period shall mean period begin date change control end second anniversary date change control psu pro rata shall mean performance award determine committee grant performance award qualify participant shall mean individual participate plan current employee immediately prior change control exhibit merck inc nonemployee directors stock option plan effective april amend restate february nonemployee directors stock option plan nonemployee director stock option plan plan establish attract retain compensate service member board director merck inc company merck highly qualified individual current employee company enable increase ownership company common stock plan beneficial company stockholder allow director great personal financial stake company ownership company stock addition underscore common interest stockholder increase value company stock long term eligibility member company board director current employee company subsidiary non employee director shall participate plan award nonqualifie stock option purchase share merck common stock nqso restrict stock grant collectively incentive grant plan share available number share available reserved issuance plan million share merck common stock par value share authorize unissued share treasury share share purchase open market recapitalization adjustment event reorganization recapitalization stock split stock dividend extraordinary cash dividend combination share merger consolidation right offer similar change capital structure share company adjustment number kind share authorize plan number kind share cover incentive option price outstanding nqso plan shall manner adjustment incentive issue company current incentive stock plan subject require action board director stockholder company compliance applicable security law annual grant nonqualified stock option year friday follow company annual meeting stockholder individual elect reelect continue nonemployee director shall automatically receive nqso purchase share merck common stock determined board time time notwithstanding forego friday general counsel company determine herhis sole discretion company possession material undisclosed information company annual grant nqsos nonemployee director shall suspend second business day public dissemination information price exercisability date option period shall determine reference later date merck common stock trade new york stock exchange date grant award grant shall day merck common stock trade option price price nqso shall closing price merck common stock date grant quote new york stock exchange option period nqso grant plan shall exercisable equal installment subject round second anniversary date grant shall expire day tenth anniversary thereof option period plan time shall mean time new york payment nqso price require tax withholding shall pay cash dollar time nqso exercise manner permit option exercise company incentive stock plan isp applicable officer define rule securities exchange act exchange act merck affiliates compensation benefit committee board director company approve use previously own share common stock portion exercise price nqso grant isp provision shall apply plan nqso shall exercise company brokerassiste stock option exercise program provide program available time option exercise mean effect time time isp cessation service cessation service nonemployee director reason retirement death nqso immediately exercisable date cessation service shall exercisable grantee nqso exercise day day month cessation service event expiration option period shall forfeit example service end january section apply nqso expire later april nqsos shall expire day cessation service retirement grantee cease service nonemployee director age year service age year service cessation service retirement begin day service end hisher outstanding nqso shall continue exercisable service continue outstanding nqso exercise expiration option period nqso shall forfeit notwithstanding forego grantee die nqsos forfeit section shall control death death grantee unvested nqso shall immediately exercisable nqso exercisable date death nqso exercisable date death exercise grantee legal representative heir early day anniversary date death expiration option period exercise early nqso shall forfeit notwithstanding forego local law applicable deceased grantee require long short exercise period provision shall comply law restrict stock grant board award actual share common stock restrict stock phantom share common stock restrict stock unit nonemployee director share shall subject term condition board prescribe time time administration amendment plan plan shall administer board director merck board delegate person group delegate board power obligation hereunder relate day day administration exercise process plan terminate amend board director deem advisable amendment revise price date exercisability option period share nqso shall frequently month necessary comply applicable law regulation approve company stockholder adjustment reduction exercise price outstanding nqso shall directly cancellation outstanding nqsos subsequent regranting nqso low price individual amendment revoke alter manner unfavorable grantee incentive outstanding board amend plan stockholder approval absence approval cause plan fail comply rule exchange act requirement applicable law regulation incentive grant plan december nqso grant prior date shall continue exercisable exercise restrict stock grant shall continue vest accord term transferability set forth section nqso grant plan shall exercisable grantee lifetime grantee grantee legal guardian grantee legal representative shall transferable law descent distribution incentive grant plan shall transferable grantee lifetime accordance follow provision grantee transfer nqso serve nonemployee director company year cease service nonemployee director retirement define section nqso transfer grantee spouse child include adopt child stepchildren grandchild collectively family member trust benefit family member discretion board director partnership grantee family member partner accordance rule set forth section grantee shall receive payment consideration transfer transfer partnership grantee shall permit receive interest partnership consideration transfer nqso transfer accordance section shall continue subject term condition hand transferee applicable nqso prior transfer grantee right transfer nqso accordance section shall apply transferee transferee natural person transferee death nqso privilege exercise legal representative beneficiary transferee exercise period applicable nqso purport transfer nqso section shall effective prior transfer grantee meet minimum stock ownership target place director company notify company transferee address number share option transfer grant date exercise price share demonstrate request board director propose transferee qualifie permit transferee rule set forth section addition transferee sign agreement bind rule regulation plan insider trading restriction apply grantee provide additional document request company order effect transfer transfer shall effective company effect registration statement file security act cover security acquire transferee exercise nqso general counsel merck determine registration share necessary compliance sec regulation company intent plan comply respect rule exchange act regulation promulgate thereunder provision plan later find compliance rule provision shall deem null void grant exercise nqso plan shall execute accordance requirement section exchange act amend regulation promulgate thereunder miscellaneous provide plan nonemployee director shall claim right grant nqso plan plan action thereunder shall construe give director right retain service company effective date plan shall effective april later date stockholder approval obtain constraint corporate action plan shall construe limit impair affect company right power adjustment reclassification reorganization change capital business structure merge consolidate liquidate sell transfer business asset provide section limit right power company subsidiary action entity deem necessary appropriate governing law plan agreement hereunder shall construe accordance govern law state new jersey exhibit august dear brad letter agreement agreement supersede peter loeschers letter date july concern employment status merck inc merck company incorporate revision early letter discuss attorney merck attorney peter discuss general restructuring merck worldwide human health business current position president human health eliminate close business september separate employment merck offer severance arrangement set forth contingent timely acceptance nonrevocation term set forth agreement employment status transition assignment effective july relieve operational responsibility sole assignment effectuate transition responsibility president human health direction status officer define rule define security exchange act end close business july agree use good effort perform assignment duty assign conduct good interest company grade base salary remain current level continue eligible participate company employee benefit plan program amend time time term condition applicable company employee grade level sole discretion employment status convert time pay inactive status prior september pay inactive status grade base salary unchanged continue receive monthly salary payment continue accrue pension credit eligible participate plan elect flexible benefit program provide eligible participate short term long term disability benefit plan benefit agree waive termination employment employment terminate september separation date provide terminate employment resignation prior separation date resignation deem occur event engage conduct inconsistent responsibility obligation merck employee voluntarily terminate employment quit commence employment termination employment separation date separation service separation merck inc separation benefit plan nonunion employee separation plan eligible benefit applicable bridged employee describe brochure entitle special separation program bridge employee bridge employee brochure separation plan summary plan description spd describe benefit available separation plan bridge employee brochure describe effect separation benefit bridgedpage employee provide incorporate reference conflict spd agreement bridge employee brochure agreement spd bridged employee brochure case shall govern separation benefit separation receive follow separation benefit accordance spd bridged employee brochure separation pay subject paragraph receive seventyeight week pay describe spd payable periodic installment accordance company normal payroll period minus applicable deduction withholding retirement plan receive bridge pension benefit describe bridge employee brochure subject paragraph medical dental benefit eligible select retiree medical dental benefit describe bridge employee brochure life insurance eligible consider retiree life insurance plan purpose describe bridge employee brochure outplacement eligible receive senior executive service outplacement service period month equity grant consider retire purpose outstanding unexercised stock option restrict stock unit leader share performance share unit case responsibility familiarize term individual equity grant special payment lieu eip bonus subject paragraph receive special payment minus applicable deduction withholding lieu eip bonus performance deferral election respect eip bonus apply special payment event die special payment payment estate payment generally payment pursuant agreement base current base salary subject applicable deduction withhold separation payment describe agreement attach bridged employee brochure compensation pay behalf section payment generally account separation service month follow termination employment specify employee define prop treas reg sec successor thereto general include employee company rank compensation specify employee payment characterize agreement subject paragraph payment prior day seventh month follow termination employment instead amount payable month immediately follow separation accumulate pay lump sum interest soon administratively practicable follow month period april deferral program account defer program account applicable pay accordance term condition merck deferral program applicable separated employee subject paragraph agreement lump sum payment soon practicable separation merck pay subject appropriate tax withholding gross lump sum lump sum payment subject delay describe paragraph agreement condition receive lump sum payment agree execute return release claim attach hereto attachment soon september merck obligation pay lump sum arise revocation period execute release pass revocation thereof financial counseling continue participate company executive financial service program end level establish management committee member time time currently reimbursement calendar year nondisparagement agree disparage merck affiliate subsidiarie joint venture product officer director employee employee representative agent way whatsoever provide set forth prohibit make statement engage conduct extent statement conduct require law court order legal process company agree employee executive officer company july member company board director disparage performance merck employee noncompete period eighteen month follow separation date agree conduct business competition merck conduct business competition merck mean purpose agreement connected manner competitor define directly indirectly individual director trustee officer employee debt equity investor consultant independent contractor competitor ownership management operation control person entity competitor provide event shall ownership outstanding equity security issuer security register securities exchange act amend stand prohibit subparagraph long exercise right manage operate control business issuer individually partnership conjunction person entity engage work work employee consultant advise manage lead employ affiliate operate enterprise endeavor define competitor discover develop market sell pharmaceutical biological product vaccine obtain consent merck general counsel request consent include company like work associate nature propose employment association relationship company information request general counsel consent general counsel require hereunder unreasonably withhold provide understand agree decision grant request consent determine general counsel exercise sole discretion consent effective set forth sign write communication general counsel competitor mean follow company parent subsidiary affiliate successor abbott laboratories amgen astrazeneca bristol myers squibb glaxo smith kline genentech johnson johnson eli lilly novartischiron pfizer rochehoffmannla roche sanofiadventis schering plough wyeth nonsolicitation period eighteen month follow separation date agree solicit entice persuade induce attempt influence person employ merck subsidiary joint venture date agreement leave employ merck subsidiary joint venture make initial contact merck employee purpose engage discussion merck employee purpose result cause party initial contact merck employee purpose soliciting enticing persuade induce leave employ merck provide party information merck employee purpose recruitment employee confidential information acknowledge agree course employment company access trade secret confidential proprietary business information confidential information own pertinent company subsidiary joint venture agree disclose confidential information determine good faith advice counsel require law legal process subpoena court order provide prior require disclosure use reasonable good effort provide sufficient notice company enable company interpose effective objection disclosure litigation connection litigation investigation inquiry proceeding court arbitrator government administrative agency tribunal ask merck testify witness provide information concern matter involve course employment merck agree cooperate fully merck counsel make available counsel reasonable advance notice discuss information review testimony reasonably advance litigation proceeding make available testify deposition trial require request merck notifying merck immediately aware litigation investigation inquiry proceeding involve merck travel expense applicable statutorily mandate witness fee agree pay connection testimony appearance participation pursuant paragraph litigation proceeding agree participate lawsuit legal action administrative proceeding initiate party involve merck participation solicit merck authorize merck command valid lawfully issue subpoena agree subject subpoena require bear witness matter concern employment knowledge merck contact company soon reasonably practicable cooperate fully company choose manner proceed provision shall construe precluding cooperate law enforcement regulatory agency connection lawful government inquiry breach agreement forfeiture benefit forfeiture benefit provision set forth spd incorporate reference agreement respect amount benefit payable hereunder separate apart remedy merck event merck reasonably determine breach violate paragraph agreement merck obligation pay amount describe paragraph agreement immediately cease date breach violation merck bepage relieve obligation payment entitle demand agree immediately tender benefit payment previously hereunder agree breach paragraph agreement cause immediate irreparable injury merck impossible estimate determine damage suffer merck event breach agree breach paragraph cause immediate irreparable injury merck impossible estimate determine damage suffer event breach separate apart remedy merck agree event breach merck entitle addition available remedy temporary permanent injunctive relief breach employer employee partner agent associate term set forth paragraph necessity prove actual damage immediate irreparable harm post bond award liquidate damage equal monie pay receive accordance paragraph agreement iii associate attorney fee cost reformation agree portion paragraph determine invalid determination affect enforceability remain portion paragraph paragraph interpret invalid portion insert agree invalidity cause length period time size area period time area need action party deem reduce period area cure invalidity confidentiality agree hold existence agreement term condition agreement strict confidence agree disclose require law legal process information party member immediate family spouse financial advisor outplacement firm tax authority tax consultant prepare tax return legal advisor notwithstanding forego disclose executive search firm prospective employer provision agreement relate agreement conduct business competition merck release consideration promise company set forth agreement intent bind legally agree irrevocably release forever discharge merck inc benefit plan subsidiary affiliate officer director employee agent predecessor partner successor fiduciary assign releasee respect manner action suit debt claim demand whatsoever law equity arise way relate employment company termination employment arise way relate transaction occurrence act omission loss damage injury occurring time include date time sign agreement claim include limited claim base law statute ordinance regulation constitution executive order base contract tort common law legal equitable theory relief claim base employee retirement income security act claim arise civil right law federal state local jurisdiction include limited title vii civil right act americans disability act section rehabilitation act family medical leave act age discrimination employment act pennsylvania human relations act new jersey law discrimination claim whistleblower law whistleblow provision law include limited new jersey conscientious employee protection act claim counsel fee cost understand signing agreement waive claim releasee release agreement great extent allowable law paragraph shall read waiver vest right saving pension plan forego release release waive claim right waive law release waive claim right indemnification merck bylaw applicable law merck director officer insurance future representation acknowledge promise promise agreement signing agreement rely statement representation behalf releasee concern merit claim nature extent duration damage relate claim money benefit compensation claim concern agreement concern thing matter voluntariness agree rely solely judgment legally competent sign agreement signing agreement free read understand agreement signing signing agreement exchange consideration believe satisfactory adequate admission agree acknowledge offer arrangement agreement construe admission evidence merck agent fail way act properly connection employment termination thereof contrary company specifically deny wrongful unlawful treatment agreement propose company solely purpose reach mutually acceptable resolution issue raise arise termination employment applicable law acknowledge agree employment relationship merck govern solely exclusively law state new jersey united states question scope interpretation effect agreement resolve substantive procedural law state new jersey give effect conflict law provision severability provision portion agreement severable provision portion agreement application provision portion agreement determine invalid unenforceable extent reason provision portion agreement remain force effect continue enforceable full great extent permit law amendment termination plan merck retain right extent permit law amend terminate separation plan benefit plan describe spd andor bridge employee brochure time agreement affect alter right current intention merck extend enhance separation plan future sign return agreement later amendment termination decrease separation pay separation benefit eligible receive describe agreement complete agreement agreement constitute complete final agreement party supersede replace prior contemporaneous agreement negotiation discussion relate subject matter agreement accordance federal old worker benefit protection act fortyfive day initial receipt agreement consider sign agreement choose sign agreement entitle revoke acceptance time seven calendar day signing revoke time period agreement null void purpose agreement effective enforceable revocation period expire lastly right consult attorney signing agreement indicate acceptance agreement sign date letter return duplicate letter sign enclose record truly richard clark richard clark chief executive officer president accept date radley shearespage attachment release waiver claim consideration lump sum pay merck inc merck company set forth paragraph agreement merck date august agreement intent bind legally agree irrevocably release forever discharge merck inc benefit plan subsidiary affiliate officer director employee agent predecessor partner successor fiduciary assign releasee respect manner action suit debt claim demand whatsoever law equity arise way relate employment company termination employment arise way relate transaction occurrence act omission loss damage injury occurring time include date time sign release claim include limited claim base law statute ordinance regulation constitution executive order base contract tort common law legal equitable theory relief claim base employee retirement income security act claim arise civil right law federal state local jurisdiction include limited title vii civil right act americans disability act section rehabilitation act family medical leave act age discrimination employment act pennsylvania human relations act new jersey law discrimination claim whistleblower law whistleblow provision law include limited new jersey conscientious employee protection act claim counsel fee cost understand signing release waive claim releasee release release great extent allowable law release shall read waiver vest right saving pension plan release release waive claim right waive law release waive claim right indemnification merck bylaw applicable law merck director officers insurance arise agreement future day consider term release advise right counsel review release sign right revoke agreement term release notifying merck write calendar day execute release accept datedexhibit december david anstice dear david letter agreement agreement confirm discussion set forth arrangement concern employment status merck inc merck company agree follow employment status job assignment effective september appoint newly create position executive vice president strategic initiative report new assignment new assignment serve executive committee continue officer define rule securities exchange act job duty dutie new assignment include function primary sustain sponsor company end toend global support function initiative accountability successful realization element company plan win help refine company strategic direction key pharmaceutical emerge market particular china india iii serve member human health operating committee research strategic review committee assist successor transition role president asia pacific human health leader merckschere plough joint venture necessary perform duty assign agree devote business time attention good effort ability performance duty consent company serve employee director consultant independent contractor respect business company affiliate compensation benefit employ new assignment remain eligible salary increase bonus subject section longterm incentive continue eligible participate company employee benefit plan program amend time time term condition applicable company employee grade level bonus eligible award company executive incentive plan eip certain case lieu award follow performance year employment terminate cause define section company agree grant eip award lieu award employment end prior payout award eip award pay performance year payable time eip award generally pay employee calendar year subsequent employ entire calendar year close business december eligible eip award determine accordance manner company make determination employee level include limitation company performance division performance scope impact complexity individual contribution award payable calendar year follow performance year question time eip award generally pay employee iii severance year define section entitle lieu eip award accordance section separation agree appointment new assignment separation service meaning company separation benefit plan nonunion employee length assignment employment continue basis mean company terminate employment relationship time notice lawful reason definition big pharmaceutical competitor term big pharmaceutical competitor mean follow company parent subsidiary affiliate joint venture successor abbott laboratories amgen astrazeneca bristol myers squibb glaxo smith kline genentech johnson johnson eli lilly novartischiron pfizer rochehoffmannla roche sanofiaventis schering plough wyeth cause term cause mean intentional repeat failure refusal perform reasonably assign duty dishonesty willful misconduct gross insubordination gross negligence performance dutie iii involvement transaction connection performance dutie company affiliate transaction adverse interest company affiliate engage personal profit willful violation law rule regulation connection performance dutie traffic violation similar minor offense indictment conviction plea contest respect felony crime involve moral turpitude felony action inaction materially adversely affect reputation company affiliate vii breach covenant contain section agreement breach agreement company party competitor term competitor mean person company entity discover develop market sell pharmaceutical biological product vaccine world big pharmaceutical competitor severance event term severance event mean cessation employment company result decision decision company severance event occur cessation employment occur result decision company terminate employment cause decision leave employment company presence circumstance support decision company terminate employment cause iii employment termination entitle receive severance benefit merck inc change control separation benefit plan effect time time severance year term severance year mean calendar year severance event occur consideration acknowledge exchange agreement accept abide term agreement receive benefit provide solely pursuant agreement entitled specifically consideration ofpage initial execution company agree offer new assignment guarantee eip award lieu award set forth section term agreement consideration reexecution agreement company provide severance benefit set forth section term agreement severance benefit consideration agreement accept abide term agreement company provide follow benefit severance benefit condition employment end result severance event define section condition presentation company severance event reaffirm acceptance agreement reexecute agreement time period set forth section subsequently revoke acceptance severance pay subject section receive severance pay form continue monthly salary payment minus applicable deduction withholding period begin day severance event end early date eighteen month severance event july iii breach condition set forth section severance year bonus subject section entitled payment lieu eip award employment end severance year equal product obtain multiplying eip award performance year immediately precede severance year time fraction numerator number complete month service provide severance year number complete month work severance year immediately precede severance event denominator payable accordance section payable calendar year follow severance year time eip award generally pay employee notwithstanding contrary section apply severance year occur calendar year case payable lieu eip award set forth section financial counseling eligible continue participate company executive financial service program balance severance year current level establish executive committee member time time currently reimbursement calendar year addition company provide reimbursement tax counseling require relative tax obligation law country period commence january calendar year immediately follow severance year end december calendar year follow severance year total cost taxfinancial counseling payable merck section exceed relocation benefit decide relocate primary residence outside united states merck accordance company policy provide oneway return trip airfare temporary living maximum day accompany dependent ship household good point mutually agree area consider eligible home sale assistance buyout company current relocation policy provide relocation complete prior twoyear anniversary severance event provide merck payment benefit reduce relocation reimbursementexpense entitle arrangement employer understand agree eligibility benefit section contingent compliance procedure current company relocation policy relate company policy payment generally severance payment pursuant section agreement base current base salary time severance event subject applicable deduction withhold subject section severance payment pursuant section electronic transfer mail accordance normal manner payment regularly schedule payday merck salary employee thirty day reexecute agreement revocation period section elapse whichever later section payment generally account separation service month follow termination employment specify employee define prop reg sec successor thereto general include employee company rank compensation specify employee extent require section internal revenue code amend payment prior day sixth month follow termination employment instead amount payable accumulate pay interest soon administratively practicable follow month period benefit entitlement benefit company pension health welfare plan govern relevant plan document andor company policy avoidance doubt acknowledge eligible severance benefit company current successor separation benefit plan release consideration promise company set forth agreement intent bind legally agree irrevocably release forever discharge merck inc benefit plan subsidiary affiliate joint venture officer director employee agent predecessor partner successor fiduciary assign release party respect manner action suit debt claim demand whatsoever law equity arise way relate employment company transfer new assignment cessation employment arise way relate transaction occurrence act omission loss damage injury occurring time include date time sign agreement claim include limited claim base law statute ordinance regulation constitution executive order base contract tort common law legal equitable theory relief claim base employee retirement income security act claim arise civil right law federal state local jurisdiction include limited title vii civil right act americans disability act section rehabilitation act family medical leave act age discrimination employment act pennsylvania human relations act new jersey law discrimination claim whistleblower law whistleblow provision law include limited new jersey conscientious employee protection act claim counsel fee cost understand signing agreement waive claim release party release agreement great extent allowable law paragraph shall read waiver vest right saving pension plan condition agreement term condition agreement condition abide term condition agreement term condition set forth company condition employment agreement incorporate reference confidentiality agree hold existence agreement term condition agreement circumstance surround employment merck include limitation transfer new assignment cessation thereof strict confidence agree disclose require law legal process information party member immediate family tax authority tax consultant legal advisor agree subject subpoena court process order require bear witness matter concern employment knowledge merck shall contact company immediately notification prohibit law order court provision shall construe precluding cooperate federal state law enforcement regulatory agency connection lawful government inquiry non disparagement agree communicate negatively disparage merck product release party way whatsoever agreement compete agree continued employment company period eighteen month cessation employment company conduct business competition merck conduct business competition merck mean purpose agreement connected manner big pharmaceutical competitor directly indirectly individual director trustee officer employee debt equity investor consultant independent contractor big pharmaceutical competitor ownership management operation control person entity big pharmaceutical competitor provide event shall ownership outstanding equity security issuer security register securities exchange act amend stand prohibit subparagraph long exercise right manage operate control business issuer employee consultant independent contractor director trustee officer competitor prior consent merck general counsel request consent include company like work associate nature propose employment association relationship company information request general counsel decision consent request accordance subparagraph sole discretion mercks general counsel consent unreasonably withhold consent effective set forth sign write communication general counsel non solicitation agree continued employment company period eighteen month cessation employment company solicit entice persuade induce attempt influence merck employee define leave employ merck subsidiary affiliate joint venture make initial contact merck employee purpose engage discussion merck employee purpose result cause person initial contact merck employee forpage purpose soliciting enticing persuade induce leave employ merck subsidiary affiliate joint venture iii provide person information merck employee purpose recruitment employee purpose section merck employee mean person time action anytime precede month employ merck subsidiary affiliate joint venture non disclosure acknowledge course employment company access trade secret confidential andor proprietary information own company agree disclose information party extension time period time prohibit engage activity describe subsection section extend length time breach subsection reformation agree portion section determine invalid determination affect enforceability remain portion section section interpret invalid portion insert agree invalidity cause length period time size area paragraph period time area need action party deem reduce period area cure invalidity remedy agree violation agreement contain section cause immediate irreparable injury merck impossible estimate determine damage suffer merck event breach separate apart remedy merck agree event violate agreement section merck entitle temporary permanent injunctive relief breach employer employee partner agent associate necessity prove actual damage immediate irreparable harm post bond cease desist provide benefit agreement award liquidate damage equal monie pay receive accordance section agreement associate attorney fee cost merck covenant merck agree instruct executive officer member board director disparage party litigation connection litigation investigation inquiry proceeding court arbitrator government administrative agency tribunal ask merck testify witness provide information concern matter involve course employment merck agree cooperate fully merck counsel make reasonably available counsel discuss information review testimony reasonably advance litigation proceeding make available testify deposition trial require request merck travel expense applicable statutorily mandate witness fee agree pay connection testimony appearance participation pursuant paragraph litigation proceeding paragraph affect right indemnification merck corporate bylaw policy eligibility merck advance reasonable cost disbursement counsel fee certain circumstance connection proceeding relate arising activity merck employee merck continue pay legal counsel bill incur course litigation subject term exist arrangement subject representation acknowledge promise promise agreement signing agreement rely statement representation behalf release party concern merit claim nature extent duration damage relate claim money benefit compensation claim concern agreement concern thing matter voluntariness agree rely solely judgment eighteen year age legally competent sign agreement signing agreement free read understand agreement signing signing agreement exchange consideration believe satisfactory adequate legal counsel acknowledge inform right consult legal counsel encourage fact engage legal counsel represent respect agreement counsel negotiate term agreement behalf complete agreement agreement constitute complete final agreement party supersede replace prior contemporaneous agreement negotiation discussion relate subject matter agreement applicable law acknowledge agree employment relationship merck govern solely exclusively law state new jersey united states question scope interpretation effect agreement resolve substantive procedural law state new jersey give effect conflict law provision severance pay agree merck release party owe severance pay termination indemnity amount payable termination employment nature severance unemployment compensation severance pay law regulation state country event court administrative agency authority rule owe severance pay amount payable section agreement reduce severance pay agree constructive trustee amount carry purpose section severability provision portion agreement severable provision portion agreement application provision portion agreement determine invalid unenforceable extent reason provision portion agreement remain force effect continue enforceable full great extent permit law initial execution initial execution agreement acknowledge acceptance term condition agreement initial execution acknowledge acceptance give period twentyone day consider initial execution agreement accept agreement time period time signing agreement return revocability inform initial execution agreement effective enforceable seven calendar day execution revoke acceptance agreement time seven calendar day period send write notice notice receive seven calendar day period order effective receive void agreement purpose reexecution company determination severance event occur present agreement execution agree reexecute agreement condition precedent entitlement severance benefit set forth section reexecution agreement acknowledge acceptance give period twentyone day consider reexecute agreement accept agreement time period time signing agreement return revocability inform reexecution agreement reexecute effective enforceable seven calendar day reexecution revoke acceptance agreement reexecute time seven calendar day period send write notice notice receive seven calendar day period order effective receive void agreement reexecute affect agreement initially execute release reexecution date reexecution date sign agreement purpose agreement include limitation purpose release set forth section intent bind company enter agreement intent legally bind signature follow indicate initial acceptance agreement sign date letter return duplicate letter sign enclose record truly richard clark richard clark president ceo merck inc accept david anstice date december avid anstice reexecute date avid ansticeexhibit merck inc subsidiarie computation ratio earning fix charge million ratio datum month end december year end december income continue operation taxis add subtract onethird rent interest expense gross interest capitalize net amortization equity income loss affiliate net distribution prefer stock dividend net tax earning continue operation onethird rent interest expense gross prefer stock dividend fix charge continue operation ratio earning fix charge continue operation purpose compute ratio earning consist income continue operation taxis onethird rent deem company representative interest factor inherent rent interest expense net amount capitalize equity income loss affiliate net distribution dividend prefer stock subsidiary company fix charge consist onethird rent interest expense report company consolidate financial statement dividend prefer stock subsidiary companiesexhibit merck inc subsidiary follow list subsidiary company business state country state incorporation abmaxis inc delaware amrad pharmaceuticals pty ltd australia banyu pharmaceutical company ltd japan blue jay investments netherlands brc ltd bermuda charles frosst limited united kingdom chibret denmark chibret pharmazeutische gmbh germany chinamsd hivaids public private partnership inc china chippewa holdings llc delaware cloverleaf international holding luxembourg delaware llc delaware comsort inc delaware coophavet sas france crosswind netherlands dieckmann arzneimittel gmbh germany european insurance risk excess limited ireland farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal financiere msd sas france fontelaborprodutos farmaceuticos lda portugal fregenal holding panama frosst iberica spain frosst laboratories inc delaware frosst portuguesa produto farmaceuticos lda portugal glycofi inc delaware hangzhou msd pharmaceutical company limited china hawk falcon llc delaware heptafarma companhia farmaceutica lda portugal infodoc norway international indemnity ltd bermuda istituto richerche biologia molecolare spa italy istituto gentili spainc italydelaware johnson johnson merck consumer pharmaceutical company new jersey kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware kiinteisto viistotie finland laboratoire merck sharp dohmechibret snc france laboratorios abello spain laboratorios biopat spaincountry state incorporation laboratorio chibret spain laboratorios frosst spain laboratorios medichip spain laboratorios neurogard spain laboratorios quimicofarmaceutico chibret lda portugal maple leaf holding srl barbados mcm vaccine pennsylvania medco mexico manage care mexico medco holdings mexico medco servicios mexico mexico merck company incorporate delaware merck borinquen holdings inc delaware merck capital resources inc delaware merck capital ventures llc delaware merck cardiovascular health company nevada merck finance inc delaware merck foreign sales corporation ltd bermuda merck frosst canada ltd canada merck frosst company canada merck frosst finco canada merck hamilton inc california merck hdac research llc delaware merck holdings corp delaware merck holdings inc delaware merck institute vaccinology delaware merck investment inc delaware merck lmc cash management bermuda ltd bermuda merck oncology holdings inc delaware merck resource management inc delaware merck respiratory health company nevada merck inc delaware merck sharp dohme argentina inc delaware merck sharp dohme asia limited hong kong merck sharp dohme australia pty limited australia merck sharp dohme china limited hong kong merck sharp dohme enterprise netherlands merck sharp dohme europe inc delaware merck sharp dohme holding netherlands merck sharp dohme holdings limit united kingdom merck sharp dohme corp delaware merck sharp dohme international limited bermuda merck sharp dohme investment netherlands merck sharp dohme ireland ltd bermuda merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy merck sharp dohme lebanon sal lebanon merck sharp dohme middle east limited cyprus merck sharp dohme new zealand limited new zealand merck sharp dohme panama panama country state incorporation merck sharp dohme philippines inc philippines merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda merck sharp dohme sweden sweden merck sharp dohme switzerland gmbh switzerland merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme netherlands merck sharp dohme bulgaria eood bulgaria merck sharp dohme chibret switzerland merck sharp dohme comercializadora mexico merck sharp dohme doo croatia merck sharp dohme espana spain merck sharp dohme mexico mexico merck sharp dohme venezuela srl venezuela merck sharp dohme farmaceutica ltda brazil merck sharp dohme finance europe limited united kingdom merck sharp dohme gmbh austria merck sharp dohme holdings mexico mexico merck sharp dohme idea switzerland merck sharp dohme industria quimica veterinaria limitada brazil merck sharp dohme inovativna zdravila doo slovenia merck sharp dohme international service netherlands merck sharp dohme ireland human health ltd ireland merck sharp dohme sland iceland merck sharp dohme limited united kingdom merck sharp dohme luxembourg holdings sarl luxembourg merck sharp dohme manufacturing ireland merck sharp dohme estonia merck sharp dohme pakistan limited pakistan merck sharp dohme peru srl peru merck sharp dohme pharmaceutical llc russia merck sharp dohme quimica puerto rico inc delaware merck sharp dohme research ltd bermuda merck sharp dohme romania srl romania merck sharp dohme mexico merck sharp dohme morocco merck sharp dohme sia latvia merck sharp dohme tunisie sarl tunisia merck sharp dohme limitada portugal merck sharp dohme ilaclari limited sirketi turkey merck technology company inc nevada merck ventures inc delaware merckbanyu ltd japan merial llp puerto rico merial thailand ltd thailand merial animal health ltd china merial animal health ltd united kingdom merial argentina argentina merial asia pte ltd singapore country state incorporation merial australia pty ltd australia merial netherlands merial belgium belgium merial colombia colombia merial distribution sas france merial gmbh germany merial hong kong limited hong kong merial inc delaware merial international trading shanghai ltd china merial italia spa italy merial japan limited japan merial korea ltd korea merial laboratorios spain merial limitedllc united kingdomdelaware merial nanjing animal health ltd china merial new zealand limited new zealand merial norden denmark merial philippines inc philippines merial portuguesa saude animal lda portugal merial uruguay merial sas france merial saude animal ltda brazil merial taiwan ltd taiwan merial venezuela venezuela holdings canada inc canada msd nippon holding netherlands msd norge norway msd proprietary limited south africa msd thailand ltd thailand msd australia pty ltd australia msd australia superannuation pty ltd australia msd brazil investment netherlands msd chibropharm gmbh germany msd china investment netherlands msd eurofinance bermuda msd finance netherland msd finland finland msd international holdings inc delaware msd ireland holdings luxembourg msd ireland investments ltd bermuda msd ireland resources ireland msd korea ltd korea msd lakemedel scandinavia aktiebolog sweden msd latin america services ltd bermuda msd latin america services mexico msd limited united kingdom msd magyarorszg kft hungary msd mexico investment netherlands msd overseas manufacturing bermuda country state incorporation msd overseas manufacturing ireland ireland msd pharmaceuticals private limited india msd polska spzoo poland msd puerto rico holdings inc puerto rico msd scandinavia norway msd sharp dohme gmbh germany msd somerset ltd bermuda msd stamford singapore pte ltd singapore msd technology singapore pte ltd singapore msd technology delaware msd unterstutzungskasse gmbh germany msd ventures singapore pte ltd singapore msd warwick manufacturing ltd bermuda msdessex gmbh switzerland msdj holdings canada inc canada msdsp ltd united kingdom msp distribution service llc nevada msp distribution service llc nevada msp singapore company llc delaware msp technology company llc delaware neopharme spa italy merck sharp dohme indonesia indonesia pasteur vaccin france readington investments inc new jersey rosetta biosoftware ltd united kingdom rosetta inpharmatics llc delaware ruskin limited bermuda sanofi pasteur msd denmark sanofi pasteur msd sweden sanofi pasteur msd switzerland sanofi pasteur msd norway sanofi pasteur msd ap denmark sanofi pasteur msd gestion france sanofi pasteur msd gmbh austria sanofi pasteur msd gmbh germany sanofi pasteur msd ltd united kingdom sanofi pasteur msd ltd ireland sanofi pasteur msd nvsa belgium sanofi pasteur msd finland sanofi pasteur msd portugal sanofi pasteur msd spain sanofi pasteur msd spa italy sanofi pasteur msd snc france seneca llc delaware sharp dohme spain sirna therapeutics inc delaware stellarx inc nevada telerx marketing inc pennsylvania msd foundation limited united kingdom country state incorporation thomas morson son limited united kingdom tradewind manufacture srl barbados transrow manufacturing ltd bermuda uab merck sharp dohme lithuania variopharm arzneimittel gmbh germany exhibit power attorney undersign appoint celia colbert kenneth frazier severally hisher true lawful attorney attorney execute behalf undersign behalf company officer director thereof attesting seal company annual report merck inc fiscal year end december securities exchange act include amendment thereto